# **ABALOPARATIDE (TYMLOS)**

# **MEDICATION(S)**

**TYMLOS** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Total parathyroid hormone analog therapy has exceeded 2 years. Being used with other osteoporosis drugs.

#### REQUIRED MEDICAL INFORMATION

Osteoporosis: patient has a history of a broken bone not due to trauma (non-traumatic fracture) or T-score between -1.0 and -2.5 and is at high risk for fracture or T-score lower than -2.5 AND one of the following: trial of a bisphosphonate (e.g. alendronate, ibandronate, risedronate, or zoledronic acid) or Prolia, OR side effect to bisphosphonate therapy or Prolia therapy that supports discontinuation, OR Patient is at very high risk of fracture by meeting at least one of the following: non-traumatic fracture while on bisphosphonate therapy or Prolia, patient has experienced a recent fracture (within the past 12 months) or history of multiple fractures, patient experienced a fracture while on long-term glucocorticoid therapy, or T-score less than -3.0, or patient is at high risk for falls, or 10-year hip fracture probability greater than 4.5% based on FRAX score, or 10-year major osteoporosis-related fracture probability greater than 30% based on FRAX score

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 2 EFFECTIVE 11/2025

# **ABEMACICLIB (VERZENIO)**

# **MEDICATION(S)**

**VERZENIO** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 3 EFFECTIVE 11/2025

# **ABIRATERONE (ZYTIGA)**

# **MEDICATION(S)**

ABIRATERONE ACETATE, ABIRTEGA

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 4 EFFECTIVE 11/2025

# **ACALABRUTINIB (CALQUENCE)**

### **MEDICATION(S)**

**CALQUENCE** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 5 EFFECTIVE 11/2025

# **ACYCLOVIR CREAM (ZOVIRAX)**

# **MEDICATION(S)**

**ACYCLOVIR 5 % CREAM** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 6 EFFECTIVE 11/2025

# **ACYCLOVIR OINTMENT (ZOVIRAX)**

### **MEDICATION(S)**

**ACYCLOVIR 5 % OINTMENT** 

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial of or has a medical reason for not trying a herpes antiviral drug you take by mouth (e.g. acyclovir, valacyclovir).

### **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 7 EFFECTIVE 11/2025

# **ADAGRASIB (KRAZATI)**

# **MEDICATION(S)**

KRAZATI

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 8 EFFECTIVE 11/2025

# **ADALIMUMAB (HADLIMA)**

### **MEDICATION(S)**

HADLIMA, HADLIMA PUSHTOUCH

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

### REQUIRED MEDICAL INFORMATION

Ankylosing spondylitis (AS): patient is not able to take NSAIDs due to history of GI bleed or ulcer OR patient has tried one RX strength NSAID in combination with a PPI and had GI side effects OR patient's condition did not respond to a trial of two different RX strength NSAIDs. Crohn's Disease (CD) weekly dosing: patient has tried every other week dosing and had a flare or loss in response.

Hidradenitis suppurativa (HS): patient has Hurley stage II or III HS.

Non-infectious uveitis: patient has tried a systemic corticosteroid (e.g. prednisone, dexamethasone, hydrocortisone) or has a medical reason why corticosteroids cannot be used. Plaque Psoriasis (PsO), initial use: patient tried and failed or had a side effect to one DMARD or has a medical reason why methotrexate (MTX), cyclosporine, and acitretin cannot be used AND baseline PASI score 10 or more OR BSA 3% or more OR sensitive areas are involved OR disease affects daily living. Ongoing use: PASI or BSA improved on Hadlima.

Rheumatoid Arthritis (RA): patient has tried and failed or had a side effect to methotrexate (MTX) or has a medical reason why MTX cannot be used.

Polyarticular Juvenile Idiopathic Arthritis (pJIA): patient has tried and failed or had a side effect to one DMARD or has a medical reason why methotrexate (MTX) cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

RA, PsA, pJIA, AS: Rheumatologist. PsO: Rheumatologist or Dermatologist. HS: Dermatologist. Non-infectious uveitis: Ophthalmologist.

PAGE 9 EFFECTIVE 11/2025

# **COVERAGE DURATION**

PsO, initial: 24 weeks - ongoing use: plan year. All other indications: plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 10 EFFECTIVE 11/2025

# **ADALIMUMAB RYVK (SIMLANDI)**

### **MEDICATION(S)**

SIMLANDI (1 PEN), SIMLANDI (1 SYRINGE), SIMLANDI (2 PEN), SIMLANDI (2 SYRINGE)

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

### REQUIRED MEDICAL INFORMATION

Ankylosing spondylitis (AS): patient is not able to take NSAIDs due to history of GI bleed or ulcer OR patient has tried one RX strength NSAID in combination with a PPI and had GI side effects OR patient's condition did not respond to a trial of two different RX strength NSAIDs. Crohn's Disease (CD) weekly dosing: patient has tried every other week dosing and had a flare or loss in response.

Hidradenitis suppurativa (HS): patient has Hurley stage II or III HS.

Non-infectious uveitis: patient has tried a systemic corticosteroid (e.g. prednisone, dexamethasone, hydrocortisone) or has a medical reason why corticosteroids cannot be used. Plaque Psoriasis (PsO), initial use: patient tried and failed or had a side effect to one DMARD or has a medical reason why methotrexate (MTX), cyclosporine, and acitretin cannot be used AND baseline PASI score 10 or more OR BSA 3% or more OR sensitive areas are involved OR disease affects daily living. Ongoing use: PASI or BSA improved on Simlandi.

Rheumatoid Arthritis (RA): patient has tried and failed or had a side effect to methotrexate (MTX) or has a medical reason why MTX cannot be used.

Polyarticular Juvenile Idiopathic Arthritis (pJIA): patient has tried and failed or had a side effect to one DMARD or has a medical reason why methotrexate (MTX) cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

RA, PsA, pJIA, AS: Rheumatologist. PsO: Rheumatologist or Dermatologist. HS: Dermatologist. Non-infectious uveitis: Ophthalmologist.

PAGE 11 EFFECTIVE 11/2025

# **COVERAGE DURATION**

PsO, initial: 24 weeks - ongoing use: plan year. All other indications: plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 12 EFFECTIVE 11/2025

# **ADAPALENE (DIFFERIN)**

### MEDICATION(S)

ADAPALENE 0.1 % CREAM, ADAPALENE 0.3 % GEL

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

### **AGE RESTRICTION**

40 years of age or older. No prior authorization required for less than 40 years old.

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 13 EFFECTIVE 11/2025

# **AFATINIB DIMALEATE (GILOTRIF)**

### **MEDICATION(S)**

**GILOTRIF** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan Year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 14 EFFECTIVE 11/2025

# **ALECTINIB (ALECENSA)**

### **MEDICATION(S)**

**ALECENSA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan Year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 15 EFFECTIVE 11/2025

# **ALITRETINOIN (PANRETIN)**

# **MEDICATION(S)**

**PANRETIN** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 16 EFFECTIVE 11/2025

# **ALOSETRON (LOTRONEX)**

# MEDICATION(S)

ALOSETRON HCL

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Irritable bowel syndrome with diarrhea (IBS-D), initial use: patient is female, and trial and failure or side effect to an anti-diarrheal drug (i.e., diphenoxylate-atropine (Lomotil), loperamide) OR has a medical reason not to use (contraindication) anti-diarrheal therapies. Ongoing use: IBS symptoms improved with alosetron and patient does not have constipation problems.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Initial: 2 months

Ongoing use: plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 17 EFFECTIVE 11/2025

# **ALPELISIB (PIQRAY)**

### **MEDICATION(S)**

PIQRAY (200 MG DAILY DOSE), PIQRAY (250 MG DAILY DOSE), PIQRAY (300 MG DAILY DOSE)

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 18 EFFECTIVE 11/2025

# **ALPROSTADIL (MUSE)**

# **MEDICATION(S)**

**MUSE** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another ED drug.

# REQUIRED MEDICAL INFORMATION

Erectile dysfunction (ED) is caused by a drug that has been reported in the medical literature to cause erectile dysfunction or erectile dysfunction is caused by an underlying medical condition.

#### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

ED: Limited to 6 tablets per month.

Dose and duration is not more than the FDA labeled maximum.

PAGE 19 EFFECTIVE 11/2025

# **AMBRISENTAN (LETAIRIS)**

# **MEDICATION(S)**

**AMBRISENTAN** 

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Confirmation of Pulmonary Arterial Hypertension (WHO Group I) by right heart catheterization test.

# **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 20 EFFECTIVE 11/2025

# **AMIKACIN INHALATION (ARIKAYCE)**

# **MEDICATION(S)**

**ARIKAYCE** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

MAC (mycobactium avium complex) lung infection: being used as part of a multidrug antibacterial regimen (i.e., macrolide, rifamycin, or ethambutol) AND sputum culture is still positive despite 6 months or more of multidrug antibiotic therapy.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 21 EFFECTIVE 11/2025

# **APALUTAMIDE (ERLEADA)**

### **MEDICATION(S)**

**ERLEADA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 22 EFFECTIVE 11/2025

# **APOMORPHINE (APOKYN)**

### MEDICATION(S)

**APOMORPHINE HCL** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Loss of control of body movements due to advanced Parkinson's disease (hypomobility): Treatment failure to at least one antiparkinsonian drug (i.e., pramipexole, entacapone, rasagiline, etc.).

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

Neurologist

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 23 EFFECTIVE 11/2025

# **APREMILAST (OTEZLA)**

# **MEDICATION(S)**

OTEZLA, OTEZLA XR, OTEZLA/OTEZLA XR INITIATION PK

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

# REQUIRED MEDICAL INFORMATION

Plaque Psoriasis (PsO), initial use: treatment failure or side effect with one of the following: a DMARD, a topical corticosteroid (i.e., betamethasone), a calcineurin inhibitor (i.e., tacrolimus ointment), or calcipotriene OR has a medical reason why methotrexate, cyclosporine, acitretin, or topical agents cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

PsO: Dermatologist or Rheumatologist. PsA: Rheumatologist.

#### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 24 EFFECTIVE 11/2025

# **APREPITANT 40MG CAPSULE (EMEND)**

# **MEDICATION(S)**

APREPITANT 40 MG CAP

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Prevention of post-surgery nausea and vomiting (PONV): patient cannot use other antiemetics (e.g. ondansetron, promethazine, transdermal scopolamine) prior to surgery because of history of treatment failure or side effects and dose will be given within 3 hours of surgery.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

PONV: once per surgery.

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 25 EFFECTIVE 11/2025

# **ARIPIPRAZOLE (OPIPZA)**

### **MEDICATION(S)**

**OPIPZA** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Medical reason why oral generic aripiprazole (e.g., tablet, solution, disintegrating tablet) cannot be used.

# **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 26 EFFECTIVE 11/2025

# **ARMODAFINIL (NUVIGIL)**

# **MEDICATION(S)**

**ARMODAFINIL** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Bipolar disorder

#### **EXCLUSION CRITERIA**

N/A

### REQUIRED MEDICAL INFORMATION

Narcolepsy: patient has positive sleep study (polysomnography) for narcolepsy. Trial and failure or side effect with modafinil or there is a medical reason why modafinil cannot be used.

Obstructive sleep apnea/hypopnea syndrome (OSAHS): patient has a positive sleep study for OSAHS, Trial and failure or side effect with modafinil or there is a medical reason why modafinil cannot be used. Shift work sleep disorder: patient is a night shift worker working between 11pm and 7am OR patient is an early morning shift worker with starting hours between 4am and 7am OR patient is a rotating shift worker with night shifts. Trial and failure or side effect with modafinil or there is a medical reason why modafinil cannot be used.

Bipolar Disorder: being added to current treatment regimen AND Trial and failure or side effect with modafinil or there is a medical reason why modafinil cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Bipolar Disorder: Psychiatrist

#### **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 28 EFFECTIVE 11/2025

# **ASCIMINIB (SCEMBLIX)**

# MEDICATION(S)

**SCEMBLIX** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 29 EFFECTIVE 11/2025

# **ASENAPINE (SAPHRIS)**

### MEDICATION(S)

**ASENAPINE MALEATE** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to one generic atypical antipsychotic drug (e.g. aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) or there is a medical reason why all the generic atypical antipsychotics cannot be used.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 30 EFFECTIVE 11/2025

# **ASENAPINE (SECUADO)**

# **MEDICATION(S)**

**SECUADO** 

### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Side effect to asenapine tablet (Saphris) not seen with Secuado.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 31 EFFECTIVE 11/2025

# **ATOVAQUONE (MEPRON)**

# **MEDICATION(S)**

**ATOVAQUONE** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

### REQUIRED MEDICAL INFORMATION

Toxoplasmosis prevention or treatment: patient is immunocompromised or at high risk of infection. Toxoplasmosis primary prevention: patient has failed or had a side effect to tmp/smx or has a medical reason (contraindication) for not using tmp/smx. PCP prevention or treatment: patient is immunocompromised or at high risk of infection and patient has failed or had a side effect to tmp/smx or has a medical reason (contraindication) for not using tmp/smx. Babesiosis treatment: active infection confirmed by blood smear test that is positive for Babesia microti parasites, PCR blood sample positive for Babesia microti DNA, or FISH test positive for Babesia microti RNA.

#### **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

PCP: 21days, Toxo: 6wks, Babesiosis: 10 days, PCP/Toxo prevention: Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **AVAPRITINIB (AYVAKIT)**

# MEDICATION(S)

**AYVAKIT** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 33 EFFECTIVE 11/2025

# **AVUTOMETINIB AND DEFACTINIB (AVMAPKI-FAKZYNJA CO-PACK)**

# **MEDICATION(S)**

AVMAPKI FAKZYNJA CO-PACK

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 34 EFFECTIVE 11/2025

# **AXITINIB (INLYTA)**

### **MEDICATION(S)**

**INLYTA** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 35 EFFECTIVE 11/2025

# **AZACITIDINE (ONUREG)**

# **MEDICATION(S)**

**ONUREG** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 36 EFFECTIVE 11/2025

# **AZTREONAM LYSINE (CAYSTON)**

# MEDICATION(S)

**CAYSTON** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Being used for acute treatment of an infection.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 37 EFFECTIVE 11/2025

# **BECAPLERMIN (REGRANEX)**

# MEDICATION(S)

**REGRANEX** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Treating pressure ulcers or venous stasis ulcers.

# REQUIRED MEDICAL INFORMATION

Diabetic ulcer has not responded to standard therapy for wound management (i.e. debridement, dressing changes, pressure relief).

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

3 months

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 38 EFFECTIVE 11/2025

# **BEDAQUILINE (SIRTURO)**

# MEDICATION(S)

**SIRTURO** 

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

**PLAN YEAR** 

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 39 EFFECTIVE 11/2025

# **BELIMUMAB (BENLYSTA)**

# **MEDICATION(S)**

BENLYSTA 200 MG/ML SOLN A-INJ, BENLYSTA 200 MG/ML SOLN PRSYR

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Diagnosis is severe CNS lupus. Benlysta is being used with Rituxan, other biologics, or IV cyclophosphamide.

# REQUIRED MEDICAL INFORMATION

Systemic Lupus Erythematous (SLE) initial use: patient is currently taking one or more of the following: prednisone, methylprednisolone, azathioprine, methotrexate, mycophenolate, chloroquine, hydroxychloroquine.

Lupus Nephritis: being added to standard SLE therapy (e.g. corticosteroids, immunomodulators).

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

SLE: Rheumatologist

Lupus Nephritis: Rheumatologist or Nephrologist.

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **BELUMOSUDIL (REZUROCK)**

# MEDICATION(S)

REZUROCK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

# **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 41 EFFECTIVE 11/2025

# **BELZUTIFAN (WELIREG)**

# **MEDICATION(S)**

**WELIREG** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan Year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 42 EFFECTIVE 11/2025

# **BEXAROTENE (TARGRETIN TOPICAL GEL)**

# **MEDICATION(S)**

**BEXAROTENE 1% GEL** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 43 EFFECTIVE 11/2025

# **BEXAROTENE CAPSULE (TARGRETIN)**

# **MEDICATION(S)**

**BEXAROTENE 75 MG CAP** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 44 EFFECTIVE 11/2025

# **BINIMETINIB (MEKTOVI)**

# **MEDICATION(S)**

**MEKTOVI** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 45 EFFECTIVE 11/2025

# **BOSENTAN (TRACLEER)**

# **MEDICATION(S)**

BOSENTAN, TRACLEER 32 MG TAB SOL

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Confirmation of Pulmonary Arterial Hypertension (WHO Group I) by right heart catheterization test.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 46 EFFECTIVE 11/2025

# **BOSUTINIB (BOSULIF)**

# **MEDICATION(S)**

**BOSULIF** 

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 47 EFFECTIVE 11/2025

# **BREXPIPRAZOLE (REXULTI)**

# **MEDICATION(S)**

**REXULTI** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

MDD: being used as a single agent

# REQUIRED MEDICAL INFORMATION

Schizophrenia or MDD: Trial and failure or side effect with aripiprazole or medical reason why aripiprazole cannot be used.

# **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 48 EFFECTIVE 11/2025

# **BRIGATINIB (ALUNBRIG)**

# **MEDICATION(S)**

**ALUNBRIG** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 49 EFFECTIVE 11/2025

# **BUDESONIDE (ENTOCORT EC)**

# **MEDICATION(S)**

**BUDESONIDE 3 MG CP DR PART** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Microscopic colitis (aka lymphocytic and collagenous colitis), Autoimmune hepatitis

#### **EXCLUSION CRITERIA**

Being used for severe Crohn's disease (CD). Autoimmune hepatitis: patient has liver cirrhosis.

# REQUIRED MEDICAL INFORMATION

CD, initial use: budesonide will be used to induce remission.

CD, ongoing use: patient responded to induction of remission therapy and there is a medical reason why guideline supported therapies (e.g. infliximab, mesalamine, azathioprine) for maintaining CD remission cannot be used.

Autoimmune hepatitis: being used with azathioprine and has a medical reason not to use prednisone and prednisolone or had severe side effect to prednisone and prednisolone that is not also seen with budesonide and initial dose is not more than 9 mg per day.

Microscopic colitis: initial dose is not more than 9 mg per day. For ongoing use: responded to initial therapy but symptoms returned after therapy was completed and dose is not more than 6 mg per day.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Microscopic colitis: gastroenterologist or infectious disease specialist. Autoimmune hepatitis: gastroenterologist, hepatologist, or infectious disease specialist.

#### **COVERAGE DURATION**

Autoimmune hepatitis: plan year. CD and Microscopic colitis: see other criteria.

PAGE 50 EFFECTIVE 11/2025

# **OTHER CRITERIA**

CD and Microscopic colitis initial: 8 weeks. CD maintenance: 3 months.

Microscopic colitis ongoing: plan year.

Dose and duration is not more than the FDA labeled maximum.

PAGE 51 EFFECTIVE 11/2025

# **BUDESONIDE ER TABLET (UCERIS)**

# **MEDICATION(S)**

**BUDESONIDE ER** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Microscopic colitis (aka lymphocytic and collagenous colitis), Autoimmune hepatitis

#### **EXCLUSION CRITERIA**

Microscopic colititis: Used for maintenance

# REQUIRED MEDICAL INFORMATION

Ulcerative colitis (UC): being used to start remission of active UC, and patient has tried or has a medical reason for not trying one drug from the mesalamine class (e.g. balsalazide, mesalamine), and for moderate disease, medical reason why patient cannot use a generic corticosteroid drug that is taken by mouth (e.g. prednisone, methylprednisolone, hydrocortisone, and dexamethasone).

Autoimmune hepatitis: being used with azathioprine and has a medical reason not to use prednisone or prednisolone or had severe side effect to prednisone or prednisolone that is not also seen with budesonide and dose is not more than 9 mg per day.

Microscopic colitis: being used to start remission of symptoms and dose is not more than 9 mg per day.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

UC: Gastroenterologist. Microscopic colitis: Gastroenterologist, Infectious Disease. Autoimmune hepatitis: Gastroenterologist, Hepatologist or Infectious Disease.

#### **COVERAGE DURATION**

UC, Microscopic colitis: 8 weeks. Autoimmune hepatitis: plan year.

PAGE 52 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 53 EFFECTIVE 11/2025

# **BUPRENORPHINE PATCH (BUTRANS) – NARCOTIC SAFETY INITIATIVE**

# **MEDICATION(S)**

**BUPRENORPHINE** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other long-acting narcotic drugs.

# REQUIRED MEDICAL INFORMATION

Cancer pain: dose has been consolidated to the least number of higher strength forms.

Non-cancer pain, initial: cause of pain cannot be removed or treated with other treatment options, and pain occurs daily and has lasted for at least 3 months, and pain is severe enough to need daily around-the-clock long-term narcotic use, and total daily dose across all narcotic drugs is less than 90 MME, and dose has been consolidated to the least number of higher strength forms and patient has tried at least one short-acting narcotic drug, and chart notes document pain history including baseline pain intensity score and functional interference score, a plan for monitoring side effects and misuse, and a plan to taper down narcotics.

Non-cancer pain, reauth: total daily dose across all narcotic drugs is less than 90 MME per day, and dose has been consolidated to the least number of higher strength forms, and chart notes document current pain intensity score, functional interference score, any side effects and/or misuse with current pain treatment regimen, and plan to taper narcotic use.

### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Cancer pain: Oncologist or Pain Specialist.

#### **COVERAGE DURATION**

Cancer pain: plan year Non-cancer pain: initial 30 days,1st reauth 3mos, ongoing reauths plan year

PAGE 54 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 55 EFFECTIVE 11/2025

#### **BUTALBITAL CONTAINING PRODUCTS**

# **MEDICATION(S)**

ASCOMP-CODEINE, BAC (BUTALBITAL-ACETAMIN-CAFF), BUTALBITAL-ACETAMINOPHEN 50-300 MG CAP, BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB, BUTALBITAL-APAP-CAFF-COD 50-325-40-30 MG CAP, BUTALBITAL-APAP-CAFFEINE 50-300-40 MG CAP, BUTALBITAL-APAP-CAFFEINE 50-325-40 MG TAB, BUTALBITAL-ASA-CAFF-CODEINE, BUTALBITAL-ASPIRIN-CAFFEINE, ESGIC 50-325-40 MG CAP, TENCON, ZEBUTAL

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# **REQUIRED MEDICAL INFORMATION**

Tension Headache: trial of two prescription strength non-steroidal anti-inflammatory drugs (NSAIDs) and amount requested does not exceed the amount needed to treat the number of headache days per month.

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

If more than 8 headache days per month: neurologist or headache or pain specialist

# **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **C1 ESTERASE INHIBITOR (HAEGARDA)**

# **MEDICATION(S)**

**HAEGARDA** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other Hereditary Angioedema (HAE) preventive therapies (e.g. danazol, Cinryze).

# **REQUIRED MEDICAL INFORMATION**

Prevention: chart documentation or labs that show C4 and C1-INH (antigenic or functional) levels confirm HAE type I or II, and prescriber states that patient has symptomatic disease.

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 57 EFFECTIVE 11/2025

# **CABOZANTINIB (CABOMETYX)**

# **MEDICATION(S)**

**CABOMETYX** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 58 EFFECTIVE 11/2025

# **CABOZANTINIB S-MALATE (COMETRIQ)**

# **MEDICATION(S)**

COMETRIQ (100 MG DAILY DOSE), COMETRIQ (140 MG DAILY DOSE), COMETRIQ (60 MG DAILY DOSE)

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 59 EFFECTIVE 11/2025

# **CALCIPOTRIENE-BETAMETHASONE OINTMENT (TACLONEX)**

# **MEDICATION(S)**

CALCIPOTRIENE-BETAMETH DIPROP 0.005-0.064 % OINTMENT

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial and failure of either calcipotriene or a topical steroid from the high or very high potency class.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 60 EFFECTIVE 11/2025

# **CANNABIDIOL (CBD) EXTRACT (EPIDIOLEX)**

# **MEDICATION(S)**

**EPIDIOLEX** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Dravet Syndrome: Trial and failure of valproic acid, divalproex, or clobazam.

Lennox-Gastaut syndrome: trial and failure or side effect to two of the following anti-seizure drugs: clonazepam, felbamate, lamotrigine, and topiramate or there is a medical reason why all these other drugs cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 61 EFFECTIVE 11/2025

# **CAPIVASERTIB (TRUQAP)**

# **MEDICATION(S)**

**TRUQAP** 

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 62 EFFECTIVE 11/2025

# **CAPLACIZUMAB-YHDP (CABLIVI)**

# **MEDICATION(S)**

**CABLIVI** 

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

# **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Continuation from inpatient hospital Cablivi treatment.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

58 days for inpatient or 103 days for outpatient plasma exchange

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 63 EFFECTIVE 11/2025

# **CAPMATINIB (TABRECTA)**

# **MEDICATION(S)**

**TABRECTA** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **CARGLUMIC ACID (CARBAGLU)**

# **MEDICATION(S)**

**CARGLUMIC ACID** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 65 EFFECTIVE 11/2025

# **CARIPRAZINE HYDROCHLORIDE (VRAYLAR)**

# **MEDICATION(S)**

**VRAYLAR** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Major Depressive Disorder: Being used as single agent therapy

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to one generic atypical antipsychotic drug (e.g. aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) or there is a medical reason why all the generic atypical antipsychotics cannot be used.

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 66 EFFECTIVE 11/2025

# **CASPOFUNGIN (CANCIDAS)**

# **MEDICATION(S)**

**CASPOFUNGIN ACETATE** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Oropharyngeal or Esophageal Candidiasis: patient has tried fluconazole OR fungal culture confirms infection is resistant to azole antifungals.

Invasive Aspergillosis: patient has tried an oral or IV azole antifungal or fungal culture confirms infection is resistant to azole antifungals.

Antifungal prophylaxis in cancer patients at high risk of febrile neutropenia [e.g. due to chemotherapy regimen, AML/MDS patient, undergoing HCST]: patient has tried fluconazole, voriconazole, or posaconazole or has a medical reason (contraindications) to azole antifungals.

Pulmonary Aspergillosis: patient has tried itraconazole or voriconazole.

Ongoing use for all conditions: continued neutropenia, culture remains positive, or ongoing symptoms.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

2 months

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 68 EFFECTIVE 11/2025

# **CENOBAMATE (XCOPRI)**

# **MEDICATION(S)**

XCOPRI, XCOPRI (250 MG DAILY DOSE), XCOPRI (350 MG DAILY DOSE)

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Treatment failure or side effect with two preferred partial seizure drugs (e.g. carbamazepine, clorazepate, divalproex, felbamate lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, zonisamide) OR medical reason why the preferred partial seizure drugs cannot be used (contraindication).

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 69 EFFECTIVE 11/2025

# **CERITINIB (ZYKADIA)**

# **MEDICATION(S)**

**ZYKADIA** 

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 70 EFFECTIVE 11/2025

# **CLOBAZAM (ONFI)**

# **MEDICATION(S)**

**CLOBAZAM** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Dravet syndrome: trial and failure or side effect to valproic acid or divalproex.

Lennox-Gastaut syndrome: trial and failure or side effect to two of the following anti-seizure drugs: clonazepam, felbamate, lamotrigine, and topiramate or there is a medical reason why all these other drugs cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **CLOBAZAM ORAL FILM (SYMPAZAN)**

# **MEDICATION(S)**

**SYMPAZAN** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Seizures due to Dravet Syndrome: Trial and failure or side effect with valproic acid or divalproex AND side effect to clobazam (Onfi) tablet and suspension that is not seen with Sympazan.

Lennox-Gastaut Syndrome: side effect to clobazam (Onfi) tablet and suspension that is not seen with Sympazan.

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 72 EFFECTIVE 11/2025

# **CLOBETASOL FOAM (OLUX, OLUX-E)**

## **MEDICATION(S)**

CLOBETASOL PROPIONATE EMULSION, TOVET 0.05 % FOAM

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to clobetasol 0.05% topical solution.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 73 EFFECTIVE 11/2025

# **CLOZAPINE SUSPENSION (VERSACLOZ)**

# **MEDICATION(S)**

**VERSACLOZ** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

## **OFF LABEL USES**

Parkinson's psychosis disorder

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Patient has a medical reason not to use clozapine tablets.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 74 EFFECTIVE 11/2025

# **COBIMETINIB (COTELLIC)**

## **MEDICATION(S)**

**COTELLIC** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 75 EFFECTIVE 11/2025

# **CORTICOTROPIN (CORTROPHIN)**

# **MEDICATION(S)**

**CORTROPHIN** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Ongoing use for treating infantile spasm: medical records show continued diagnosis (e.g. EEG confirms ongoing spasm).

Multiple Sclerosis (MS): patient is on a maintenance drug for MS (e.g. Tecfidera, Betaseron, glatiramer, Gilenya, Aubagio) but has an acute flare up and has had a side effect or contraindication to corticosteroids that is not seen with the use of Cortrophin.

Idiopathic or lupus erythematosus associated nephrotic syndrome, first use: patient's condition has not gotten better while using at least one immunosuppressive drug (cyclophosphamide, cyclosporine, and mycophenolate), and patient's condition responded to corticosteroid therapy but has had a side effect with the therapy that would not be seen with the use of Cortrophin. Ongoing use requires prescriber statement that patient's condition has gotten better while using Cortrophin.

All other FDA approved indications, first use: patient has not seen improvement of symptoms despite trying at least one different FDA approved drug for the condition other than corticosteroids, and has had a side effect to corticosteroids that is not seen with the use of Cortrophin. Ongoing use requires prescriber statement that patient's condition has gotten better while using Cortrophin.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Infantile spasms: Neurologist or Neonatologist MS: Neurologist or MS specialist Idiopathic or lupus erythematosus associated nephrotic syndrome: Nephrologist Rheumatic disorders,

Collagen diseases: Rheumatologist Skin Diseases: Dermatologist Eye diseases:

Ophthalmologist Symptomatic sarcoidosis: Pulmonologist

## **COVERAGE DURATION**

MS flare: 3 weeks, Other FDA approved uses: 1 month

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 77 EFFECTIVE 11/2025

# **CRIZOTINIB (XALKORI)**

## **MEDICATION(S)**

**XALKORI** 

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 78 EFFECTIVE 11/2025

# **CYSTEAMINE (CYSTAGON)**

## MEDICATION(S)

**CYSTAGON** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 79 EFFECTIVE 11/2025

# **CYSTEAMINE (CYSTARAN)**

## MEDICATION(S)

**CYSTARAN** 

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 80 EFFECTIVE 11/2025

# **DABRAFENIB (TAFINLAR)**

## **MEDICATION(S)**

**TAFINLAR** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 81 EFFECTIVE 11/2025

# **DACOMITINIB (VIZIMPRO)**

## **MEDICATION(S)**

**VIZIMPRO** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 82 EFFECTIVE 11/2025

# DALFAMPRIDINE EXTENDED-RELEASE TABLET (AMPYRA)

## **MEDICATION(S)**

DALFAMPRIDINE ER

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Multiple sclerosis, initial use: 25-foot walking test score. Ongoing use: updated timed 25-foot walking test shows improvement from prior or baseline test.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

Neurologist or Multiple Sclerosis specialist

#### **COVERAGE DURATION**

Initial use: 3 months. Ongoing use: plan year.

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 83 EFFECTIVE 11/2025

# **DAPSONE GEL (ACZONE)**

## MEDICATION(S)

DAPSONE 5 % GEL, DAPSONE 7.5 % GEL

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to a topical retinoin agent (i.e., adapalene, tretinoin) AND either a topical benzoyl peroxide containing agent or a topical anti-infective (e.g., clindamycin).

# **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 84 EFFECTIVE 11/2025

# **DARBEPOETIN ALFA (ARANESP)**

# **MEDICATION(S)**

ARANESP (ALBUMIN FREE)

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Low red blood cells (anemia) due to Myelodysplastic Syndrome (MDS), anemia in patients with cancer who are undergoing palliative treatment, Myelofibrosis.

#### **EXCLUSION CRITERIA**

N/A

#### REQUIRED MEDICAL INFORMATION

Chronic kidney disease (CKD), initial: Hgb is less than 10g/dL. Ongoing use: Hgb level of less than or equal to 10 g/dl in adults with CKD (not on dialysis), 11g/dL in adults with CKD (on dialysis), or 12 g/dl in children with CKD (not on dialysis). Myelosuppressive chemo related anemia Hgb is less than 10g/dl AND one of the following: patient is on chemo or completed last dose within last 8 wks or patient has multiple myeloma (MM) on Revlimid tx. MDS or Myelofibrosis: Hgb is less than 10g/dL (symptomatic anemia), and EPO level is less than or equal to 500U/ml or for MDS: patient has isolated 5q chromosome deletion [del (5q)]. Anemia in cancer patients undergoing palliative treatment: Hgb is less than or equal to 10g/dL. For all indications: target Hgb level has not been met or maintained with at least 8 weeks of max dose Retacrit OR patient has a medical reason (contraindication) not to use Retacrit OR had a side effect with Retacrit that is not seen with Aranesp OR patient has a religious belief that does not allow treatment with drugs that contain human albumin.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

CKD: 6 months. All other conditions: Plan year

PAGE 85 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 86 EFFECTIVE 11/2025

# **DAROLUTAMIDE (NUBEQA)**

## **MEDICATION(S)**

NUBEQA

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 87 EFFECTIVE 11/2025

# **DASATINIB (SPRYCEL)**

## **MEDICATION(S)**

**DASATINIB** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 88 EFFECTIVE 11/2025

# **DECITABINE-CEDAZURIDINE (INQOVI)**

## **MEDICATION(S)**

INQOVI

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 89 EFFECTIVE 11/2025

# **DEFERIPRONE (FERRIPROX)**

## MEDICATION(S)

DEFERIPRONE, FERRIPROX 100 MG/ML SOLUTION

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# **REQUIRED MEDICAL INFORMATION**

Treatment failure or side effect with deferasirox.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 90 EFFECTIVE 11/2025

# **DENOSUMAB (PROLIA)**

# **MEDICATION(S)**

**PROLIA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other osteoporosis drugs.

## REQUIRED MEDICAL INFORMATION

Treatment or prevention of postmenopausal osteoporosis in women OR to increase bone mass in men: one of the following: trial of a bisphosphonate (e.g. alendronate, ibandronate, risedronate, or zoledronic acid), OR side effect to bisphosphonate therapy that supports discontinuation, OR Patient is at very high risk of fracture by meeting at least one of the following: non-traumatic fracture while on bisphosphonate therapy, patient has experienced a recent fracture (within the past 12 months) or history of multiple fractures, patient experienced a fracture while on long-term glucocorticoid therapy, or T-score less than -3.0, or patient is at high risk for falls, or 10-year hip fracture probability of greater than 4.5% based on FRAX score, or 10-year major osteoporosis-related fracture probability greater than 30% based on FRAX score.

Glucocorticoid-induced osteoporosis: initiating or continuing long-term glucocorticoid treatment (e.g. prednisone, dexamethasone) and either has history of a non-traumatic fracture or is at high risk for fracture.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 92 EFFECTIVE 11/2025

# **DENOSUMAB (XGEVA)**

# **MEDICATION(S)**

**XGEVA** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Bone metastases from solid tumors or multiple myeloma: documentation of metastatic bone disease by scan or x-ray. Treatment of high calcium due to cancer: patient tried intravenous bisphosphonate therapy (e.g. zoledronic acid, pamidronate) within the last 30 days but did not respond well enough or had a side effect.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 93 EFFECTIVE 11/2025

# **DESONIDE 0.05% GEL (DESONATE)**

## **MEDICATION(S)**

DESONIDE 0.05 % GEL, DESRX

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# **REQUIRED MEDICAL INFORMATION**

Trial and failure or side effect to desonide 0.05% cream, lotion, or ointment

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 94 EFFECTIVE 11/2025

# **DEXAMETHASONE TABLET (HEMADY)**

## **MEDICATION(S)**

**HEMADY** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Current use of dexamethasone tablet and would like Hemady to lower pill burden.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 95 EFFECTIVE 11/2025

# **DEXTROMETHORPHAN HBR- BUPROPION HCL ER (AUVELITY)**

## MEDICATION(S)

**AUVELITY** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Treatment failure or side effect with at least two generic antidepressants (e.g., fluoxetine, bupropion, duloxetine, sertraline, venlafaxine, etc.).

# **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 96 EFFECTIVE 11/2025

# **DEXTROMETHORPHAN HBR-QUINIDINE SULFATE (NUEDEXTA)**

## **MEDICATION(S)**

**NUEDEXTA** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Pseudobulbar affect is secondary to one of the following neurologic conditions: Amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, Stroke, or traumatic brain injury.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 97 EFFECTIVE 11/2025

# **DICLOFENAC TOPICAL GEL (SOLARAZE)**

## **MEDICATION(S)**

DICLOFENAC SODIUM 3 % GEL

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Treatment failure or side effect with one preferred topical Actinic Keratosis agent (e.g. fluorouracil cream or solution, imiquimod cream) OR has a medical reason for not using all preferred topical Actinic Keratosis agents.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

90 days

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 98 EFFECTIVE 11/2025

# **DIHYDROERGOTAMINE MESYLATE (MIGRANAL NASAL SPRAY)**

## MEDICATION(S)

DIHYDROERGOTAMINE MESYLATE 4 MG/ML SOLUTION

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another triptan or ergot-type drug.

# REQUIRED MEDICAL INFORMATION

Migraine Headache: total number of doses matches the amount needed to treat the number of headache days per month, and trial of at least two preferred triptans or has a medical reason (contraindication) for not using triptans.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 99 EFFECTIVE 11/2025

# **DIMETHYL FUMARATE (TECFIDERA)**

## **MEDICATION(S)**

DIMETHYL FUMARATE, DIMETHYL FUMARATE STARTER PACK

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other disease-modifying therapies for relapsing Multiple Sclerosis.

## REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 100 EFFECTIVE 11/2025

# **DORDAVIPRONE (MODEYSO)**

## MEDICATION(S)

**MODEYSO** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 101 EFFECTIVE 11/2025

# **DOXYCYCLINE MONOHYDRATE (ORACEA)**

# **MEDICATION(S)**

**DOXYCYCLINE** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Patient has tried and failed or had a side effect to any two of the following: a topical sulfacetamide sodium product, a topical metronidazole product, topical azelaic acid, and topical ivermectin OR there is a medical reason why patient cannot use all of these drugs.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 102 EFFECTIVE 11/2025

## **DRONABINOL**

# **MEDICATION(S)**

**DRONABINOL** 

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 103 EFFECTIVE 11/2025

# **DROXIDOPA (NORTHERA)**

## **MEDICATION(S)**

**DROXIDOPA** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Orthostatic hypotension is caused by primary anatomic failure such as Parkinson's disease, multiple system neuropathy or pure autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy. For ongoing use: patient has had clinical improvement in symptoms (i.e. dizziness, lightheadedness, vision, weakness, fatigue, concentration, head/neck discomfort) or daily living activities.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Cardiologist or Neurologist

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 104 EFFECTIVE 11/2025

# **DULAGLUTIDE (TRULICITY)**

## MEDICATION(S)

**TRULICITY** 

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Being used with another GLP-1 agent

## REQUIRED MEDICAL INFORMATION

Confirmation of Type 2 diabetes

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 105 EFFECTIVE 11/2025

# **DULOXETINE (DRIZALMA SPRINKLE)**

## MEDICATION(S)

**DRIZALMA SPRINKLE** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Medical reason why patient is not able to use duloxetine delayed-release capsule.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 106 EFFECTIVE 11/2025

# **DUPILUMAB (DUPIXENT)**

# **MEDICATION(S)**

**DUPIXENT** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Asthma: Being used with another targeted immunotherapy drug. Atopic Dermatitis (AD): Being used with a JAK inhibitor or another targeted immunotherapy.

#### REQUIRED MEDICAL INFORMATION

Asthma, initial use: Treatment failure with recent use of high-dose inhaled corticosteroid along with long-acting beta agonist or leukotriene receptor antagonists, AND patient has had 1 of the following within the past year: 1 or more asthma-related ER or inpatient visits, or 2 or more asthma exacerbations that require oral corticosteroids, AND one of the following: eosinophil blood count is 150 cells/mL or more, or patient on maximally-tolerated oral corticosteroids. Atopic Dermatitis (AD) initial use: moderate to severe disease confirmed by Investigators Global Assessment (IGA) score of 3-4, Eczema Area and Severity Index (EASI) score of at least 16, Body surface area of at least 10%, or Severity Scoring of Atopic Dermatitis Index (SCORAD) score of at least 25 AND ONE of the following: patient less than 2 years of age OR treatment failure or side effect with a medium to very high potency topical corticosteroid and a topical calcineurin inhibitor (i.e., tacrolimus ointment) OR has a medical reason why these topical therapies cannot be used. Eosinophilic Esophagitis (EOE) initial use: treatment failure or side effect with a proton pump inhibitor (PPI) or inhaled fluticasone or budesonide OR has a medical reason why PPIs and inhaled fluticasone and budesonide cannot be used. Chronic rhinosinusitis with nasal polyps (CRSwNP): Treatment failure with an intranasal corticosteroid or medical reason why intranasal corticosteroids cannot be used. COPD: initial use: moderate to severe disease with an eosinophilic phenotype and ONE of the following: being used as an add-on therapy in combo with a long-acting beta agonist (LABA), long-acting muscarinic antagonist (LAMA), and inhaled corticosteroid (ICS) OR in combo with a LABA and LAMA in those who has tried and failed or had a side effect to ICS or has a medical reason why ICS cannot be used. CSU and Bullous Pemphigoid: see Other Criteria. Ongoing use for all Dx: symptoms improved and/or controlled while on Dupixent.

PAGE 107 EFFECTIVE 11/2025

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Asthma: Immunologist, Pulmonologist, or Allergist. AD: Dermatologist, Immunologist, Allergist. EoE: Allergist, Immunologist, or Gastroenterologist. CRSwNP: Allergist, Immunologist, or Otolaryngologist. Prurigo Nodularis (PN), Bullous Pemphigoid: Dermatologist. COPD. Pulmonologist. CSU: Allergist, or Immunologist

#### **COVERAGE DURATION**

Asthma, AD, EoE, CSU, BP initial use: 6 mo, ongoing use: plan year. PN: 6 mo. CRSwNP: plan year.

#### **OTHER CRITERIA**

Chronic Spontaneous Urticaria (CSU): Inadequate response or intolerance after titration up to the maximally tolerated dose of a second-generation antihistamine (up to 4 times FDA approved dose), or contraindication to second-generation antihistamines. Bullous Pemphigoid: treatment failure or side effect to ONE of the following, or contraindication to ALL of the following: High or very high potency topical steroid, Systemic corticosteroid, Tetracycline antibiotic (e.g., doxycycline, minocycline, tetracycline) AND initiated in combination with a tapering course of oral corticosteroids, unless contraindicated.

Dose and duration is not more than the FDA labeled maximum.

PAGE 108 EFFECTIVE 11/2025

# **DUVELISIB (COPIKTRA)**

## **MEDICATION(S)**

**COPIKTRA** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 109 EFFECTIVE 11/2025

# **EFLORNITHINE HYDROCHLORIDE (IWILFIN)**

### **MEDICATION(S)**

**IWILFIN** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 110 EFFECTIVE 11/2025

# **ELACESTRANT (ORSERDU)**

### **MEDICATION(S)**

**ORSERDU** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 111 EFFECTIVE 11/2025

# **ELEXACAFTOR-TEZACAFTOR-IVACAFTOR (TRIKAFTA)**

## **MEDICATION(S)**

TRIKAFTA 100-50-75 & 150 MG TAB THPK, TRIKAFTA 50-25-37.5 & 75 MG TAB THPK

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another CFTR modulator agent (e.g. Kalydeco, Symdeko, Orkambi)

## REQUIRED MEDICAL INFORMATION

Documentation that confirms there is at least one CFTR gene mutation sensitive to Trikafta.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 112 EFFECTIVE 11/2025

# **ELTROMBOPAG OLAMINE (PROMACTA)**

## **MEDICATION(S)**

**PROMACTA** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Myelodysplastic syndrome (MDS)-related thrombocytopenia, Thrombocytopenia post-hematopoietic cell transplant (HSCT)

#### **EXCLUSION CRITERIA**

Chronic immune thrombocytopenia (ITP): being used with another thrombopoietin receptor agonist (TPO-RA). MDS: being used in high-risk MDS.

## REQUIRED MEDICAL INFORMATION

Chronic Hepatitis C: on interferon-based therapy and platelet count is less than or equal to 75,000/mcl prior to therapy or falls to less than or equal to 50,000/mcl during therapy. Chronic ITP, initial: platelet count is less than 30,000/mcl, and patient had a side effect or did not respond well enough to one of the following treatments: corticosteroids, IVIG, anti-D, and splenectomy OR has a medical reason not to use (contraindication) corticosteroids, IVIG, and anti-D.

Aplastic anemia: Platelet count is less than 50,000 cells/mcl and for first-line treatment: being used with cyclosporine and antithymocyte globulin (ATG) therapy.

Thrombocytopenia due to MDS: treatment failure or side effect to at least one supported first line therapy for low risk MDS (e.g. decitabine, cyclosporine, ATG, lenalidomide) Or used in combination with ATG or by itself as initial therapy. Ongoing use: platelet count has improved since starting Promacta but is not more than 400,000 and for MDS only disease has not progressed to acute leukemia.

Thrombocytopenia post-HSCT: prolonged low platelet count (thrombocytopenia) after allogenic transplant and poor graft function.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

ITP, initial: 3 months all other conditions: 6 months Ongoing use: 6 months

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 114 EFFECTIVE 11/2025

# **ENASIDENIB MESYLATE (IDHIFA)**

# **MEDICATION(S)**

**IDHIFA** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 115 EFFECTIVE 11/2025

# **ENCORAFENIB (BRAFTOVI)**

### **MEDICATION(S)**

**BRAFTOVI** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 116 EFFECTIVE 11/2025

# **ENSARTINIB (ENSACOVE)**

## **MEDICATION(S)**

**ENSACOVE** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 117 EFFECTIVE 11/2025

# **ENTRECTINIB (ROZLYTREK)**

## **MEDICATION(S)**

**ROZLYTREK** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 118 EFFECTIVE 11/2025

# **ENZALUTAMIDE (XTANDI)**

### **MEDICATION(S)**

**XTANDI** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 119 EFFECTIVE 11/2025

# **EPOETIN ALFA-EPBX (RETACRIT)**

## **MEDICATION(S)**

**RETACRIT** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Low red blood cells (anemia) due to Myelodysplastic Syndrome (MDS), Myelofibrosis, anemia in patients with cancer who are undergoing palliative treatment.

#### **EXCLUSION CRITERIA**

N/A

#### REQUIRED MEDICAL INFORMATION

Chronic kidney disease (CKD), initial use: Hgb is less than 10g/dL. Ongoing use: Hgb level of less than or equal to 10 g/dl in adults with CKD (not on dialysis), 11g/dL in adults with CKD (on dialysis), or 12 g/dl in children with CKD (not on dialysis). Anemia due to cancer drug therapy (myelosuppressive chemotherapy): Hgb is less than 10g/dl AND one of the following: patient is on chemo or completed last dose within last 8 wks or patient has multiple myeloma (MM) on Revlimid tx. MDS or Myelofibrosis: Hgb is less than 10g/dL (symptomatic anemia), and EPO level is less than or equal to 500U/ml or for MDS: patient has isolated 5q chromosome deletion [del (5q)]. HIV: currently on zidovudine and Hgb is less than 10g/dl. Anemia prior to a planned surgery: Hgb is less than or equal to 13g/dl and patient is likely to have significant blood loss and need of blood transfusions during surgery. Anemia in cancer patients undergoing palliative treatment: Hgb is less than or equal to 10g/dL.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

CKD: 6 months. Anemia prior to planned surgery: 1 month. All other conditions: Plan year

PAGE 120 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 121 EFFECTIVE 11/2025

# **ERDAFITINIB (BALVERSA)**

### **MEDICATION(S)**

**BALVERSA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 122 EFFECTIVE 11/2025

# **ERENUMAB-AOOE (AIMOVIG)**

## **MEDICATION(S)**

**AIMOVIG** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Migraine headache prevention: 4 or more headache days per month

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 123 EFFECTIVE 11/2025

# **ERLOTINIB (TARCEVA)**

### **MEDICATION(S)**

**ERLOTINIB HCL** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 124 EFFECTIVE 11/2025

# **ETANERCEPT (ENBREL)**

### **MEDICATION(S)**

ENBREL, ENBREL MINI, ENBREL SURECLICK

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

hidradenitis suppurativa and graft vs host disease (GVHD)

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

### REQUIRED MEDICAL INFORMATION

Ankylosing spondylitis (AS): patient is not able to take NSAIDs due to history of GI bleed or ulcer OR patient has tried one RX strength NSAID in combination with a PPI and had GI side effects OR patient's condition did not respond to a trial of two different RX strength NSAIDs. Plaque Psoriasis (PsO), initial use: patient tried and failed or had a side effect to one DMARD or has a medical reason why methotrexate, cyclosporine, and acitretin cannot be used AND baseline PASI score 10 or more OR BSA 3% or more OR sensitive areas are involved OR disease affects daily living. Ongoing use: PASI or BSA improved on Enbrel.

Rheumatoid Arthritis (RA): patient has tried and failed or had a side effect to methotrexate (MTX) or has a medical reason why MTX cannot be used.

Polyarticular Juvenile Idiopathic Arthritis (pJIA): patient has tried and failed or had a side effect to one DMARD or has a medical reason why methotrexate cannot be used.

Hidradenitis suppurativa (HS): Patient has Hurley stage II or III HS and has tried and failed or had a side effect with Hadlima or has a medical reason not to use Hadlima.

GVHD: treatment failure or side effect to one drug for GVHD (i.e., systemic corticosteroids, immunosuppressants).

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

RA, PsA, pJIA, AS: Rheumatologist. PsO: Rheumatologist or Dermatologist. HS: Dermatologist

#### **COVERAGE DURATION**

PsO: initial 12 weeks, ongoing All other indications: plan year

PAGE 125 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 126 EFFECTIVE 11/2025

# **EVEROLIMUS (AFINITOR DISPERZ)**

# **MEDICATION(S)**

EVEROLIMUS 2 MG TAB SOL, EVEROLIMUS 3 MG TAB SOL, EVEROLIMUS 5 MG TAB SOL

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 127 EFFECTIVE 11/2025

# **EVEROLIMUS (AFINITOR)**

## **MEDICATION(S)**

EVEROLIMUS 10 MG TAB, EVEROLIMUS 2.5 MG TAB, EVEROLIMUS 5 MG TAB, EVEROLIMUS 7.5 MG TAB

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 128 EFFECTIVE 11/2025

# **EVOLOCUMAB (REPATHA)**

### **MEDICATION(S)**

REPATHA, REPATHA PUSHTRONEX SYSTEM, REPATHA SURECLICK

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

### REQUIRED MEDICAL INFORMATION

Primary Hyperlipidemia [including Heterozygous Familial Hypercholesterolemia (HeFH) or reduction of death due to Cardiovascular Disease (CVD)]: current LDL cholesterol (LDL-C) is at or above 70mg/dl (or at or above 55mg/dl if prescriber states extreme risk for heart disease) on lipid lowering therapy (such as statins and/or ezetimibe), and being used with a high-intensity statin like atorvastatin 40-80mg or rosuvastatin 20-40mg unless patient cannot use statins due to a medical reason (contraindication) or is intolerant to statins as defined by statin related rhabdomyolysis or has had skeletal-related muscle symptoms with the use of two different statins.

Homozygous Familial Hypercholesterolemia (HoFH): a positive genetic test for LDL-R genetic mutations OR clinical evidence that confirms HoFH, current lipid-lowering regimen has not worked well enough and being used with other lipid lowering therapies (e.g. statins, ezetimibe, LDL apheresis).

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

HoFH: Cardiologist or Endocrinologist

#### **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 130 EFFECTIVE 11/2025

# FECAL MICROBIOTA SPORES, LIVE-BRPK (VOWST)

### **MEDICATION(S)**

**VOWST** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Patient had 3 or more episodes of C.difficile infection and has completed antibiotic treatment before starting Vowst.

#### **AGE RESTRICTION**

Age consistent with FDA label

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

one course (3 days)

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 131 EFFECTIVE 11/2025

# **FEDRATINIB (INREBIC)**

### MEDICATION(S)

**INREBIC** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another agent that treats myelofibrosis.

## REQUIRED MEDICAL INFORMATION

Myelofibrosis: platelet count of at least 50,000 cells/mcl

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 132 EFFECTIVE 11/2025

# **FENFLURAMINE (FINTEPLA)**

## MEDICATION(S)

**FINTEPLA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Dravet Syndrome: Trial and failure of valproic acid, divalproex, or clobazam. Lennox-Gastaut syndrome: trial and failure or side effect to two of the following anti-seizure drugs: clonazepam, felbamate, lamotrigine, and topiramate or there is a medical reason why all these other drugs cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 133 EFFECTIVE 11/2025

# **FEZOLINETANT (VEOZAH)**

## **MEDICATION(S)**

**VEOZAH** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Moderate to severe vasomotor symptoms (e.g. hot flashes, night sweats): trial and failure of one non-hormonal therapy (e.g. venlafaxine, desvenlafaxine, paroxetine, citalopram, escitalopram, and gabapentin) AND one hormone therapy (e.g. estrogen) unless not appropriate (e.g., contraindicated).

#### **AGE RESTRICTION**

Age consistent with FDA label

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 134 EFFECTIVE 11/2025

# FIDAXOMICIN (DIFICID)

# **MEDICATION(S)**

DIFICID, FIDAXOMICIN

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Clostridium difficle: evidence of current infection AND trial of oral vancomycin or has a medical reason why oral vancomycin cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

10 days

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 135 EFFECTIVE 11/2025

# **FILGRASTIM-AAFI (NIVESTYM)**

## **MEDICATION(S)**

**NIVESTYM** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

HIV/AIDS patients on myelosuppressive therapy, drug-induced neutropenia, Myelodysplastic syndrome (MDS), agranulocytosis, febrile neutropenia, Neutropenia due to radiation

#### **EXCLUSION CRITERIA**

chemo-induced febrile neutropenia: Being used along with another G-CSF (granulocyte colony stimulating factor) drug.

## **REQUIRED MEDICAL INFORMATION**

Agranulocytosis, neutropenia (congenital, cyclic, or idiopathic): neutropenia is recurring or does not go away and ONE of the following: history of recurring infections (e.g. multiple episodes of infections requiring antibiotics) or patient had one hospitalization for an infection within the past year. Febrile neutropenia, neutropenia due to HIV/AIDs, or neutropenia caused by drugs other than cancer drugs: absolute neutrophil count (ANC) is less than 800/mm3 or ANC is less than 1000/mm3 with neutropenia expected to last more than 5 days AND for febrile neutropenia: patient has not used pegfilgrastim (e.g. Udenyca, Nyvepria) in the past 14 days. MDS: ONE of the following: ANC is less than 800/mm3, or ANC is less than 1000/mm3 with neutropenia expected to last more than 5 days, or being used with an erythropoiesis-stimulating agent to improve symptoms of anemia and all of the following: Hgb less than 10 and EPO level less than or equal to 500 mU/mL.

#### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

see other criteria

PAGE 136 EFFECTIVE 11/2025

#### **OTHER CRITERIA**

Excluded under Part D if covered by Part B. Dose and duration is not more than the FDA labeled maximum.

Coverage duration: Febrile neutropenia: 2 months. Peripheral blood cell collection: 3 months. Congenital, cyclic, idiopathic neutropenia, agranulocytosis, MDS: plan year. Neutropenia due to cancer drug therapy and AML: duration of cancer drug therapy. Neutropenia due to radiation: duration of radiation therapy. Drug induced neutropenia, HIV/AIDs neutropenia: duration of drug therapy. Bone Marrow Transplantation: 6 months.

PAGE 137 EFFECTIVE 11/2025

# FILGRASTIM-SNDZ (ZARXIO)

## **MEDICATION(S)**

ZARXIO

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Agranulocytosis, Febrile neutropenia, Drug-Induced neutropenia, Myelodysplastic Syndrome (MDS), AIDS - neutropenia

#### **EXCLUSION CRITERIA**

Being used to treat low white bloods called neutrophils (neutropenia) due to autoimmune disorders, burn victims, or chronic infections.

## **REQUIRED MEDICAL INFORMATION**

Agranulocytosis, congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia: neutropenia is recurring or does not go away and there is a history of recurring infections (e.g. multiple episodes of infections requiring antibiotics) or at least one hospitalization for an infection within the past year.

Febrile neutropenia, neutropenia due to HIV/AIDs, or neutropenia caused by drugs other than cancer drugs: no use of pegfilgrastim within the past 14 days and absolute neutrophil count (ANC) is less than 800/mm3 or ANC is less than 1000/mm3 with neutropenia expected to last more than 5 days.

Neutropenia due to cancer drug therapy: not being used with pegfilgrastim.

Neutropenia due to radiation therapy: not being used with pegfilgrastim.

Acute myeloid leukemia (AML): being used to prevent or reduce neutropenia due to use of cancer drug therapy.

MDS: Hgb less than 10 gm/dL AND EPO level less than or equal to 500 mU/mL AND One of the following: ANC is less than 800/mm3 or ANC is less than 1000/mm3 with neutropenia expected to last more than 5 days or being used with epoetin (e.g. Retacrit) to improve symptoms of low red blood cells (anemia).

PAGE 138 EFFECTIVE 11/2025

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Febrile neutropenia, peripheral blood cell collection: 2 mos. HIV: plan year. (see other criteria)

#### **OTHER CRITERIA**

Excluded under Part D if covered by Part B. Dose and duration is not more than the FDA labeled maximum.

Coverage duration:

Congenital, cyclic, idiopathic neutropenia and agranulocytosis: plan year. Neutropenia due to cancer drug therapy and AML: duration of cancer drug therapy.

Neutropenia due to radiation: duration of radiation therapy.

MDS: 3 months.

PAGE 139 EFFECTIVE 11/2025

# **FINERENONE (KERENDIA)**

## MEDICATION(S)

**KERENDIA** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Treatment failure or side effect to Farxiga or there is a medical reason why Farxiga cannot be used.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 140 EFFECTIVE 11/2025

# FINGOLIMOD HCL (GILENYA)

# **MEDICATION(S)**

FINGOLIMOD HCL

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Being used with other disease-modifying therapies for relapsing Multiple Sclerosis.

# **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan Year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 141 EFFECTIVE 11/2025

# FLURANDRENOLIDE LOTION, OINTMENT (CORDRAN, NOLIX)

### **MEDICATION(S)**

FLURANDRENOLIDE 0.05 % LOTION, FLURANDRENOLIDE 0.05 % OINTMENT, NOLIX 0.05 % LOTION

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Treatment failure or side effect to two generically available topical corticosteroids in the same or higher potency class.

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 142 EFFECTIVE 11/2025

# FRUQUINTINIB (FRUZAQLA)

## **MEDICATION(S)**

FRUZAQLA

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 143 EFFECTIVE 11/2025

# **FUTIBATINIB (LYTGOBI)**

### **MEDICATION(S)**

LYTGOBI (12 MG DAILY DOSE), LYTGOBI (16 MG DAILY DOSE), LYTGOBI (20 MG DAILY DOSE)

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 144 EFFECTIVE 11/2025

## **GANAXOLONE SUSPENSION (ZTALMY)**

#### **MEDICATION(S)**

**ZTALMY** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

A genetic test confirms CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Neurologist

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 145 EFFECTIVE 11/2025

## **GEFITINIB (IRESSA)**

#### **MEDICATION(S)**

**GEFITINIB** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 146 EFFECTIVE 11/2025

## **GILTERITINIB FUMARATE (XOSPATA)**

#### **MEDICATION(S)**

**XOSPATA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 147 EFFECTIVE 11/2025

# **GLASDEGIB MALEATE (DAURISMO)**

#### **MEDICATION(S)**

**DAURISMO** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 148 EFFECTIVE 11/2025

## **GLATIRAMER ACETATE (COPAXONE, GLATOPA)**

## MEDICATION(S)

GLATIRAMER ACETATE, GLATOPA

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other disease-modifying therapies for relapsing Multiple Sclerosis.

## REQUIRED MEDICAL INFORMATION

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 149 EFFECTIVE 11/2025

## **GLECAPREVIR-PIBRENTASVIR (MAVYRET)**

## **MEDICATION(S)**

**MAVYRET** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current AASLD/IDSA guidelines.

## REQUIRED MEDICAL INFORMATION

Required medical information will be aligned with current AASLD/IDSA guidelines.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Hepatologist, Gastroenterologist, or Infectious Disease.

#### **COVERAGE DURATION**

Length of therapy will be based on current AASLD/IDSA guidelines and FDA labeling.

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 150 EFFECTIVE 11/2025

# **GLUTAMINE (ENDARI)**

## **MEDICATION(S)**

L-GLUTAMINE 5 GM PACKET

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Treatment failure or side effect with hydroxyurea OR medical reason for not using hydroxyurea.

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 151 EFFECTIVE 11/2025

## **GLYCOPYRROLATE ORAL SOLUTION (CUVPOSA)**

## **MEDICATION(S)**

GLYCOPYRROLATE 1 MG/5ML SOLUTION

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 152 EFFECTIVE 11/2025

#### **HIGH RISK MEDICATION**

#### **MEDICATION(S)**

AMITRIPTYLINE HCL, CLOMIPRAMINE HCL, CYPROHEPTADINE HCL 4 MG TAB, DICYCLOMINE HCL 10 MG CAP, DICYCLOMINE HCL 10 MG/5ML SOLUTION, DICYCLOMINE HCL 20 MG TAB, DOXEPIN HCL 10 MG CAP, DOXEPIN HCL 10 MG/ML CONC, DOXEPIN HCL 100 MG CAP, DOXEPIN HCL 150 MG CAP, DOXEPIN HCL 50 MG CAP, DOXEPIN HCL 50 MG CAP, DOXEPIN HCL 75 MG CAP, HYDROXYZINE HCL 10 MG TAB, HYDROXYZINE HCL 10 MG/5ML SYRUP, HYDROXYZINE HCL 25 MG TAB, HYDROXYZINE HCL 50 MG TAB, HYDROXYZINE PAMOATE, IMIPRAMINE HCL, PERPHENAZINE-AMITRIPTYLINE, PHENOBARBITAL, PROMETHAZINE HCL 12.5 MG SUPPOS, PROMETHAZINE HCL 12.5 MG TAB, PROMETHAZINE HCL 25 MG SUPPOS, PROMETHAZINE HCL 25 MG TAB, PROMETHAZINE HCL 25 MG SUPPOS, PROMETHAZINE HCL 25 MG TAB, PROMETHAZINE HCL 50 MG TAB, PROMETHAZINE HCL 6.25 MG/5ML SOLUTION, PROMETHAZINE VC, PROMETHAZINE VC/CODEINE, PROMETHAZINE-CODEINE, PROMETHAZINE-DM, PROMETHAZINE-PHENYLEPH-CODEINE, PROMETHAZINE-PHENYLEPHRINE, PROMETHEGAN 12.5 MG SUPPOS, PROMETHEGAN 25 MG SUPPOS, THIORIDAZINE HCL, TRIMIPRAMINE MALEATE

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

#### REQUIRED MEDICAL INFORMATION

Prescriber confirms the benefits of the drug outweigh any risks and will monitor for side effects.

#### **AGE RESTRICTION**

65 years and older. No prior authorization required for less than 65 years old.

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan Year

PAGE 153 EFFECTIVE 11/2025

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 154 EFFECTIVE 11/2025

## **IBRUTINIB (IMBRUVICA)**

#### **MEDICATION(S)**

IMBRUVICA 140 MG CAP, IMBRUVICA 280 MG TAB, IMBRUVICA 420 MG TAB, IMBRUVICA 70 MG CAP, IMBRUVICA 70 MG/ML SUSPENSION

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## REQUIRED MEDICAL INFORMATION

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 155 EFFECTIVE 11/2025

## **ICATIBANT (FIRAZYR)**

## MEDICATION(S)

ICATIBANT ACETATE, SAJAZIR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 156 EFFECTIVE 11/2025

## **IDELALISIB (ZYDELIG)**

#### **MEDICATION(S)**

**ZYDELIG** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 157 EFFECTIVE 11/2025

## **ILOPERIDONE (FANAPT)**

#### **MEDICATION(S)**

FANAPT, FANAPT TITRATION PACK A, FANAPT TITRATION PACK B, FANAPT TITRATION PACK C

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Trial and failure or side effect to one generic atypical antipsychotic drug (e.g. aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) or there is a medical reason why all the generic atypical antipsychotics cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 158 EFFECTIVE 11/2025

## **IMATINIB MESYLATE (GLEEVEC)**

## **MEDICATION(S)**

**IMATINIB MESYLATE** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Hypereosinophilic syndrome (HES): Allergist, Immunologist, or Hematologist.

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 159 EFFECTIVE 11/2025

## **IMATINIB ORAL SOLUTION (IMKELDI)**

## MEDICATION(S)

**IMKELDI** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

Medical reason why imatinib tablet cannot be used.

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 160 EFFECTIVE 11/2025

## **IMMUNE GLOBULIN (GAMUNEX-C)**

## **MEDICATION(S)**

**GAMUNEX-C** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Autoimmune mucocutaneous blistering disease (AMBD), Guillian-Barre syndrome, Bone marrow transplant, Autoimmune Hemolytic anemia, Multiple myeloma, Polymyositis and dermatomyositis, Solid organ transplants, Bone marrow transplants, Hemopoietic stem cell transplant, Small lymphocytic leukemia, Multifocal Motor Neuropathy (MMN), Myasthenia Gravis (MG)

#### **EXCLUSION CRITERIA**

AMBD: being used with another immunomodulator

#### REQUIRED MEDICAL INFORMATION

Primary Immunodeficiency Disorder (PIDD), SQ and IV administration: current IgG is less than 200mg/dL or ALL of the following: history of recurrent bacterial infections, and failure to respond to antigenic challenge test with diphtheria and tetanus toxoids or pneumococcal polysaccharide vaccine, and history of IgG less than 500mg/dL documented on two occasions or diagnosed by an allergist or immunologist.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Acquired Demyelinating Polyneuropathy, or pure sensory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): IV administration, diagnosis confirmed by electrodiagnostic criteria and two of the following criteria: motor or sensory dysfunction in more than one limb lasting at least 2 months, no reflexes (areflexia), nerve biopsy shows evidence of demyelination and remyelination, or CSF cell count is less than 10cells/mm3 (if HIV positive then CSF count less than 50cells/mm-3).

Primary immune thrombocytopenia (ITP): IV administration, platelet count is less than 30,000cells/mm3. For ongoing use: continued thrombocytopenia with prior response to IVIG or is scheduled for surgery or invasive procedure.

Myasthenia Gravis (MG): IV administration, treatment failure, side effect, or medical reason for not using one of the following: a corticosteroid, mycophenolate, azathioprine, cyclosporine, or cyclophosphamide.

Multifocal Motor Neuropathy (MMN): IV administration and condition confirmed with nerve conduction studies (electrodiagnostic testing).

PAGE 161 EFFECTIVE 11/2025

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

CIDP, MMN, MG: Neurologist

#### **COVERAGE DURATION**

MG: 3 months ITP: 6 months GBS: 5 days all other conditions: plan year

#### **OTHER CRITERIA**

AMBD (pemphigus, epidermolysis bullosa acquisita): IV administration, condition is confirmed by testing the sore or blister (lesional tissue biopsy or serology)and did not respond to trial of an immunosuppressant drug (e.g. azathioprine, cyclophosphamide) and an oral or IV corticosteroid (e.g. prednisone) or has a medical reason not to use these types of drugs. Autoimmune hemolytic anemia, Polymyositis, or Dermatomyositis: IV administration, trial and failure of high dose corticosteroids.

Bone marrow transplant or HSCT: IV administration, being used to prevent bacterial infections and one of the following: within 100 days post-transplant, immunoglobulin G (IgG) level is less than 400 mg/dl, IgG is below normal and chronic graft vs host disease (GVHD) on steroids or GVHD with lung infection, or has cytomegalovirus (CMV).

Chronic lymphocytic leukemia/small lymphocytic leukemia: history of hypogammaglobulinemia (IgG below 500 mg/dl) or recurrent bacterial infections. Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 162 EFFECTIVE 11/2025

## **IMMUNE GLOBULIN SQ (HIZENTRA)**

## **MEDICATION(S)**

**HIZENTRA** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

#### REQUIRED MEDICAL INFORMATION

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Acquired Demyelinating Polyneuropathy, or pure sensory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): diagnosis confirmed by electrodiagnostic criteria (nerve conduction studies), and patient has been started on IVIG and is switching to Hizentra for ongoing therapy.

Primary Immunodeficiency Disorder (PIDD): current IgG is less than 200mg/dL or ALL of the following: history of recurrent bacterial infections, and failure to respond to antigenic challenge test with diphtheria and tetanus toxoids or pneumococcal polysaccharide vaccine, and history of IgG less than 500mg/dL documented on two occasions or diagnosed by an allergist or immunologist.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

CIDP, Multifocal acquired Demyelinating Polyneuropathy, or pure sensory CIDP: Neurologist

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 163 EFFECTIVE 11/2025

## **INAVOLISIB (ITOVEBI)**

#### **MEDICATION(S)**

**ITOVEBI** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 164 EFFECTIVE 11/2025

# **INTERFERON BETA-1B (BETASERON)**

#### **MEDICATION(S)**

**BETASERON** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Being used with other disease-modifying therapies for relapsing Multiple Sclerosis.

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 165 EFFECTIVE 11/2025

## **INTERFERON GAMMA-1B (ACTIMMUNE)**

## **MEDICATION(S)**

**ACTIMMUNE** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 166 EFFECTIVE 11/2025

## **ITRACONAZOLE ORAL SOLUTION (SPORANOX)**

#### **MEDICATION(S)**

ITRACONAZOLE 10 MG/ML SOLUTION

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Systemic infections due to sporotrichosis (cutaneous, lymphonodular, osteoarticular, pulmonary, disseminated, or meningeal), coccidiomycosis, cryptococcosis, tinea corporis, cruris, pedis, manuum, capitis, versicolor, and unguium (onychomycosis), allergic bronchopulmonary aspergillosis (ABPA). Prophylaxis (primary or secondary) or maintenance treatment of talaromycosis (Talaromyces marneffei). treatment of pulmonary aspergillosis, chronic (cavitary or necrotizing). Prophylaxis of aspergillosis and histoplasmosis.

#### **EXCLUSION CRITERIA**

N/A

#### REQUIRED MEDICAL INFORMATION

Blastomycosis, Histoplasmosis, Sporotrichosis, Cryptococcosis, or Aspergillosis infection: culture confirms infection. Tinea Capitas: patient has tried or has a medical reason for not using oral terbinafine. Tinea Corporus, Curis, Pedis or Manuum: patient has tried or has a medical reason for not using topical antifungal or oral terbinafine. Tinea Versicolor: patient has tried or has a medical reason for not using topical ketoconazole or oral fluconazole. Onychomycosis: patient has tried or has a medical reason for not using oral terbinafine. Coccidioidomycosis culture confirms infection, and patient has tried or has a medical reason for not using fluconazole. Aspergillosis or Histoplasmosis prevention: patient is immunosuppressed/compromised. Prophylaxis (primary or secondary) or maintenance treatment of talaromycosis (Talaromyces marneffei): Patient with HIV infection.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

PAGE 167 EFFECTIVE 11/2025

## **COVERAGE DURATION**

T. Vesicolor: 1wk T. Capitas: 8wks Onyc: 3mo Other Tinea: 1mo ABPA: 4mo All other dx: plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 168 EFFECTIVE 11/2025

## **IVABRADINE (CORLANOR)**

## **MEDICATION(S)**

CORLANOR 5 MG/5ML SOLUTION, IVABRADINE HCL

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Left heart ventricular ejection fraction (LVEF) less than or equal to 35%, patient is in sinus rhythm with resting heart rate of at least 70 beats per minute, and patient is on the highest tolerated dose of guideline supported therapies including a renin-angiotensin inhibitor drug (e.g. ACE-Inhibitor, ARB agent, Entresto) and beta-blocker drug (e.g. bisoprolol, carvedilol, metoprolol succinate) unless there is a medical reason for not using (contraindication) the supported therapies. Pediatric patients: CHF is due to dilated cardiomyopathy.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 169 EFFECTIVE 11/2025

## **IVACAFTOR (KALYDECO)**

#### MEDICATION(S)

**KALYDECO** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another CFTR modulator agent (i.e., Orkambi, Symdeko, Trikafta)

## REQUIRED MEDICAL INFORMATION

Documentation that confirms there is at least one CFTR gene mutation sensitive to Kalydeco.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 170 EFFECTIVE 11/2025

## **IVOSIDENIB (TIBSOVO)**

#### **MEDICATION(S)**

**TIBSOVO** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 171 EFFECTIVE 11/2025

# **IXAZOMIB CITRATE (NINLARO)**

#### **MEDICATION(S)**

**NINLARO** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 172 EFFECTIVE 11/2025

## **LAPATINIB DITOSYLATE (TYKERB)**

## **MEDICATION(S)**

LAPATINIB DITOSYLATE

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 173 EFFECTIVE 11/2025

# LAROTRECTINIB SULFATE (VITRAKVI)

#### **MEDICATION(S)**

**VITRAKVI** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 174 EFFECTIVE 11/2025

## LAZERTINIB (LAZCLUZE)

#### **MEDICATION(S)**

LAZCLUZE

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 175 EFFECTIVE 11/2025

## **LENALIDOMIDE (REVLIMID)**

## **MEDICATION(S)**

LENALIDOMIDE, REVLIMID

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

MDS: transfusion dependent or hemoglobin less than 10 g/dL confirming anemia associated disease.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 176 EFFECTIVE 11/2025

## **LENVATINIB (LENVIMA)**

#### MEDICATION(S)

LENVIMA (10 MG DAILY DOSE), LENVIMA (12 MG DAILY DOSE), LENVIMA (14 MG DAILY DOSE), LENVIMA (18 MG DAILY DOSE), LENVIMA (20 MG DAILY DOSE), LENVIMA (24 MG DAILY DOSE), LENVIMA (4 MG DAILY DOSE)

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

#### REQUIRED MEDICAL INFORMATION

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 177 EFFECTIVE 11/2025

# **LEVALBUTEROL SOLUTION (XOPENEX)**

## **MEDICATION(S)**

LEVALBUTEROL HCL

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Patient has had a side effect with albuterol nebulized solution (not MDI or oral syrup) that is not seen with the use of levalbuterol.

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 178 EFFECTIVE 11/2025

# **LEVETIRACETAM (SPRITAM)**

#### **MEDICATION(S)**

**SPRITAM** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Medical reason why patient is not able to use generic levetiracetam oral solution and tablet.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 179 EFFECTIVE 11/2025

# **LEVOMILNACIPRAN HCL (FETZIMA)**

## **MEDICATION(S)**

FETZIMA, FETZIMA TITRATION

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Treatment failure or side effect with at least two generic antidepressants (e.g., fluoxetine, bupropion, duloxetine, sertraline, venlafaxine, etc.).

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 180 EFFECTIVE 11/2025

# **LIDOCAINE PATCH (LIDODERM)**

# **MEDICATION(S)**

LIDOCAINE 5 % PATCH, LIDOCAN

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 181 EFFECTIVE 11/2025

# **LINEZOLID ORAL (ZYVOX)**

# **MEDICATION(S)**

LINEZOLID 100 MG/5ML RECON SUSP, LINEZOLID 600 MG TAB

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

VRE, MRSA, or VISA skin or soft tissue infection confirmed by culture and sensitivity (C&S): treatment failure or side effect with one oral drug noted on the C&S to work on the bacteria causing the infection or recommended by an Infectious Disease (ID) specialist. MSSA skin or soft tissue infection: recommended by an ID specialist and treatment failure or side effect with two preferred oral drugs noted on the C&S to work on the bacteria causing the infection or medical reason why the preferred drugs cannot be used. Empiric therapy for suspected MRSA infection: prescribed or recommended by an ID specialist OR trial of one oral antibiotic supported for MRSA including clindamycin, doxycycline, or minocycline, and double strength trimethoprim/sulfamethoxazole, OR medical reason why all oral antibiotics supported for MRSA empiric therapy cannot be used. Infection of the bone or joint OR infective endocarditis: culture and sensitivity report confirm VRE, MRSA, or VISA/VRSA and prescribed or recommended by ID specialist. Multidrug-resistant tuberculosis infection (MDR-TB): being used with pretomanid and bedaguiline.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

VRE 28 days. Osteo 42 days. Endocarditis 56 days. MDR-TB 26 wks. Empiric tx/pneumonia/SSTI 14days.

PAGE 182 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 183 EFFECTIVE 11/2025

# LONG-ACTING NARCOTIC DRUGS (NARCOTIC SAFETY INITIATIVE)

# MEDICATION(S)

FENTANYL 100 MCG/HR PATCH 72HR, FENTANYL 12 MCG/HR PATCH 72HR, FENTANYL 25 MCG/HR PATCH 72HR, FENTANYL 50 MCG/HR PATCH 72HR, FENTANYL 75 MCG/HR PATCH 72HR, HYDROMORPHONE HCL ER, METHADONE HCL 10 MG TAB, METHADONE HCL 10 MG/5ML SOLUTION, METHADONE HCL 10 MG/ML CONC, METHADONE HCL 10 MG/ML SOLUTION, METHADONE HCL 5 MG TAB, METHADONE HCL 5 MG/5ML SOLUTION, METHADONE HCL INTENSOL, OXYMORPHONE HCL ER

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other long-acting narcotic drugs.

# **REQUIRED MEDICAL INFORMATION**

Cancer pain: dose has been consolidated to the least number of higher strength forms. Non-cancer pain, initial: cause of pain cannot be removed or treated with other treatment options, and pain occurs daily and has lasted for at least 3 months, and pain is severe enough to need daily around-the-clock long-term narcotic use, and total daily dose across all narcotic drugs is less than 90 MME, and dose has been consolidated to the least number of higher strength forms and trial of at least one short-acting and morphine sulfate ER tablet (MS Contin), and chart notes document pain history including baseline pain intensity score and functional interference score and a plan for monitoring side effects and misuse and to taper down narcotics exists. Non-cancer pain, reauth: total daily dose across all narcotic drugs is less than 90 MME per day, and dose has been consolidated to the least number of higher strength forms, and chart notes document current pain intensity score, functional interference score, any side effects and/or misuse with current pain treatment regimen, and plan to taper narcotic use.

# **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Cancer pain: Oncologist or Pain Specialist.

PAGE 184 EFFECTIVE 11/2025

# **COVERAGE DURATION**

Cancer pain: plan year

Non-cancer pain: initial 30 days, 1st reauth 3mos, ongoing reauths plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 185 EFFECTIVE 11/2025

# **LORLATINIB (LORBRENA)**

# **MEDICATION(S)**

**LORBRENA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 186 EFFECTIVE 11/2025

# **LOTILANER (XDEMVY)**

# **MEDICATION(S)**

**XDEMVY** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

# **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

Ophthalmologist or Optometrist

## **COVERAGE DURATION**

6 weeks

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 187 EFFECTIVE 11/2025

# **LUMATEPERONE (CAPLYTA)**

# **MEDICATION(S)**

**CAPLYTA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to one generic atypical antipsychotic drug (e.g. aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) or there is a medical reason why all the generic atypical antipsychotics cannot be used.

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 188 EFFECTIVE 11/2025

# **MACITENTAN (OPSUMIT)**

# **MEDICATION(S)**

**OPSUMIT** 

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Confirmation of Pulmonary Arterial Hypertension (WHO Group I) by right heart catheterization test.

# **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 189 EFFECTIVE 11/2025

# **MARIBAVIR (LIVTENCITY)**

# **MEDICATION(S)**

LIVTENCITY

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with ganciclovir or valganciclovir

# REQUIRED MEDICAL INFORMATION

CMV (cytomegalovirus) treatment: undergone a solid organ transplant or hematopoietic stem cell transplant (HSCT) AND treatment failure with one of the following: ganciclovir, valganciclovir, cidofovir, or foscarnet.

## **AGE RESTRICTION**

12 years of age or older

# PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 190 EFFECTIVE 11/2025

# **MECASERMIN (INCRELEX)**

# **MEDICATION(S)**

**INCRELEX** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Severe primary IGF-1 deficiency: being used with growth hormone therapy.

# REQUIRED MEDICAL INFORMATION

Initial use: height is at or more than 3.0 standard deviations below standard range for sex and age, and basal IGF-1 is at or more than 3.0 standard deviations below standard range for sex and age, and evidence of delayed bone age, and for severe IGF-1 deficiency growth hormone level is normal or higher for sex and age. Ongoing use: response to therapy and evidence of delayed bone age.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Endocrinologist

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 191 EFFECTIVE 11/2025

# **MECHLORETHAMINE (VALCHLOR)**

# **MEDICATION(S)**

**VALCHLOR** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

# **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 192 EFFECTIVE 11/2025

# **MEGESTROL ACETATE (MEGACE)**

# **MEDICATION(S)**

MEGESTROL ACETATE 20 MG TAB, MEGESTROL ACETATE 40 MG TAB, MEGESTROL ACETATE 40 MG/ML SUSPENSION, MEGESTROL ACETATE 400 MG/10ML SUSPENSION, MEGESTROL ACETATE 800 MG/20ML SUSPENSION

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 193 EFFECTIVE 11/2025

# **MEGESTROL ACETATE ES (MEGACE ES)**

# **MEDICATION(S)**

MEGESTROL ACETATE 625 MG/5ML SUSPENSION

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Patient has tried megestrol acetate 200mg/5ml oral suspension.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 194 EFFECTIVE 11/2025

# **MERCAPTOPURINE MONOHYDRATE (PURIXAN)**

# **MEDICATION(S)**

MERCAPTOPURINE 2000 MG/100ML SUSPENSION

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Medical reason why patient cannot use mercaptopurine tablet.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 195 EFFECTIVE 11/2025

# **METHOTREXATE ORAL SOLUTION (XATMEP)**

# **MEDICATION(S)**

**XATMEP** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Medical reason why patient cannot take tablet form of methotrexate.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 196 EFFECTIVE 11/2025

# **METHYLTESTOSTERONE (ANDROID, TESTRED)**

# **MEDICATION(S)**

**METHYLTESTOSTERONE** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 197 EFFECTIVE 11/2025

# **METOCLOPRAMIDE ODT (METOZOLV ODT)**

# **MEDICATION(S)**

METOCLOPRAMIDE HCL 5 MG TAB DISP

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Medical condition that prevents swallowing a tablet.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 198 EFFECTIVE 11/2025

# **MIDOSTAURIN (RYDAPT)**

# **MEDICATION(S)**

**RYDAPT** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 199 EFFECTIVE 11/2025

# **MIFEPRISTONE (KORLYM)**

# MEDICATION(S)

MIFEPRISTONE 300 MG TAB

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 200 EFFECTIVE 11/2025

# **MIRDAMETINIB (GOMEKLI)**

# **MEDICATION(S)**

**GOMEKLI** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 201 EFFECTIVE 11/2025

# **MODAFINIL (PROVIGIL)**

# MEDICATION(S)

**MODAFINIL** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Narcolepsy: sleep study (polysomnography) confirms narcolepsy.

Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS): sleep study (polysomnography) confirms OSAHS.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 202 EFFECTIVE 11/2025

# MOMELOTINIB DIHYDROCHLORIDE (OJJAARA)

# MEDICATION(S)

OJJAARA

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

Myelofibrosis (MF): Not being used with another agent for myelofibrosis.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 203 EFFECTIVE 11/2025

# **NERATINIB (NERLYNX)**

# **MEDICATION(S)**

**NERLYNX** 

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 204 EFFECTIVE 11/2025

# **NILOTINIB (TASIGNA)**

# MEDICATION(S)

**TASIGNA** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 205 EFFECTIVE 11/2025

# **NINTEDANIB ESYLATE (OFEV)**

# **MEDICATION(S)**

**OFEV** 

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

# **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 206 EFFECTIVE 11/2025

# **NIRAPARIB TOSYLATE (ZEJULA)**

# **MEDICATION(S)**

ZEJULA 100 MG TAB, ZEJULA 200 MG TAB, ZEJULA 300 MG TAB

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 207 EFFECTIVE 11/2025

# **NIRAPARIB-ABIRATERONE (AKEEGA)**

# **MEDICATION(S)**

**AKEEGA** 

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 208 EFFECTIVE 11/2025

# **NIROGACESTAT HYDROBROMIDE (OGSIVEO)**

# **MEDICATION(S)**

**OGSIVEO** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 209 EFFECTIVE 11/2025

# **NITAZOXANIDE (ALINIA)**

# **MEDICATION(S)**

ALINIA 100 MG/5ML RECON SUSP, NITAZOXANIDE

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Cryptosporidiosis in HIV+ patients, Clostridium difficile colitis, viral gastroenteritis, amebiasis (Entamoeba histolytica), liver fluke infection (Fasciola hepatica), Cestode (tapeworm)

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

All medically accepted conditions: stool culture results confirm diagnosis.

Giardiasis: treatment failure or side effect with metronidazole OR medical reason for not using metronidazole (contraindication).

Clostridium difficle colitis: treatment failure or side effect with vancomycin OR medical reason for not using vancomycin (contraindication).

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

One course (see other criteria)

PAGE 210 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Giardiasis: 3 days.

Cryptosporidiosis: 3 days unless HIV+ then 14 days.

Clostridium difficle colitis: 10 days.

viral gastroenteritis: 3 days amebiasis (Entamoeba histolytica): 3 days.

liver fluke infection (Fasciola hepatica): 7 days.

Cestode (tapeworm): 3 days.

Dose and duration is not more than the FDA labeled maximum.

PAGE 211 EFFECTIVE 11/2025

# **NITISINONE (ORFADIN)**

# MEDICATION(S)

NITISINONE 10 MG CAP, NITISINONE 2 MG CAP, NITISINONE 5 MG CAP

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan Year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 212 EFFECTIVE 11/2025

# NON-PREFERRED DOXYCYCLINE PRODUCTS

# **MEDICATION(S)**

DOXYCYCLINE HYCLATE 100 MG TAB DR, DOXYCYCLINE HYCLATE 150 MG TAB, DOXYCYCLINE HYCLATE 150 MG TAB DR, DOXYCYCLINE HYCLATE 200 MG TAB DR, DOXYCYCLINE HYCLATE 75 MG TAB, DOXYCYCLINE HYCLATE 75 MG TAB DR

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Side effect with preferred doxycycline that does not occur with the use of the non-preferred doxycycline product.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 213 EFFECTIVE 11/2025

#### NON-PREFERRED HYDROCODONE-ACETAMINOPHEN PRODUCTS

# **MEDICATION(S)**

HYDROCODONE-ACETAMINOPHEN 10-300 MG TAB, HYDROCODONE-ACETAMINOPHEN 5-300 MG TAB, HYDROCODONE-ACETAMINOPHEN 7.5-300 MG TAB

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other short-acting opioid narcotics.

#### REQUIRED MEDICAL INFORMATION

Moderate to severe pain, initial use: side effect to the preferred hydrocodone-acetaminophen product that would not occur with the non-preferred hydrocodone-acetaminophen product and total dose across all narcotics is not more than 90 MME/day or if more than 90 MME/day the prescriber states the total dose is medically necessary to treat the pain. Ongoing use (more than 90 days of narcotic therapy): evaluation by pain specialist, and a patient-specific treatment plan exists for evaluating ongoing need for narcotic pain relief, monitoring side effects and misuse and to taper down narcotics, AND total dose across all narcotics is not more than 90 MME/day or if more than 90 MME/day the prescriber states the total dose is medically necessary to treat the pain.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

30 days

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **OCTREOTIDE ACETATE (SANDOSTATIN)**

# **MEDICATION(S)**

OCTREOTIDE ACETATE 100 MCG/ML SOLN PRSYR, OCTREOTIDE ACETATE 100 MCG/ML SOLUTION, OCTREOTIDE ACETATE 1000 MCG/ML SOLUTION, OCTREOTIDE ACETATE 200 MCG/ML SOLUTION, OCTREOTIDE ACETATE 50 MCG/ML SOLN PRSYR, OCTREOTIDE ACETATE 50 MCG/ML SOLN PRSYR, OCTREOTIDE ACETATE 500 MCG/ML SOLN PRSYR, OCTREOTIDE ACETATE 500 MCG/ML SOLUTION

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

AIDS-associated diarrhea, Bleeding esophageal varices, Chemotherapy-induced diarrhea, Cryptosporidiosis, Dumping syndrome, Neuroendocrine Tumor of the GI tract, lung, or thymus, Lymphorrhagia, Pancreatitis, necrotizing Pituitary adenoma, Prevention of postoperative complications of pancreatic surgery, Pancreatic tumors (gastrinoma, glucagonoma, insulinoma), paraganglioma, pheochromocytoma, Polycystic Ovary Syndrome (PCOS), Radiation-induced diarrhea, Thymoma, Zollinger-Ellison syndrome.

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Diarrhea due to HIV: patient has been on anti-retroviral therapy (ART) for at least one month, and prescriber states other causes (i.e. infection, underlying GI disease, malabsorption) have been ruled out, and patient has tried diphenoxylate/atropine or loperamide.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Acromegaly: Endocrinologist

#### **COVERAGE DURATION**

Acromegaly: plan year, Other conditions: 6 months

PAGE 215 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 216 EFFECTIVE 11/2025

# **OLANZAPINE-SAMIDORPHAN (LYBALVI)**

## **MEDICATION(S)**

**LYBALVI** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to one generic atypical antipsychotic drug (e.g. aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) or there is a medical reason why all the generic atypical antipsychotics cannot be used.

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 217 EFFECTIVE 11/2025

# **OLAPARIB (LYNPARZA)**

## **MEDICATION(S)**

LYNPARZA

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 218 EFFECTIVE 11/2025

# **OLSALAZINE SODIUM (DIPENTUM)**

# **MEDICATION(S)**

**DIPENTUM** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial of one of the following: mesalamine 0.375g long-acting capsule, mesalamine 1.2g long-acting tablet, or balsalazide 750 mg capsule OR medical reason why these drugs cannot be used (contraindication).

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 219 EFFECTIVE 11/2025

# **OLUTASIDENIB (REZLIDHIA)**

# **MEDICATION(S)**

**REZLIDHIA** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 220 EFFECTIVE 11/2025

# **OMALIZUMAB (XOLAIR)**

# **MEDICATION(S)**

XOLAIR 150 MG/ML SOLN A-INJ, XOLAIR 150 MG/ML SOLN PRSYR, XOLAIR 300 MG/2ML SOLN A-INJ, XOLAIR 300 MG/2ML SOLN PRSYR, XOLAIR 75 MG/0.5ML SOLN A-INJ, XOLAIR 75 MG/0.5ML SOLN PRSYR

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Refractory immunotherapy-related severe pruritus, Systemic Mastocytosis

#### **EXCLUSION CRITERIA**

Allergic asthma: being used with other targeted therapies for asthma treatment (e.g. Nucala, Cinqair, Dupixent, Fasenra). IgE-mediated food allergy: being used with food allergen.

# **REQUIRED MEDICAL INFORMATION**

Allergic Asthma, initial use: recent total serum IgE level is more than 30IU/ml, documented treatment failure with recent use of high-dose inhaled corticosteroid along with long-acting beta agonist or leukotriene receptor antagonists (i.e., montelukast), and patient has had at least one of the following within the past year: one or more acute asthma-related ER visit(s), one or more acute inpatient visits where asthma was the diagnosis, or two or more acute asthma exacerbations that require oral corticosteroids, or use of chronic systemic steroids due to severe asthma. Ongoing use:asthma symptoms improved and/or controlled while on Xolair. Chronic Idiopathic Urticaria (CIU): failure to respond to hydroxyzine, doxepin, or high dose second-generation antihistamines OR has a medical reason not to use (contraindication) or had a side effect to hydroxyzine, doxepin, and second-generation antihistamines. Nasal polyps: treatment failure or side effect with a nasal corticosteroid (e.g. fluticasone). IgE-mediated food allergy: diagnosis confirmed by positive skin prick test (SPT), serum IgE level, or food challenge to one or more foods (e.g., peanut, milk, egg, wheat, cashew, hazelnut, walnut).

Systemic Mastocytosis: treatment failure or side effect to an antihistamine and an oral corticosteroid, or has a medical reason why antihistamines and oral corticosteroids can not be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

CIU, IgE-mediated food allergy: Allergist or Immunologist. Allergic asthma: Allergist, Pulmonologist or Immunologist. Nasal polyps: allergist, immunologist, or otolaryngologist. Immunotherapy-related severe pruritus: dermatologist, allergist, hematologist, oncologist, or immunologist.

#### **COVERAGE DURATION**

Allergic asthma, initial 6 months, ongoing use: plan year All other Dx: plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 222 EFFECTIVE 11/2025

# **OSIMERTINIB (TAGRISSO)**

## **MEDICATION(S)**

**TAGRISSO** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 223 EFFECTIVE 11/2025

# **OSPEMIFENE (OSPHENA)**

# **MEDICATION(S)**

**OSPHENA** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Painful sex (dyspareunia) due to menopause: patient has tried Premarin Vaginal cream.

Vaginal dryness due to menopause: patient has tried at least two of the following: Premarin vaginal cream, estradiol vaginal cream, estradiol vaginal tablet, Yuvafem, or Estring.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 224 EFFECTIVE 11/2025

# **OXYMORPHONE IMMEDIATE-RELEASE (OPANA)**

# **MEDICATION(S)**

**OXYMORPHONE HCL** 

# PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other short-acting opioid narcotics.

# REQUIRED MEDICAL INFORMATION

Moderate to severe pain, initial use: trial of at least two preferred short-acting narcotic drugs, and total dose across all narcotics is not more than 90 MME/day or if more than 90 MME/day the prescriber states the total dose is medically necessary to treat the pain. Ongoing use (more than 90 days of narcotic therapy): evaluation by pain specialist, and a patient-specific treatment plan exists for evaluating ongoing need for narcotic pain relief, monitoring side effects and misuse and to taper down narcotics, AND total dose across all narcotics is not more than 90 MME/day or if more than 90 MME/day the prescriber states the total dose is medically necessary to treat the pain.

#### **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

30 days

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **PACRITINIB (VONJO)**

## **MEDICATION(S)**

OLNOV

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

Being used along with another agent for myelofibrosis

# REQUIRED MEDICAL INFORMATION

Platelet count is less than 50,000 cells/mcl.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 226 EFFECTIVE 11/2025

# PALBOCICLIB (IBRANCE)

## **MEDICATION(S)**

**IBRANCE** 

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 227 EFFECTIVE 11/2025

# PALIPERIDONE ER (INVEGA)

# **MEDICATION(S)**

PALIPERIDONE ER

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Older adults (65 years and older) with dementia-related psychosis.

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to risperidone or there is a medical reason why risperidone cannot be tried.

# **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 228 EFFECTIVE 11/2025

# **PART D VS PART B**

PAGE 229 EFFECTIVE 11/2025

# **MEDICATION(S)**

ABELCET, ABILIFY ASIMTUFII, ABILIFY MAINTENA, ACETYLCYSTEINE 10 % SOLUTION, ACETYLCYSTEINE 20 % SOLUTION, ACYCLOVIR SODIUM, ALBUTEROL SULFATE (2.5 MG/3ML) 0.083% NEBU SOLN, ALBUTEROL SULFATE (5 MG/ML) 0.5% NEBU SOLN, ALBUTEROL SULFATE 0.63 MG/3ML NEBU SOLN, ALBUTEROL SULFATE 1.25 MG/3ML NEBU SOLN, ALBUTEROL SULFATE 2.5 MG/0.5ML NEBU SOLN, ALDURAZYME, AMINOSYN II 10 % SOLUTION, AMINOSYN-PF 10 % SOLUTION, AMPHOTERICIN B, APREPITANT 125 MG CAP, APREPITANT 80 & 125 MG CAP, APREPITANT 80 MG CAP, ARFORMOTEROL TARTRATE, ARISTADA, ARISTADA INITIO, AZASAN, AZATHIOPRINE, AZATHIOPRINE SODIUM, BUDESONIDE 0.25 MG/2ML SUSPENSION, BUDESONIDE 0.5 MG/2ML SUSPENSION, BUDESONIDE 1 MG/2ML SUSPENSION, CABENUVA, CALCITRIOL 0.25 MCG CAP, CALCITRIOL 0.5 MCG CAP, CALCITRIOL 1 MCG/ML SOLUTION, CINACALCET HCL, CROMOLYN SODIUM 20 MG/2ML NEBU SOLN, CYCLOPHOSPHAMIDE 25 MG CAP, CYCLOPHOSPHAMIDE 25 MG TAB, CYCLOPHOSPHAMIDE 50 MG CAP, CYCLOPHOSPHAMIDE 50 MG TAB, CYCLOSPORINE 100 MG CAP, CYCLOSPORINE 25 MG CAP, CYCLOSPORINE 50 MG/ML SOLUTION, CYCLOSPORINE MODIFIED, DEXAMETHASONE SOD PHOSPHATE PF, DOXERCALCIFEROL, ELAPRASE, ENGERIX-B, ERZOFRI, EVEROLIMUS 0.25 MG TAB, EVEROLIMUS 0.5 MG TAB, EVEROLIMUS 0.75 MG TAB, EVEROLIMUS 1 MG TAB, FORMOTEROL FUMARATE, GENGRAF, GRANISETRON HCL 1 MG TAB, HEPARIN SODIUM (PORCINE) 1000 UNIT/ML SOLUTION, HEPARIN SODIUM (PORCINE) 10000 UNIT/ML SOLUTION, HEPARIN SODIUM (PORCINE) 20000 UNIT/ML SOLUTION, HEPARIN SODIUM (PORCINE) 5000 UNIT/ML SOLUTION, HEPARIN SODIUM (PORCINE) PF 1000 UNIT/ML SOLUTION, HEPLISAV-B, HUMULIN R U-500 (CONCENTRATED), IBANDRONATE SODIUM 3 MG/3ML SOLUTION, INTRALIPID, INVEGA HAFYERA, INVEGA SUSTENNA, INVEGA TRINZA, IPRATROPIUM BROMIDE 0.02 % SOLUTION, IPRATROPIUM-ALBUTEROL, LACOSAMIDE 200 MG/20ML SOLUTION, LILETTA (52 MG), MELPHALAN, METHOTREXATE SODIUM 1 GM RECON SOLN, METHOTREXATE SODIUM 250 MG/10ML SOLUTION, METHOTREXATE SODIUM 50 MG/2ML SOLUTION, METHOTREXATE SODIUM (PF), METHYLPREDNISOLONE SODIUM SUCC 125 MG RECON SOLN, MOXIFLOXACIN HCL 400 MG/250ML SOLUTION, MOXIFLOXACIN HCL IN NACL, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HCL, MYCOPHENOLATE SODIUM, MYCOPHENOLIC ACID, NAGLAZYME, NUTRILIPID, ONDANSETRON 4 MG TAB DISP, ONDANSETRON 8 MG TAB DISP, ONDANSETRON HCL 24 MG TAB, ONDANSETRON HCL 4 MG TAB, ONDANSETRON HCL 4 MG/5ML SOLUTION, ONDANSETRON HCL 8 MG TAB, PARICALCITOL, PENTAMIDINE ISETHIONATE, PERSERIS, PREMASOL, PROLASTIN-C, PULMOZYME, RECOMBIVAX HB, RIBAVIRIN 6 GM RECON SOLN, RISPERIDONE MICROSPHERES ER, SANDIMMUNE 100 MG/ML SOLUTION, SIROLIMUS, SMOFLIPID, SUNLENCA 463.5 MG/1.5ML SOLUTION, SYNRIBO, TACROLIMUS 0.5 MG CAP, TACROLIMUS 1 MG CAP, TACROLIMUS 5 MG CAP, THIOTEPA, TPN ELECTROLYTES, TRELSTAR MIXJECT, TWINRIX, VANCOMYCIN HCL 5 GM RECON SOLN, VORICONAZOLE 200 MG RECON SOLN, ZOLEDRONIC ACID, ZYPREXA RELPREVV

PAGE 230 EFFECTIVE 11/2025

# **DETAILS**

This drug may be covered under Medicare Part B or D depending on the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

PAGE 231 EFFECTIVE 11/2025

# **PASIREOTIDE (SIGNIFOR)**

# **MEDICATION(S)**

**SIGNIFOR** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Cushings disease: pituitary surgery is not an option or has not been curative.

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 232 EFFECTIVE 11/2025

# **PAZOPANIB HCL (VOTRIENT)**

# MEDICATION(S)

PAZOPANIB HCL

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 233 EFFECTIVE 11/2025

# **PEGFILGRASTIM-APGF (NYVEPRIA)**

## **MEDICATION(S)**

**NYVEPRIA** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Hematopoietic Cell Transplantation (HCT)

#### **EXCLUSION CRITERIA**

Prophylaxis of chemo-induced febrile neutropenia: Being used along with another G-CSF (granulocyte colony stimulating factor) drug.

# REQUIRED MEDICAL INFORMATION

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

HCT: one dose. Prophylaxis of chemo-induced febrile neutropenia: duration of chemotherapy.

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

Excluded under Part D if covered by Part B.

PAGE 234 EFFECTIVE 11/2025

# PEGFILGRASTIM-CBQV (UDENYCA)

## **MEDICATION(S)**

**UDENYCA** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Hematopoietic Cell Transplantation (HCT)

#### **EXCLUSION CRITERIA**

Prophylaxis of chemo-induced febrile neutropenia: Being used along with another G-CSF (granulocyte colony stimulating factor) drug.

## REQUIRED MEDICAL INFORMATION

N/A

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

HCT: one dose. Febrile neutropenia: duration of chemo. Acute Radiation Syndrome: 2 doses (one week).

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

Excluded under Part D if covered by Part B.

PAGE 235 EFFECTIVE 11/2025

# **PEGINTERFERON ALFA-2A (PEGASYS)**

# **MEDICATION(S)**

**PEGASYS** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

myelofibrosis, polycythemia vera, essential thrombocythemia, systemic mastocytosis, Chronic Myeloid Leukemia (CML), Hairy cell leukemia, Mycosis fungoides/Sezary syndrome, Primary cutaneous anaplastic large cell lymphoma (ALCL), T-cell leukemia/lymphoma, Erdheim-Chester disease histiocytic neoplasm.

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Chronic hepatitis C viral infection: criteria will be applied consistent with FDA labeling. Polycythemia vera or Essential thrombocythemia: trial and failure or side effect to hydroxyurea or medical reason why hydroxyurea cannot be used. Myelofibrosis, systemic mastocytosis, Chronic Myeloid Leukemia (CML), Hairy cell leukemia, Mycosis fungoides/Sezary syndrome, Primary cutaneous anaplastic large cell lymphoma (ALCL), T-cell leukemia/lymphoma, Erdheim-Chester disease histiocytic neoplasm: criteria will be applied consistent with current National Comprehensive Cancer Network (NCCN) guidelines.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Hep B: 48 weeks. Hep C: up to 48 weeks. CML: length of pregnancy. All other Dx: plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **PEGVISOMANT (SOMAVERT)**

# MEDICATION(S)

**SOMAVERT** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# **REQUIRED MEDICAL INFORMATION**

Failed radiation or surgery or not a candidate for both radiation and surgery AND failed treatment or had a side effect with octreotide or Somatuline.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

Endocrinologist

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 237 EFFECTIVE 11/2025

# **PEMIGATINIB (PEMAZYRE)**

# **MEDICATION(S)**

**PEMAZYRE** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 238 EFFECTIVE 11/2025

# **PENCICLOVIR (DENAVIR)**

## MEDICATION(S)

**PENCICLOVIR** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

# **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 239 EFFECTIVE 11/2025

# **PENICILLAMINE (DEPEN)**

## **MEDICATION(S)**

PENICILLAMINE 250 MG TAB

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis: treatment failure or side effect to two of the following: methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide, OR has a medical reason why methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide cannot be used.

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 240 EFFECTIVE 11/2025

# PEXIDARTINIB (TURALIO)

## **MEDICATION(S)**

**TURALIO 125 MG CAP** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 241 EFFECTIVE 11/2025

# **PIMAVANSERIN (NUPLAZID)**

# **MEDICATION(S)**

**NUPLAZID** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used for dementia-related psychosis.

# REQUIRED MEDICAL INFORMATION

Evaluation by psychiatrist confirms Parkinson's disease psychosis (PDP) – symptoms of hallucinations (seeing, hearing, or experiencing things that others don't) and delusions (believing things that aren't true) due to Parkinson's disease.

## **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

Neurologist or Psychiatrist

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 242 EFFECTIVE 11/2025

# **PIRFENIDONE (ESBRIET)**

# MEDICATION(S)

**PIRFENIDONE** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

# **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 243 EFFECTIVE 11/2025

# PIRTOBRUTINIB (JAYPIRCA)

## **MEDICATION(S)**

**JAYPIRCA** 

# **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 244 EFFECTIVE 11/2025

# **POMALIDOMIDE (POMALYST)**

# **MEDICATION(S)**

**POMALYST** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 245 EFFECTIVE 11/2025

# **PONATINIB (ICLUSIG)**

# MEDICATION(S)

**ICLUSIG** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 246 EFFECTIVE 11/2025

# **POSACONAZOLE (NOXAFIL)**

## **MEDICATION(S)**

POSACONAZOLE 100 MG TAB DR, POSACONAZOLE 40 MG/ML SUSPENSION

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Esophageal candidiasis treatment, fusariosis, histoplasmosis, phaeohyphomycosis, Allergic Bronchopulmonary Aspergillosis (ABPA), refractory treatment of pulmonary aspergillosis, chronic (cavitary or necrotizing).

#### **EXCLUSION CRITERIA**

N/A

# **REQUIRED MEDICAL INFORMATION**

Prevention of aspergillus or candida infection when there is high risk for developing these type of infections (e.g. weakened defense system due to cancer drug therapy, HIV, GVHD). Aspergillosis, fusariosis, histoplasmosis, phaeohyphomycosis within the body that is confirmed by a positive culture test. Treatment of candida infection of the esophagus: trial of fluconazole or there is a medical reason not to use fluconazole. Oropharyngeal candidiasis (suspension only): trial of fluconazole or there is a medical reason not to use fluconazole. Treatment of candida infection within the body that is confirmed by a positive culture and failure of fluconazole or other anti-fungal shown by culture results to treat the infection. ABPA: use after trial of itraconazole or there is a medical reason not to use itraconazole.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

oral or esophageal candidiasis: one month all other conditions:Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

# **PRALSETINIB (GAVRETO)**

## **MEDICATION(S)**

**GAVRETO** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 248 EFFECTIVE 11/2025

# **PYRIMETHAMINE (DARAPRIM)**

# **MEDICATION(S)**

**PYRIMETHAMINE** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Toxoplasmosis prevention, Toxoplasmosis chronic manintenance (secondary prophylaxis), Pneumocystis jiroveci (formerly Pneumocystis carinii) Pneumonia (PCP) prevention, Cystoisospora belli (formerly Isospora Belli) treatment or secondary prevention.

#### **EXCLUSION CRITERIA**

N/A

# **REQUIRED MEDICAL INFORMATION**

Primary pevention of toxoplasmosis: treatment failure or side effect with trimethoprim-sulfamethoxazole (TMP-SMX) or has a medical reason for not using TMP-SMX and patient is immunocompromised (i.e. cancer, HIV+, post-transplantation).

Chronic maintenance (secondary prophylaxis) of toxoplasmosis: follows initial treatment in HIV-infected patients.

Prevention of Pneumocystis jiroveci (formerly Pneumocystis carinii) Pneumonia (PCP): treatment failure or side effect with trimethoprim-sulfamethoxazole (TMP-SMX) or has a medical reason for not using TMP-SMX AND patient is HIV+.

Treatment of cystoisospora belli (formerly Isospora Belli): Patient is HIV+ AND treatment failure or side effect with trimethoprim-sulfamethoxazole (TMP-SMX) or has a medical reason for not using TMP-SMX.

Chronic manintenance (secondary prophylaxis) of cystoisospora belli (formerly Isospora Belli): follows initial treatment in HIV-infected patients AND treatment failure or side effect with trimethoprim-sulfamethoxazole (TMP-SMX) or has a medical reason for not using TMP-SMX

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

Toxoplasmosis: infectious disease specialist, ophthalmologist, or gynecologist. Pneumocystis jiroveci (formerly Pneumocystis carinii) Pneumonia (PCP) prevention and cystoisospora belli (formerly Isospora Belli) treatment or secondary prevention: infectious disease specialist.

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 250 EFFECTIVE 11/2025

# **QUIZARTINIB (VANFLYTA)**

# **MEDICATION(S)**

**VANFLYTA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

#### REQUIRED MEDICAL INFORMATION

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Induction: 2 months. Consolidation: 4 months. Maintenance therapy: 36 months. (see other criteria)

#### **OTHER CRITERIA**

Treatment course consists of:

- a. Up to two cycles for use with standard cytarabine and anthracycline for induction, and
- b. Up to four cycles for use with cytarabine for consolidation, and
- c. Up to 36 cycles as a single agent for maintenance after consolidation therapy or until disease progression.

PAGE 251 EFFECTIVE 11/2025

# **REGORAFENIB (STIVARGA)**

## **MEDICATION(S)**

**STIVARGA** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 252 EFFECTIVE 11/2025

# **RELUGOLIX (ORGOVYX)**

### **MEDICATION(S)**

**ORGOVYX** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 253 EFFECTIVE 11/2025

# **REPOTRECTINIB (AUGTYRO)**

### **MEDICATION(S)**

**AUGTYRO** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 254 EFFECTIVE 11/2025

# **REVUMENIB (REVUFORJ)**

## **MEDICATION(S)**

**REVUFORJ** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 255 EFFECTIVE 11/2025

# **RIBOCICLIB SUCCINATE (KISQALI)**

### **MEDICATION(S)**

KISQALI (200 MG DOSE), KISQALI (400 MG DOSE), KISQALI (600 MG DOSE)

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 256 EFFECTIVE 11/2025

# RIBOCICLIB SUCCINATE-LETROZOLE (KISQALI FEMARA)

### **MEDICATION(S)**

KISQALI FEMARA (200 MG DOSE), KISQALI FEMARA (400 MG DOSE), KISQALI FEMARA (600 MG DOSE)

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## REQUIRED MEDICAL INFORMATION

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 257 EFFECTIVE 11/2025

## **RIFAXIMIN (XIFAXAN)**

## **MEDICATION(S)**

**XIFAXAN** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Clostridium difficile associated diarrhea (CDAD), Crohn's Disease, Small bowel bacterial overgrowth syndrome/Small intestinal bacterial overgrowth (SIBO)

### **EXCLUSION CRITERIA**

N/A

### REQUIRED MEDICAL INFORMATION

Travelers diarrhea: patient has tried azithromycin or a fluoroquinolone like ciprofloxacin or has a medical reason why ciprofloxacin and azithromycin cannot be used.

Hepatic Encephalopathy: patient has tried lactulose.

Irritable bowel syndrome with diarrhea (IBS-D): patient has tried an anti-diarrheal drug (diphenoxylate/atropine, loperamide) OR has a medical reason not to use (contraindication) anti-diarrheal therapies.

Clostridium difficile associated diarrhea (CDAD): patient has tried vancomycin.

Crohn's Disease: patient has tried metronidazole or ciprofloxacin or has a medical reason why metronidazole and ciprofloxacin cannot be used.

SIBO: Confirmation by a current positive breath test (e.g., lactulose hydrogen or glucose hydrogen) AND patient has tried and failed or had side effects with two of the following antibiotics: metronidazole (Flagyl), and ciprofloxacin (Cipro), amoxicillin-clavulanic acid (Augmentin), doxycycline, tetracycline, and trimethoprim-sulfamethoxazole (Bactrim, Septra) or there is a medical reason why all the other antibiotics cannot be tried first.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

One course (see other criteria)

### **OTHER CRITERIA**

Travelers diarrhea: 3 days. Hepatic encephalopathy: plan year. IBS-D: 2 weeks. CDAD: 20 days. Crohn's Disease: 12 weeks. SIBO: 14 days.

PAGE 259 EFFECTIVE 11/2025

## **RILONACEPT (ARCALYST)**

## **MEDICATION(S)**

**ARCALYST** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Recurrent Pericarditis: trial of colchicine in combination with oral non-steroidal anti-inflammatory drug (NSAID) or contraindication to colchicine in combination with oral NSAID OR patient did not respond to corticosteroids or is on corticosteroids.

### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Recurrent Pericarditis: Cardiologist

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 260 EFFECTIVE 11/2025

# **RIMEGEPANT (NURTEC)**

## **MEDICATION(S)**

**NURTEC** 

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Migraine Tx: Trial of at least ONE triptan (e.g., sumatriptan, rizatriptan, naratriptan) or has a medical reason (contraindication) for not using triptans.

Migraine HA prevention: documentation of 4 or more headache days per month

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 261 EFFECTIVE 11/2025

## **RIOCIGUAT (ADEMPAS)**

### **MEDICATION(S)**

**ADEMPAS** 

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Confirmation of Pulmonary Arterial Hypertension (WHO Group I) by right heart catheterization test AND patient has tried an endothelin-receptor antagonist (e.g. Tracleer) and a phosphodiesterase type 5 (PDE-5) inhibitor (e.g. sildenafil).

Confirmation of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) by a right heart catheterization or V/Q scan AND patient has been treated with surgery or cannot be treated surgery.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 262 EFFECTIVE 11/2025

# RIPRETINIB (QINLOCK)

### MEDICATION(S)

**QINLOCK** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 263 EFFECTIVE 11/2025

## **RISANKIZUMAB-RZAA IV (SKYRIZI IV)**

### **MEDICATION(S)**

SKYRIZI 600 MG/10ML SOLUTION

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

### REQUIRED MEDICAL INFORMATION

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

one time induction course (8 weeks)

### **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 264 EFFECTIVE 11/2025

# **RISANKIZUMAB-RZAA SQ (SKYRIZI SQ)**

### **MEDICATION(S)**

SKYRIZI 150 MG/ML SOLN PRSYR, SKYRIZI 180 MG/1.2ML SOLN CART, SKYRIZI 360 MG/2.4ML SOLN CART, SKYRIZI (150 MG DOSE), SKYRIZI PEN

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

#### REQUIRED MEDICAL INFORMATION

Plaque Psoriasis (PsO), initial use: treatment failure or side effect with one DMARD or has a medical reason why methotrexate, cyclosporine, and acitretin cannot be used AND moderate to severe disease confirmed by Psoriasis Area and Severity Index (PASI) score of 10 or more OR Body Surface Area (BSA) of at least 3% OR sensitive areas are involved OR disease affects daily living. PsO, ongoing use: PASI or BSA improved with use of Skyrizi.

Ulcerative colitis (UC): disease is moderate to severe AND SQ formulation will be started after initial IV dose.

#### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

PsO: Dermatologist or Rheumatologist. PsA: Rheumatologist

#### **COVERAGE DURATION**

PsO initial use: 24 weeks. PsO ongoing use: plan year. PsA, Crohn's, and UC: plan year,

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 265 EFFECTIVE 11/2025

# **ROFLUMILAST (DALIRESP)**

### MEDICATION(S)

**ROFLUMILAST** 

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 266 EFFECTIVE 11/2025

## **ROPEGINTERFERON ALFA-2B (BESREMI)**

### **MEDICATION(S)**

**BESREMI** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Polycythemia Vera (PV): treatment failure or side effect with hydroxyurea OR medical reason for not using hydroxyurea OR being used as initial treatment for symptomatic low-risk PV.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 267 EFFECTIVE 11/2025

# **RUCAPARIB CAMSYLATE (RUBRACA)**

## **MEDICATION(S)**

**RUBRACA** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 268 EFFECTIVE 11/2025

# **RUXOLITINIB (JAKAFI)**

## **MEDICATION(S)**

**JAKAFI** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Myeloid, lymphoid, or mixed phenotype neoplasms with eosinophilia, CAR-T cell related toxicities, Myelodysplastic/ Myeloproliferative overlap neoplasms, Essential thrombocythemia, T-cell Lymphomas, Pediatric acute lymphoblastic leukemia (ALL).

#### **EXCLUSION CRITERIA**

Myelofibrosis (MF): Being used along with another agent for myelofibrosis.

### **REQUIRED MEDICAL INFORMATION**

MF: platelet count is equal to or more than 50,000 cells/mcl or being used in combination with Reblozyl for low blood cells (anemia). Polycythemia Vera (PV): treatment failure or side effect with hydroxyurea OR medical reason for not using hydroxyurea and hematocrit of at least 40%. Graft vs Host Disease (GvHD): treatment failure to at least one prior drug for GVHD (e.g systemic corticosteroids, cyclophosphamide, cyclosporine, mycophenolate, and tacrolimus). All off-label uses: criteria will be applied consistent with current National Comprehensive Cancer Network (NCCN) guidelines.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

## SAPROPTERIN DIHYDROCHLORIDE (KUVAN)

### **MEDICATION(S)**

SAPROPTERIN DIHYDROCHLORIDE

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used in combination with pegvaliase-pqpz (Palynziq)

## REQUIRED MEDICAL INFORMATION

Phenylketonuria (PKU), initial: chart notes confirm PKU and baseline (just prior to therapy) blood phenylalanine (Phe) levels are given. PKU, ongoing use: phenylalanine level improved from baseline

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Initial: 3 months dose increases: 3 months, ongoing use: plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 270 EFFECTIVE 11/2025

# **SECUKINUMAB (COSENTYX)**

### **MEDICATION(S)**

COSENTYX 150 MG/ML SOLN PRSYR, COSENTYX 75 MG/0.5ML SOLN PRSYR, COSENTYX (300 MG DOSE), COSENTYX SENSOREADY (300 MG), COSENTYX SENSOREADY PEN, COSENTYX UNOREADY

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

### REQUIRED MEDICAL INFORMATION

Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA): patient is not able to take NSAIDs due to history of GI bleed or ulcer OR patient has tried one RX strength NSAID in combination with a PPI and had GI side effects OR patient's condition did not respond to a trial of two different RX strength NSAIDs.

Hidradenitis suppurativa (HS): patient has Hurley stage II or III HS.

Enthesitis-related arthritis (ERA): patient has tried and failed one NSAID or has a medical reason why all NSAIDs cannot be used.

Plaque Psoriasis (PsO), initial use: patient tried and failed or had a side effect to one DMARD or has a medical reason why methotrexate (MTX), cyclosporine, and acitretin cannot be used AND baseline PASI score 10 or more OR BSA 3% or more OR sensitive areas are involved OR disease affects daily living. Ongoing use: PASI or BSA improved on Cosentyx.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

PsA, AS, nr-axSpA: Rheumatologist. HS: Dermatologist. PsO: Rheumatologist or Dermatologist.

#### **COVERAGE DURATION**

PsO initial: 24 weeks. PsO ongoing and all other indications: plan year

PAGE 271 EFFECTIVE 11/2025

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 272 EFFECTIVE 11/2025

## **SELEGILINE TRANSDERMAL (EMSAM)**

## **MEDICATION(S)**

**EMSAM** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Treatment failure or side effect with at least one preferred drug that treats depression (e.g. bupropion, maprotiline, citalopram, paroxetine, sertraline, venlafaxine, duloxetine).

## **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 273 EFFECTIVE 11/2025

# **SELINEXOR (XPOVIO)**

### **MEDICATION(S)**

XPOVIO (100 MG ONCE WEEKLY) 50 MG TAB THPK, XPOVIO (40 MG ONCE WEEKLY) 10 MG TAB THPK, XPOVIO (40 MG ONCE WEEKLY) 40 MG TAB THPK, XPOVIO (40 MG TWICE WEEKLY) 40 MG TAB THPK, XPOVIO (60 MG ONCE WEEKLY) 60 MG TAB THPK, XPOVIO (60 MG TWICE WEEKLY), XPOVIO (80 MG ONCE WEEKLY) 40 MG TAB THPK, XPOVIO (80 MG TWICE WEEKLY)

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 274 EFFECTIVE 11/2025

# **SELPERCATINIB (RETEVMO)**

## **MEDICATION(S)**

**RETEVMO** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 275 EFFECTIVE 11/2025

# **SELUMETINIB (KOSELUGO)**

### **MEDICATION(S)**

KOSELUGO 10 MG CAP, KOSELUGO 25 MG CAP

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 276 EFFECTIVE 11/2025

# **SEMAGLUTIDE (RYBELSUS)**

### MEDICATION(S)

**RYBELSUS** 

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Being used with another GLP-1 agent

## REQUIRED MEDICAL INFORMATION

Confirmation of Type 2 diabetes

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 277 EFFECTIVE 11/2025

# **SEMAGLUTIDE SQ (OZEMPIC)**

### **MEDICATION(S)**

OZEMPIC (0.25 OR 0.5 MG/DOSE) 2 MG/3ML SOLN PEN, OZEMPIC (1 MG/DOSE) 4 MG/3ML SOLN PEN, OZEMPIC (2 MG/DOSE)

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Being used with another GLP-1 agent

### **REQUIRED MEDICAL INFORMATION**

Confirmation of Type 2 diabetes

#### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 278 EFFECTIVE 11/2025

## **SILDENAFIL (REVATIO)**

### **MEDICATION(S)**

SILDENAFIL CITRATE 10 MG/ML RECON SUSP, SILDENAFIL CITRATE 20 MG TAB

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Raynauds phenomenon

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

PAH: confirmation of WHO Group I by right heart catheterization test.

Raynaud's phenomenon: treatment failure or side effect with a calcium-channel blocker (e.g. nifedipine).

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 279 EFFECTIVE 11/2025

# SKELETAL MUSCLE RELAXANTS (HIGH RISK MEDICATION)

### **MEDICATION(S)**

CARISOPRODOL 350 MG TAB, CYCLOBENZAPRINE HCL 10 MG TAB, CYCLOBENZAPRINE HCL 5 MG TAB, METAXALONE 400 MG TAB, METAXALONE 800 MG TAB, METHOCARBAMOL 500 MG TAB, METHOCARBAMOL 750 MG TAB, VANADOM

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Prescriber confirms the benefits of the drug outweigh any risks and will monitor for side effects.

#### **AGE RESTRICTION**

65 years and older. No prior authorization required for less than 65 years old.

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

3 weeks

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 280 EFFECTIVE 11/2025

## **SODIUM OXYBATE (XYREM)**

### **MEDICATION(S)**

**SODIUM OXYBATE** 

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with sedative hypnotic drugs or other CNS depressant drugs.

## REQUIRED MEDICAL INFORMATION

Narcolepsy is confirmed by sleep study and patient has brief losses of muscle tone (cataplexy). Excessive daytime sleepiness due to narcolepsy: Trial and failure or side effect to modafinil, or has a medical reason not to use modafinil.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 281 EFFECTIVE 11/2025

# SODIUM PHENYLBUTYRATE (BUPHENYL)

## **MEDICATION(S)**

SODIUM PHENYLBUTYRATE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Chart documentation for inherited Urea Cycle enzyme deficiency.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 282 EFFECTIVE 11/2025

## **SOMATROPIN (OMNITROPE)**

## **MEDICATION(S)**

**OMNITROPE** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

### REQUIRED MEDICAL INFORMATION

Adult Growth hormone deficiency (GHD): low IGF-1 (below mean of reference range) AND history of hypothalamic-pituitary disease (i.e., structural, trauma, treatment induced), AND one of the following: failed one growth hormone stimulation test or three or more documented pituitary hormone deficiencies. Adult GHD continuing from childhood with prior use of GH: One of the following: growth not complete OR growth complete and low IGF-1 (below mean of reference range) AND for patients with pituitary gland: patient failed one standard growth hormone stimulation test. Pediatric GHD with pituitary disease: One of the following: growth rate (velocity) decline, AND presence of hypothalamic-pituitary disease (i.e., structural, trauma, treatment induced), AND one of the following: failed one growth hormone stimulation test or at least one documented pituitary hormone deficiency OR newborn with congenital pituitary defect or at least one pituitary hormone deficiency and low blood sugar and blood growth hormone level less than 5 ug/L, OR three or more documented pituitary hormone deficiencies. Pediatric GHD without pituitary disease: height is 2 or more standard deviations below mean (less than 3rd percentile) for age and sex, height rate is less than 10th percentile of normal for age and sex within the last year, and failure of two standard growth hormone stimulation tests. Small for Gestational Age (SGA): length at birth or birth weight are two or more standard deviations below the mean (less than the 3rd percentile) for gestational age and height is two or more standard deviations below the mean.

Ongoing use in Adult GHD: responding to GH. Ongoing use in SGA or pediatric GHD: growth rate improved or maintained while on GH. Ongoing use for Turners or Prader-Willi syndrome: provider has determined that benefits outweigh risk and continuation is necessary.

#### **AGE RESTRICTION**

N/A

PAGE 283 EFFECTIVE 11/2025

### PRESCRIBER RESTRICTION

Endocrinologist

## **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 284 EFFECTIVE 11/2025

# **SONIDEGIB (ODOMZO)**

### **MEDICATION(S)**

ODOMZO

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 285 EFFECTIVE 11/2025

# **SORAFENIB (NEXAVAR)**

## **MEDICATION(S)**

**SORAFENIB TOSYLATE** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 286 EFFECTIVE 11/2025

# **SOTORASIB (LUMAKRAS)**

### **MEDICATION(S)**

**LUMAKRAS** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 287 EFFECTIVE 11/2025

# **STIRIPENTOL (DIACOMIT)**

### **MEDICATION(S)**

DIACOMIT

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Seizures due to Dravet syndrome: being used with clobazam.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 288 EFFECTIVE 11/2025

# **SUNITINIB MALATE (SUTENT)**

## **MEDICATION(S)**

**SUNITINIB MALATE** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 289 EFFECTIVE 11/2025

# **TACROLIMUS (ENVARSUS XR)**

### **MEDICATION(S)**

**ENVARSUS XR** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Currently using immediate-release (IR) tacrolimus and would like Envarsus to lower pill burden.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 290 EFFECTIVE 11/2025

# **TACROLIMUS FOR ORAL SUSPENSION (PROGRAF PACKET)**

## **MEDICATION(S)**

PROGRAF 0.2 MG PACKET, PROGRAF 1 MG PACKET

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Patient has a medical reason for not using tacrolimus capsules.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 291 EFFECTIVE 11/2025

# **TADALAFIL (ADCIRCA)**

## MEDICATION(S)

ALYQ, TADALAFIL (PAH)

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Raynaud's phenomenon

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

PAH: confirmation of WHO Group I by right heart catheterization test. Raynaud's phenomenon: treatment failure or side effect with a calcium-channel blocker (e.g. nifedipine).

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 292 EFFECTIVE 11/2025

# **TADALAFIL (CIALIS)**

### **MEDICATION(S)**

TADALAFIL 2.5 MG TAB, TADALAFIL 5 MG TAB

### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Raynaud's phenomenon

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Raynauds phenomenon: treatment failure or side effect with a calcium-channel blocker (e.g. nifedipine).

Benign Prostatic Hyperplasia (BPH): treatment failure or side effect with both finasteride and tamsulosin. Dose not to exceed 5 mg per day.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Raynaud's, BPH: plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 293 EFFECTIVE 11/2025

# **TALAZOPARIB TOSYLATE (TALZENNA)**

### **MEDICATION(S)**

**TALZENNA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 294 EFFECTIVE 11/2025

# **TALETRECTINIB (IBTROZI)**

### **MEDICATION(S)**

**IBTROZI** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 295 EFFECTIVE 11/2025

# **TASIMELTEON (HETLIOZ)**

### **MEDICATION(S)**

**TASIMELTEON** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Non 24 Sleep Wake Cycle, initial use: patient not able to maintain a stable 24-hour sleep-wake pattern synchronized to 24-hr light/dark cycle. Non 24 Sleep Wake Cycle, ongoing use: patients total sleep time at night is longer since starting tasimelteon.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Non 24 Sleep Wake Cycle: sleep specialist, neurologist

#### **COVERAGE DURATION**

Non 24 Sleep Wake Cycle, initial use: 3mos. Ongoing use: plan year Smith-Magenis Syndrome: plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 296 EFFECTIVE 11/2025

# **TAZEMETOSTAT (TAZVERIK)**

### **MEDICATION(S)**

**TAZVERIK** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 297 EFFECTIVE 11/2025

# **TELOTRISTAT ETHYL (XERMELO)**

### **MEDICATION(S)**

**XERMELO** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Treatment failure of octreotide (Sandostatin) or lanretotide (Somatuline) AND being used in combination with octreotide (Sandostatin) or lanreotide (Somatuline).

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 298 EFFECTIVE 11/2025

# **TEPOTINIB (TEPMETKO)**

## **MEDICATION(S)**

**TEPMETKO** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 299 EFFECTIVE 11/2025

# **TERIFLUNOMIDE (AUBAGIO)**

### MEDICATION(S)

**TERIFLUNOMIDE** 

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Being used with other disease-modifying therapies for relapsing Multiple Sclerosis.

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 300 EFFECTIVE 11/2025

# **TERIPARATIDE (RECOMBINANT)**

## MEDICATION(S)

**TERIPARATIDE** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other osteoporosis drugs.

## **REQUIRED MEDICAL INFORMATION**

Osteoporosis: one of the following: patient has a history of a broken bone not due to trauma (non-traumatic fracture) or T-score between -1.0 and -2.5 and is at high risk for fracture or T-score lower than -2.5 AND trial of a bisphosphonate (e.g. alendronate, ibandronate, or zoledronic acid) or Prolia, OR side effect to bisphosphonate therapy or Prolia therapy that supports discontinuation, OR Patient is at very high risk of fracture by meeting at least one of the following: non-traumatic fracture while on bisphosphonate therapy or Prolia, patient has experienced a recent fracture (within the past 12 months) or history of multiple fractures, or T-score less than -3.0, or patient is at high risk for falls, or 10-year hip fracture probability greater than 4.5% based on FRAX score, or 10-year major osteoporosis-related fracture probability greater than 30% based on FRAX score.

Glucocorticoid-induced osteoporosis: initiating or continuing long-term glucocorticoid treatment (e.g. prednisone, dexamethasone) and either has history of a non-traumatic fracture or is at high risk for fracture.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 302 EFFECTIVE 11/2025

# **TETRABENAZINE (XENAZINE)**

### **MEDICATION(S)**

**TETRABENAZINE** 

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Tardive Dyskinesia, Chronic Tics or Tourette's Syndrome

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Chronic Tics or Tourette's Syndrome: trial and failure or side effect to two of the following first line therapies: haloperidol (Haldol), pimozide (Orap), clonidine (Catapres), guanfacine (Tenex), risperidone (Risperdal), or aripiprazole (Abilify) or there is a medical reason not to use all first therapies.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Chronic Tics or Tourette's Syndrome, Huntington's Chorea: Neurologist. Tardive Dyskinesia: Neurologist or Psychiatrist.

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 303 EFFECTIVE 11/2025

# **THALIDOMIDE (THALOMID)**

## **MEDICATION(S)**

**THALOMID** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 304 EFFECTIVE 11/2025

# **TIRZEPATIDE (MOUNJARO)**

### **MEDICATION(S)**

**MOUNJARO** 

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Being used with another GLP-1 agent

## **REQUIRED MEDICAL INFORMATION**

Confirmation of type 2 diabetes

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 305 EFFECTIVE 11/2025

# **TIVOZANIB (FOTIVDA)**

## **MEDICATION(S)**

**FOTIVDA** 

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 306 EFFECTIVE 11/2025

#### **TOBRAMYCIN INHALATION AGENTS**

## MEDICATION(S)

TOBRAMYCIN 300 MG/4ML NEBU SOLN, TOBRAMYCIN 300 MG/5ML NEBU SOLN

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

bronchiectasis

#### **EXCLUSION CRITERIA**

Being used for acute treatment of an infection.

## REQUIRED MEDICAL INFORMATION

Patient has cystic fibrosis or a bronchiectasis and copy of sputum culture is positive for Pseudomonas Aeruginosa.

## **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 307 EFFECTIVE 11/2025

# **TOFACITINIB (XELJANZ, XELJANZ XR)**

### **MEDICATION(S)**

XELJANZ, XELJANZ XR

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

### REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis: treatment failure or side effect with methotrexate OR medical reason why methotrexate cannnot be used AND trial of a TNF inhibitor (i.e., adalimumab). Polyarticular Juvenile Idiopathic Arthritis (pJIA): treatment failure or side effect with one DMARD OR has a medical reason why methotrexate cannnot be used AND trial of a TNF inhibitor (i.e., adalimumab).

Psoriatic arthritis (PsA): Trial of a TNF inhibitor (i.e., adalimumab). Spondyloarthritis (SpA): trial of a TNF inhibitor (i.e., adalimumab).

For oral solution for all indications: patient is unable to swallow a tablet.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

RA, PsA, pJIA, SpA: Rheumatologist.

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

#### **TOPICAL TESTOSTERONE PRODUCTS**

## **MEDICATION(S)**

TESTOSTERONE 1.62 % GEL, TESTOSTERONE 10 MG/ACT (2%) GEL, TESTOSTERONE 12.5 MG/ACT (1%) GEL, TESTOSTERONE 20.25 MG/1.25GM (1.62%) GEL, TESTOSTERONE 20.25 MG/ACT (1.62%) GEL, TESTOSTERONE 25 MG/2.5GM (1%) GEL, TESTOSTERONE 30 MG/ACT SOLUTION, TESTOSTERONE 40.5 MG/2.5GM (1.62%) GEL, TESTOSTERONE 50 MG/5GM (1%) GEL

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

transgender, gender dysphoria

#### **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 309 EFFECTIVE 11/2025

# **TOPIRAMATE EXTENDED RELEASE (QUDEXY XR)**

### **MEDICATION(S)**

TOPIRAMATE ER 100 MG CP24 SPRNK, TOPIRAMATE ER 150 MG CP24 SPRNK, TOPIRAMATE ER 200 MG CP24 SPRNK, TOPIRAMATE ER 25 MG CP24 SPRNK, TOPIRAMATE ER 50 MG CP24 SPRNK

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Patient has tried immediate-release topiramate or has a medical reason why patient cannot use immediate-release topiramate.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 310 EFFECTIVE 11/2025

# **TOPIRAMATE ORAL SOLUTION (EPRONTIA)**

### **MEDICATION(S)**

TOPIRAMATE 25 MG/ML SOLUTION

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Medical reason why patient cannot use topiramate tablet or sprinkle capsules

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 311 EFFECTIVE 11/2025

# **TOVORAFENIB (OJEMDA)**

## MEDICATION(S)

OJEMDA

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 312 EFFECTIVE 11/2025

# TRAMADOL ER (RYZOLT) - NARCOTIC SAFETY INITIATIVE

### **MEDICATION(S)**

TRAMADOL HCL (ER BIPHASIC)

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other long-acting narcotic drugs.

### REQUIRED MEDICAL INFORMATION

Cancer pain: dose has been consolidated to the least number of higher strength forms. Non-cancer pain, initial: cause of pain cannot be removed or treated with other treatment options, and pain occurs daily and has lasted for at least 3 months, and pain is severe enough to need daily around-the-clock long-term narcotic use, and total daily dose across all narcotic drugs is less than 90 MME, and dose has been consolidated to the least number of higher strength forms and trial of tramadol immediate-release and intolerable side effect to the preferred tramadol extended release (generic Ultram ER), and chart notes document pain history including baseline pain intensity score and functional interference score, and a plan for monitoring side effects and misuse and to taper down narcotics exists. Non-cancer pain, reauth: total daily dose across all narcotic drugs is less than 90 MME per day, and dose has been consolidated to the least number of higher strength forms, and chart notes document current pain intensity score, functional interference score, any side effects and/or misuse with current pain treatment regimen, and plan to taper narcotic use.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Cancer Pain: Oncologist or Pain Specialist.

#### **COVERAGE DURATION**

Cancer pain: plan year

Non-cancer pain: initial 30 days, 1st reauth 3mos, ongoing reauths plan year

PAGE 313 EFFECTIVE 11/2025

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 314 EFFECTIVE 11/2025

# TRAMADOL ER (ULTRAM ER) - NARCOTIC SAFETY INITIATIVE

### **MEDICATION(S)**

TRAMADOL HCL ER 100 MG TAB ER 24H, TRAMADOL HCL ER 200 MG TAB ER 24H, TRAMADOL HCL ER 300 MG TAB ER 24H

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with other long-acting narcotic drugs.

#### REQUIRED MEDICAL INFORMATION

Cancer pain: dose has been consolidated to the least number of higher strength forms. Non-cancer pain, initial: cause of pain cannot be removed or treated with other treatment options, and pain occurs daily and has lasted for at least 3 months, and pain is severe enough to need daily around-the-clock long-term narcotic use, and total daily dose across all narcotic drugs is less than 90 MME, and dose has been consolidated to the least number of higher strength forms and trial of short-acting tramadol, and chart notes document pain history including baseline pain intensity score and functional interference score, and a plan for monitoring side effects and misuse and to taper down narcotics exists. Non-cancer pain, reauth: total daily dose across all narcotic drugs is less than 90 MME per day, and dose has been consolidated to the least number of higher strength forms, and chart notes document current pain intensity score, functional interference score, any side effects and/or misuse with current pain treatment regimen, and plan to taper narcotic use.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Cancer pain: Oncologist or Pain Specialist.

#### **COVERAGE DURATION**

Cancer pain: plan year Non-cancer pain: initial 30 days,1st reauth 3mos, ongoing reauths plan year

PAGE 315 EFFECTIVE 11/2025

## **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 316 EFFECTIVE 11/2025

# **TRAMETINIB (MEKINIST)**

### **MEDICATION(S)**

**MEKINIST** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 317 EFFECTIVE 11/2025

## TRANSMUCOSAL FENTANYL PRODUCTS

### MEDICATION(S)

FENTANYL CITRATE 100 MCG TAB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Documentation of pain due to cancer.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Oncologist or Pain Management Specialist

#### **COVERAGE DURATION**

6 months

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 318 EFFECTIVE 11/2025

# TRAZODONE ORAL SOLUTION (RALDESY)

## **MEDICATION(S)**

**RALDESY** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Medical reason why trazodone tablet cannot be used.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 319 EFFECTIVE 11/2025

# TRETINOIN PRODUCTS (AVITA, RETIN-A, ATRALIN)

### **MEDICATION(S)**

TRETINOIN 0.01 % GEL, TRETINOIN 0.025 % CREAM, TRETINOIN 0.025 % GEL, TRETINOIN 0.05 % CREAM, TRETINOIN 0.05 % GEL, TRETINOIN 0.1 % CREAM

#### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

#### **AGE RESTRICTION**

40 years of age or older. No prior authorization required for less than 40 years old.

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 320 EFFECTIVE 11/2025

# TRIAMCINOLONE TOPICAL SPRAY (KENALOG)

### **MEDICATION(S)**

TRIAMCINOLONE ACETONIDE 0.147 MG/GM AERO SOLN

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Trial of triamcinolone cream, ointment, or lotion AND one other topical steroid in the same or higher potency (strength) class.

#### **AGE RESTRICTION**

N/A

## PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 321 EFFECTIVE 11/2025

# TRIENTINE HCL (SYPRINE)

### MEDICATION(S)

TRIENTINE HCL

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Side effect to penicillamine.

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 322 EFFECTIVE 11/2025

# TRIFLURIDINE-TIPIRACIL (LONSURF)

### **MEDICATION(S)**

**LONSURF** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

## **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 323 EFFECTIVE 11/2025

# **TUCATINIB (TUKYSA)**

## **MEDICATION(S)**

**TUKYSA** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 324 EFFECTIVE 11/2025

# **UBROGEPANT (UBRELVY)**

# MEDICATION(S)

**UBRELVY** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to at least ONE triptan (e.g., sumatriptan, rizatriptan, naratriptan) or has a medical reason (contraindication) for not using triptans.

### **AGE RESTRICTION**

N/A

# PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 325 EFFECTIVE 11/2025

# **UPADACITINIB** (RINVOQ)

## **MEDICATION(S)**

RINVOQ, RINVOQ LQ

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

## REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis: treatment failure or side effect with methotrexate or medical reason why methotrexate cannot be used AND trial of a TNF inhibitor (i.e., adalimumab). Psoriatic arthritis (PsA): trial of a TNF inhibitor (i.e., adalimumab). Atopic Dermatitis: moderate to severe disease confirmed by Investigators Global Assessment (IGA) score of 3-4, Eczema Area and Severity Index (EASI) score of at least 16, Body surface area of at least 10%, or Severity Scoring of Atopic Dermatitis Index (SCORAD) score of at least 25 AND treatment failure or side effect with a medium to very high potency topical corticosteroid and a topical calcineurin inhibitor (i.e., tacrolimus ointment) OR has a medical reason why these topical therapies cannot be used. Crohn's Disease (CD): Trial of a TNF inhibitor (i.e., adalimumab). Spondyloarthritis (SpA): non-radiographic axial SpA or trial of a TNF inhibitor (i.e., adalimumab). Polyarticular juvenile idiopathic arthritis (pJIA): treatment failure or side effect with one DMARD drug or medical reason why methotrexate cannot be used AND trial of a TNF inhibitor (i.e., adalimumab). Giant cell arteritis (GCA): currently taking steroids, ongoing use: responding to therapy

### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

RA, PsA, SpA, pJIA: Rheumatologist. Atopic Dermatitis: Dermatologist, Allergist, or Immunologist.

#### **COVERAGE DURATION**

Plan year

PAGE 326 EFFECTIVE 11/2025

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 327 EFFECTIVE 11/2025

# **USTEKINUMAB IV (STELARA IV)**

## **MEDICATION(S)**

STELARA 130 MG/26ML SOLUTION

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

# REQUIRED MEDICAL INFORMATION

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

one time induction infusion

#### **OTHER CRITERIA**

Excluded under Part D if covered by Part B.

Dose and duration is not more than the FDA labeled maximum.

PAGE 328 EFFECTIVE 11/2025

# **USTEKINUMAB SQ (STELARA)**

## **MEDICATION(S)**

STELARA 45 MG/0.5ML SOLN PRSYR, STELARA 45 MG/0.5ML SOLUTION, STELARA 90 MG/ML SOLN PRSYR

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another targeted immunotherapy drug.

## REQUIRED MEDICAL INFORMATION

Plaque Psoriasis (PsO), initial use: treatment failure or side effect with one DMARD or has a medical reason why methotrexate, cyclosporine, and acitretin cannot be used AND moderate to severe disease confirmed by Psoriasis Area and Severity Index (PASI) score of 10 or more OR Body Surface Area (BSA) of at least 3% OR sensitive areas are involved OR disease affects daily living. PsO, ongoing use: PASI or BSA improved with use of Stelara.

Crohn's Disease (CD), initial use: SQ formulation will be started after initial IV dose. CD, ongoing use: symptom improvement with use of Stelara.

Ulcerative colitis (UC), initial use: disease is moderate to severe AND SQ formulation will be started after initial IV dose. UC, ongoing use: symptom improvement with use of Stelara.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

PsO: Dermatologist or Rheumatologist. PsA: Rheumatologist.

# **COVERAGE DURATION**

PsO and PsA: refer to other criteria. CD and UC: plan year.

# **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PsO and PsA initial: one loading dose and 2 maintenance doses (28 weeks total). PsO and PsA onging maintenance use: plan year.

PAGE 330 EFFECTIVE 11/2025

# **VANCOMYCIN ORAL SOLUTION (FIRVANQ)**

## **MEDICATION(S)**

VANCOMYCIN HCL 250 MG/5ML RECON SOLN, VANCOMYCIN HCL 50 MG/ML RECON SOLN

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Clostridium difficile: evidence of current infection.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

10 days

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 331 EFFECTIVE 11/2025

# **VANDETANIB (CAPRELSA)**

## **MEDICATION(S)**

**CAPRELSA** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 332 EFFECTIVE 11/2025

# **VARDENAFIL (LEVITRA, STAXYN)**

# **MEDICATION(S)**

VARDENAFIL HCL

# **PA INDICATION INDICATOR**

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Benign Prostatic Hyperplasia, Raynaud's phenomenon

#### **EXCLUSION CRITERIA**

N/A

## REQUIRED MEDICAL INFORMATION

Raynaud's phenomenon: treatment failure or side effect with a calcium-channel blocker (e.g. nifedipine) and treatment failure or side effect with sildenafil (Viagra) and tadalafil (Cialis). BPH: treatment failure or side effect with both finasteride and tamsulosin AND teatment failure or side effect with tadalafil (Cialis).

ED: due to a drug or medical condition that has been reported in the medical literature to cause ED and treatment failure or side effect with sildenafil (Viagra) and tadalafil (Cialis).

#### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

ED: limited to 8 tablets per month.

Dose and duration is not more than the FDA labeled maximum.

PAGE 333 EFFECTIVE 11/2025

# **VEMURAFENIB (ZELBORAF)**

## **MEDICATION(S)**

**ZELBORAF** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 334 EFFECTIVE 11/2025

# **VENETOCLAX (VENCLEXTA)**

## **MEDICATION(S)**

VENCLEXTA, VENCLEXTA STARTING PACK

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 335 EFFECTIVE 11/2025

# **VERICIGUAT (VERQUVO)**

# **MEDICATION(S)**

**VERQUVO** 

#### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Left heart ventricular ejection fraction (LVEF) less than or equal to 45% AND patient is on the highest tolerated dose of guideline supported therapies including a renin-angiotensin inhibitor drug (e.g. ACE-Inhibitor, ARB agent, Entresto) and beta-blocker drug (e.g. bisoprolol, carvedilol, metoprolol succinate) unless there is a medical reason for not using (contraindication) the supported therapies.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 336 EFFECTIVE 11/2025

# **VIGABATRIN (SABRIL, VIGADRONE)**

## **MEDICATION(S)**

VIGABATRIN, VIGADRONE, VIGPODER

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Infantile spasm continued use: ongoing diagnosis of infantile spasm is confirmed by EEG OR prescriber provides medical reason for continued use.

Complex partial seizures: patient has tried two preferred partial seizure drugs (e.g. carbamazepine, clorazepate, divalproex, felbamate lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, zonisamide)

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

Infantile spasms: Neurologist

#### **COVERAGE DURATION**

Seizures: annual

Infantile spasms: 6 months

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 337 EFFECTIVE 11/2025

# **VIGABATRIN (VIGAFYDE)**

## MEDICATION(S)

**VIGAFYDE** 

## PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Diagnosis of infantile spasm is confirmed by EEG.

### **AGE RESTRICTION**

Age consistent with FDA label

### PRESCRIBER RESTRICTION

Neurologist

### **COVERAGE DURATION**

Up to plan year (depends on patient's age)

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 338 EFFECTIVE 11/2025

# **VIMSELTINIB (ROMVIMZA)**

# MEDICATION(S)

**ROMVIMZA** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 339 EFFECTIVE 11/2025

# **VISMODEGIB (ERIVEDGE)**

# **MEDICATION(S)**

**ERIVEDGE** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 340 EFFECTIVE 11/2025

# **VORASIDENIB (VORANIGO)**

## **MEDICATION(S)**

**VORANIGO** 

## **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 341 EFFECTIVE 11/2025

# **VORICONAZOLE ORAL (VFEND)**

## **MEDICATION(S)**

VORICONAZOLE 200 MG TAB, VORICONAZOLE 40 MG/ML RECON SUSP, VORICONAZOLE 50 MG TAB

#### PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

#### **OFF LABEL USES**

Prophylaxis of Disseminated Candidiasis, Candida Endopthalmitis, Oropharyngeal Candidiasis, Allergic bronchopulmonary aspergillosis, maintenance treatment of talaromycosis (Talaromyces marneffei -formerly Penicillium marneffei) in HIV-positive patients, treatment of Lomentospora (formerly Scedosporium) prolificans infection, treatment of pulmonary aspergillosis, chronic (cavitary or necrotizing), prophylaxis of Invasive Aspergillosis in high-risk patients.

#### **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Systemic fungal infection treatment: culture test confirms Aspergillosis, candidemia, deeptissue candida infection, blastomycosis, scedosporium apiospermum, fusarium species.

Candida infection of the esophagus, throat, mouth (esophageal or oropharyngeal candidiasis) after trial of fluconazole or there is a medical reason not to use fluconazole.

Prophylaxis of asperillosis or candidiasis after a bone marrow or lung transplant.

#### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

BMT:6mo Lung tx:3mo Esophageal candida:1mo Candidemia/deep-tissue:1mo Other ind in other criteria

PAGE 342 EFFECTIVE 11/2025

# **OTHER CRITERIA**

coverage duration:

ABPA: 4 month.

systemic treatment: plan year.

Dose and duration is not more than the FDA labeled maximum.

PAGE 343 EFFECTIVE 11/2025

# **VORINOSTAT (ZOLINZA)**

## **MEDICATION(S)**

**ZOLINZA** 

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 344 EFFECTIVE 11/2025

# **XANOMELINE-TROSPIUM (COBENFY)**

## **MEDICATION(S)**

COBENFY, COBENFY STARTER PACK

#### PA INDICATION INDICATOR

3 - All Medically-Accepted Indications

#### **OFF LABEL USES**

N/A

#### **EXCLUSION CRITERIA**

Being used with another antipsychotic agent

# REQUIRED MEDICAL INFORMATION

Trial and failure or side effect to one generic atypical antipsychotic drug (e.g., aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) or there is a medical reason why all the generic atypical antipsychotics cannot be used.

### **AGE RESTRICTION**

N/A

#### PRESCRIBER RESTRICTION

N/A

#### **COVERAGE DURATION**

Plan year

#### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 345 EFFECTIVE 11/2025

# **ZANUBRUTINIB (BRUKINSA)**

# **MEDICATION(S)**

**BRUKINSA** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

# **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 346 EFFECTIVE 11/2025

# **ZONGERTINIB (HERNEXEOS)**

## **MEDICATION(S)**

**HERNEXEOS** 

#### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Exclusion criteria will be based on current National Comprehensive Cancer Network (NCCN) guidelines and FDA labeling.

# **REQUIRED MEDICAL INFORMATION**

N/A

# **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

N/A

### **COVERAGE DURATION**

Plan year

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 347 EFFECTIVE 11/2025

# **ZURANOLONE (ZURZUVAE)**

## **MEDICATION(S)**

**ZURZUVAE** 

# **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

# **EXCLUSION CRITERIA**

N/A

# REQUIRED MEDICAL INFORMATION

Postpartum depression confirmed by DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) criteria.

### **AGE RESTRICTION**

N/A

### PRESCRIBER RESTRICTION

Psychiatrist or Obstetrician

### **COVERAGE DURATION**

One course per pregnancy (14 days)

### **OTHER CRITERIA**

Dose and duration is not more than the FDA labeled maximum.

PAGE 348 EFFECTIVE 11/2025

# Part B vs D drugs

These drugs may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drugs to make the determination.

# Medication(s)

MEDICATION NAME	ROUTE	DOSE FORM
Abelcet 5 MG/ML SUSPENSION	IV	SUSPENSION
Abilify Asimtufii 720 MG/2.4ML PRSYR	IM	PRSYR
Abilify Asimtufii 960 MG/3.2ML PRSYR	IM	PRSYR
Abilify Maintena 300 MG PRSYR	IM	PRSYR
Abilify Maintena 300 MG SRER	IM	
Abilify Maintena 300 MG SRER	IM	
Abilify Maintena 400 MG PRSYR	IM	PRSYR
Abilify Maintena 400 MG SRER	IM	
Abilify Maintena 400 MG SRER	IM	
Abraxane 100 MG RECON SUSP	IV	RECON SUSP
Acetadote 200 MG/ML SOLUTION	IV	SOLUTION
Acetaminophen 10 MG/ML SOLUTION	IV	SOLUTION
Acetaminophen 1000 MG/100ML SOLUTION	IV	SOLUTION
Acetylcysteine 10 % SOLUTION	IN	SOLUTION
Acetylcysteine 20 % SOLUTION	IN	SOLUTION
Acetylcysteine 200 MG/ML SOLUTION	IV	SOLUTION
Actemra 200 MG/10ML SOLUTION	IV	SOLUTION
Actemra 400 MG/20ML SOLUTION	IV	SOLUTION
Actemra 80 MG/4ML SOLUTION	IV	SOLUTION
Acyclovir Sodium 50 MG/ML SOLUTION	IV	SOLUTION
Acyclovir Sodium-NaCl 200-0.9 MG/100ML-% SOLUTION	IV	SOLUTION
Adcetris 50 MG RECON SOLN	IV	RECON SOLN
Adrenalin 1 MG/ML SOLUTION	IJ	SOLUTION
Adrenalin 30 MG/30ML SOLUTION	IJ	SOLUTION
Adriamycin 10 MG RECON SOLN	IV	RECON SOLN
Adriamycin 2 MG/ML SOLUTION	IV	SOLUTION
Adriamycin 50 MG RECON SOLN	IV	RECON SOLN
Adzynma 1500 UNIT KIT	IV	KIT
Adzynma 500 UNIT KIT	IV	KIT
Akynzeo (Ready-to-Use) 235-0.25 MG/20ML SOLUTION	IV	SOLUTION
Akynzeo 235-0.25 MG RECON SOLN	IV	RECON SOLN
Akynzeo 235-0.25 MG/20ML SOLUTION	IV	SOLUTION
Akynzeo 300-0.5 MG CAP	PO	CAP
Albuterol Sulfate (2.5 MG/3ML) 0.083% NEBU SOLN	IN	NEBU SOLN

PAGE 349 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Albuterol Sulfate (5 MG/ML) 0.5% NEBU SOLN	IN	NEBU SOLN
Albuterol Sulfate 0.63 MG/3ML NEBU SOLN	IN	NEBU SOLN
Albuterol Sulfate 1.25 MG/3ML NEBU SOLN	IN	NEBU SOLN
Albuterol Sulfate 2.5 MG/0.5ML NEBU SOLN	IN	NEBU SOLN
Aldurazyme 2.9 MG/5ML SOLUTION	IV	SOLUTION
Alferon N 5000000 UNIT/ML SOLUTION	IJ	SOLUTION
Alimta 100 MG RECON SOLN	IV	RECON SOLN
Alimta 500 MG RECON SOLN	IV	RECON SOLN
Aligopa 60 MG RECON SOLN	IV	RECON SOLN
Alkeran 2 MG TAB	PO	TAB
Alkeran 50 MG RECON SOLN	IV	RECON SOLN
Allopurinol Sodium 500 MG RECON SOLN	IV	RECON SOLN
Aloprim 500 MG RECON SOLN	IV	RECON SOLN
Alyglo 10 GM/100ML SOLUTION	IV	SOLUTION
Alygio 20 GM/200ML SOLUTION	IV	SOLUTION
Alyglo 5 GM/50ML SOLUTION	IV	SOLUTION
Alymsys 100 MG/4ML SOLUTION	IV	SOLUTION
Alymsys 400 MG/16ML SOLUTION	IV	SOLUTION
AmBisome 50 MG RECON SUSP	IV	RECON SUSP
Amino Acid 5 % SOLUTION	IV	SOLUTION
Aminophylline 25 MG/ML SOLUTION	IV	SOLUTION
AminoProtect 5 % SOLUTION	IV	SOLUTION
Aminosyn II 10 % SOLUTION	IV	SOLUTION
Aminosyn II 15 % SOLUTION	IV	SOLUTION
Aminosyn-PF 10 % SOLUTION	IV	SOLUTION
Aminosyn-PF 7 % SOLUTION	IV	SOLUTION
Aminosyn-PF 7% 7 % SOLUTION	IV	SOLUTION
Amiodarone HCI 150 MG/3ML SOLUTION	IV	SOLUTION
Amiodarone HCI 450 MG/9ML SOLUTION	IV	SOLUTION
Amiodarone HCI 900 MG/18ML SOLUTION	IV	SOLUTION
Amphotericin B 50 MG RECON SOLN	IV	RECON SOLN
Amphotericin B Liposome 50 MG RECON SUSP	IV	RECON SUSP
Amvuttra 25 MG/0.5ML SOLN PRSYR	SC	SOLN PRSYR
Anzemet 100 MG TAB	PO	TAB
Anzemet 50 MG TAB	PO	TAB
Aprepitant 125 MG CAP	PO	CAP
Aprepitant 80 & 125 MG CAP	PO	CAP
Aprepitant 80 MG CAP	PO	CAP
Aralast NP 1000 MG RECON SOLN	IV	RECON SOLN
Aralast NP 500 MG RECON SOLN	IV	RECON SOLN
Arformoterol Tartrate 15 MCG/2ML NEBU SOLN	IN	NEBU SOLN
Argatroban 250 MG/2.5ML SOLUTION	IV	SOLUTION
Argatroban 50 MG/50ML SOLUTION	IV	SOLUTION
Aristada 1064 MG/3.9ML PRSYR	IM	PRSYR

PAGE 350 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Aristada 441 MG/1.6ML PRSYR	IM	PRSYR
Aristada 662 MG/2.4ML PRSYR	IM	PRSYR
Aristada 882 MG/3.2ML PRSYR	IM	PRSYR
Aristada Initio 675 MG/2.4ML PRSYR	IM	PRSYR
Arranon 5 MG/ML SOLUTION	IV	SOLUTION
Arsenic Trioxide 10 MG/10ML SOLUTION	IV	SOLUTION
Arsenic Trioxide 12 MG/6ML SOLUTION	IV	SOLUTION
Arzerra 100 MG/5ML CONC	IV	CONC
Arzerra 1000 MG/50ML CONC	IV	CONC
Asceniv 5 GM/50ML SOLUTION	IV	SOLUTION
Asparlas 3750 UNIT/5ML SOLUTION	IV	SOLUTION
Astagraf XL 0.5 MG CAP ER 24H	PO	CAP ER 24H
Astagraf XL 1 MG CAP ER 24H	PO	CAP ER 24H
Astagraf XL 5 MG CAP ER 24H	PO	CAP ER 24H
Atgam 50 MG/ML SOLUTION	IV	SOLUTION
Ativan 2 MG/ML SOLUTION	IJ	SOLUTION
Ativan 4 MG/ML SOLUTION	IJ	SOLUTION
Avastin 100 MG/4ML SOLUTION	IV	SOLUTION
Avastin 400 MG/16ML SOLUTION	IV	SOLUTION
Aveed 750 MG/3ML SOLUTION	IM	SOLUTION
Avgemsi 1 GM/26.3ML SOLUTION	IV	SOLUTION
Avgemsi 2 GM/52.6ML SOLUTION	IV	SOLUTION
Avsola 100 MG RECON SOLN	IV	RECON SOLN
Avtozma 200 MG/10ML SOLUTION	IV	SOLUTION
Avtozma 400 MG/20ML SOLUTION	IV	SOLUTION
Avtozma 80 MG/4ML SOLUTION	IV	SOLUTION
Avycaz 2.5 (2-0.5) GM RECON SOLN	IV	RECON SOLN
Axtle 100 MG RECON SOLN	IV	RECON SOLN
Axtle 500 MG RECON SOLN	IV	RECON SOLN
AzaCITIDine 100 MG RECON SUSP	IJ	RECON SUSP
Azasan 100 MG TAB	PO	TAB
Azasan 75 MG TAB	PO	TAB
azaTHIOprine 100 MG TAB	PO	TAB
AzaTHIOprine 50 MG TAB	PO	TAB
azaTHIOprine 75 MG TAB	PO	TAB
AzaTHIOprine Sodium 100 MG RECON SOLN	IJ	RECON SOLN
Azmiro 200 MG/ML SOLN PRSYR	IM	SOLN PRSYR
Baclofen 20000 MCG/20ML SOLUTION	IT	SOLUTION
Baclofen 40 MG/20ML SOLUTION	IT	SOLUTION
Baclofen 40000 MCG/20ML SOLUTION	IT	SOLUTION
Baclofen 50 MCG/ML SOLN PRSYR	IT	SOLN PRSYR
Bavencio 200 MG/10ML SOLUTION	IV	SOLUTION
Beleodag 500 MG RECON SOLN	IV	RECON SOLN
Belrapzo 100 MG/4ML SOLUTION	IV	SOLUTION

PAGE 351 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Bendamustine HCI 100 MG RECON SOLN	IV	RECON SOLN
Bendamustine HCI 100 MG/4ML SOLUTION	IV	SOLUTION
Bendamustine HCI 25 MG RECON SOLN	IV	RECON SOLN
Bendeka 100 MG/4ML SOLUTION	IV	SOLUTION
Benlysta 120 MG RECON SOLN	IV	RECON SOLN
Benlysta 400 MG RECON SOLN	IV	RECON SOLN
Bentyl 10 MG/ML SOLUTION	IM	SOLUTION
Besponsa 0.9 MG RECON SOLN	IV	RECON SOLN
Betamethasone Combo 6 (3-3) MG/ML SUSPENSION	IJ	SUSPENSION
Betamethasone Sod Phos & Acet 6 (3-3) MG/ML SUSPENSION	IJ	SUSPENSION
Bethkis 300 MG/4ML NEBU SOLN	IN	NEBU SOLN
BICNU 100 MG RECON SOLN	IV	RECON SOLN
Bildyos 60 MG/ML SOLN PRSYR	SC	SOLN PRSYR
Bilprevda 120 MG/1.7ML SOLUTION	SC	SOLUTION
Bivigam 10 GM/100ML SOLUTION	IV	SOLUTION
Bivigam 5 GM/50ML SOLUTION	IV	SOLUTION
Bizengri (750 MG Dose) 375 MG/18.75ML SOLN THPK	IV	SOLN THPK
BKEMV 300 MG/30ML SOLUTION	IV	SOLUTION
Blenrep 100 MG RECON SOLN	IV	RECON SOLN
Bleomycin Sulfate 15 UNIT RECON SOLN	IJ	RECON SOLN
Bleomycin Sulfate 30 UNIT RECON SOLN	IJ	RECON SOLN
Blincyto 35 MCG RECON SOLN	IV	RECON SOLN
Bomyntra 120 MG/1.7ML SOLN PRSYR	SC	SOLN PRSYR
Bomyntra 120 MG/1.7ML SOLUTION	SC	SOLUTION
Boniva 3 MG/3ML SOLUTION	IV	SOLUTION
Bortezomib 1 MG RECON SOLN	IJ	RECON SOLN
Bortezomib 2.5 MG RECON SOLN	IJ	RECON SOLN
Bortezomib 3.5 MG RECON SOLN	IJ	RECON SOLN
Bortezomib 3.5 MG RECON SOLN	IV	RECON SOLN
Bortezomib 3.5 MG/1.4ML SOLUTION	IV	SOLUTION
Boruzu 3.5 MG/1.4ML SOLUTION	IJ	SOLUTION
Botox 100 UNIT RECON SOLN	IJ	RECON SOLN
Botox 200 UNIT RECON SOLN	IJ	RECON SOLN
Briumvi 150 MG/6ML SOLUTION	IV	SOLUTION
Brovana 15 MCG/2ML NEBU SOLN	IN	NEBU SOLN
Budesonide 0.25 MG/2ML SUSPENSION	IN	SUSPENSION
Budesonide 0.5 MG/2ML SUSPENSION	IN	SUSPENSION
Budesonide 1 MG/2ML SUSPENSION	IN	SUSPENSION
Buprenex 0.3 MG/ML SOLUTION	IJ	SOLUTION
Buprenorphine HCI 0.3 MG/ML SOLUTION	IJ	SOLUTION
Busulfan 6 MG/ML SOLUTION	IV	SOLUTION

PAGE 352 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Busulfex 6 MG/ML SOLUTION	IV	SOLUTION
Butorphanol Tartrate 1 MG/ML SOLUTION	IJ	SOLUTION
Butorphanol Tartrate 2 MG/ML SOLUTION	IJ	SOLUTION
Cabenuva 400 & 600 MG/2ML SUSP	IM	SUSP
Cabenuva 600 & 900 MG/3ML SUSP	IM	SUSP
Calcitonin (Salmon) 200 UNIT/ML SOLUTION	IJ	SOLUTION
Calcitriol 0.25 MCG CAP	PO	CAP
Calcitriol 0.5 MCG CAP	PO	CAP
Calcitriol 1 MCG/ML SOLUTION	IV	SOLUTION
Calcitriol 1 MCG/ML SOLUTION	PO	SOLUTION
Calcium Gluconate 10 % SOLUTION	IV	SOLUTION
Caldolor 800 MG/200ML SOLUTION	IV	SOLUTION
Caldolor 800 MG/8ML SOLUTION	IV	SOLUTION
Camcevi 42 MG PRSYR	SC	PRSYR
Camptosar 100 MG/5ML SOLUTION	IV	SOLUTION
Camptosar 300 MG/15ML SOLUTION	IV	SOLUTION
Camptosar 40 MG/2ML SOLUTION	IV	SOLUTION
CARBOplatin 150 MG/15ML SOLUTION	IV	SOLUTION
CARBOplatin 450 MG/45ML SOLUTION	IV	SOLUTION
CARBOplatin 50 MG/5ML SOLUTION	IV	SOLUTION
CARBOplatin 600 MG/60ML SOLUTION	IV	SOLUTION
Cardene IV 20-0.86 MG/200ML-% SOLUTION	IV	SOLUTION
Cardene IV 20-4.8 MG/200ML-% SOLUTION	IV	SOLUTION
Cardene IV 40-0.83 MG/200ML-% SOLUTION	IV	SOLUTION
Carmustine 100 MG RECON SOLN	IV	RECON SOLN
Carmustine 300 MG RECON SOLN	IV	RECON SOLN
Carmustine 50 MG RECON SOLN	IV	RECON SOLN
Carnitor 200 MG/ML SOLUTION	IV	SOLUTION
ceFAZolin in Sodium Chloride 2-0.9 GM/100ML-% SOLUTION	IV	SOLUTION
CeFAZolin in Sodium Chloride 3-0.9 GM/100ML-% SOLUTION	IV	SOLUTION
CeFAZolin Sodium-Dextrose 1-4 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CeFAZolin Sodium-Dextrose 1-4 GM/50ML-% SOLUTION	IV	SOLUTION
CeFAZolin Sodium-Dextrose 2-3 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CeFAZolin Sodium-Dextrose 2-4 GM/100ML-% SOLUTION	IV	SOLUTION
ceFAZolin Sodium-Dextrose 2-5 GM/100ML-% SOLUTION	IV	SOLUTION
ceFAZolin Sodium-Dextrose 3-2 GM-%(50ML) RECON SOLN	IV	RECON SOLN
ceFAZolin Sodium-Dextrose 3-4 GM/150ML-% SOLUTION	IV	SOLUTION

PAGE 353 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Cefepime HCI 100 GM RECON SOLN	IV	RECON SOLN
Cefepime-Dextrose 1-5 GM-%(50ML) RECON SOLN	IV	RECON SOLN
Cefepime-Dextrose 2-5 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CefoTEtan Disodium-Dextrose 1-3.58 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CefoTEtan Disodium-Dextrose 2-2.08 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CefOXitin Sodium-Dextrose 1-4 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CefOXitin Sodium-Dextrose 2-2.2 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CefTAZidime and Dextrose 1-5 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CefTAZidime and Dextrose 2-5 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CefTRIAXone Sodium 100 GM RECON SOLN	IJ	RECON SOLN
CefTRIAXone Sodium in Dextrose 20 MG/ML SOLUTION	IV	SOLUTION
CefTRIAXone Sodium in Dextrose 40 MG/ML SOLUTION	IV	SOLUTION
CefTRIAXone Sodium-Dextrose 1-3.74 GM-%(50ML) RECON SOLN	IV	RECON SOLN
CefTRIAXone Sodium-Dextrose 2-2.22 GM-%(50ML) RECON SOLN	IV	RECON SOLN
Celestone Soluspan 6 (3-3) MG/ML SUSPENSION	IJ	SUSPENSION
CellCept 200 MG/ML RECON SUSP	PO	RECON SUSP
CellCept 250 MG CAP	PO	CAP
CellCept 500 MG TAB	PO	TAB
CellCept Intravenous 500 MG RECON SOLN	IV	RECON SOLN
Cerebyx 100 MG PE/2ML SOLUTION	IJ	SOLUTION
Cerebyx 500 MG PE/10ML SOLUTION	IJ	SOLUTION
Cerezyme 400 UNIT RECON SOLN	IV	RECON SOLN
Chlorothiazide Sodium 500 MG RECON SOLN	IV	RECON SOLN
Chorionic Gonadotropin 10000 UNIT RECON SOLN	IM	RECON SOLN
Cidofovir 75 MG/ML SOLUTION	IV	SOLUTION
Cinacalcet HCI 30 MG TAB	PO	TAB
Cinacalcet HCl 60 MG TAB	PO	TAB
Cinacalcet HCI 90 MG TAB	PO	TAB
Cinqair 100 MG/10ML SOLUTION	IV	SOLUTION
Ciprofloxacin in D5W 400 MG/200ML SOLUTION	IV	SOLUTION
CISplatin 100 MG/100ML SOLUTION	IV	SOLUTION
CISplatin 200 MG/200ML SOLUTION	IV	SOLUTION
CISplatin 50 MG RECON SOLN	IV	RECON SOLN
CISplatin 50 MG/50ML SOLUTION	IV	SOLUTION
Cladribine 10 MG/10ML SOLUTION	IV	SOLUTION
Clinimix E/Dextrose (2.75/5) 2.75 % SOLUTION	IV	SOLUTION

PAGE 354 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Clinimix E/Dextrose (4.25/10) 4.25 % SOLUTION	IV	SOLUTION
Clinimix E/Dextrose (4.25/5) 4.25 % SOLUTION	IV	SOLUTION
Clinimix E/Dextrose (5/15) 5 % SOLUTION	IV	SOLUTION
Clinimix E/Dextrose (5/20) 5 % SOLUTION	IV	SOLUTION
Clinimix E/Dextrose (8/10) 8 % SOLUTION	IV	SOLUTION
Clinimix E/Dextrose (8/14) 8 % SOLUTION	IV	SOLUTION
Clinimix/Dextrose (4.25/10) 4.25 % SOLUTION	IV	SOLUTION
Clinimix/Dextrose (4.25/5) 4.25 % SOLUTION	IV	SOLUTION
Clinimix/Dextrose (5/15) 5 % SOLUTION	IV	SOLUTION
Clinimix/Dextrose (5/20) 5 % SOLUTION	IV	SOLUTION
Clinimix/Dextrose (6/5) 6 % SOLUTION	IV	SOLUTION
Clinimix/Dextrose (8/10) 8 % SOLUTION	IV	SOLUTION
Clinimix/Dextrose (8/14) 8 % SOLUTION	IV	SOLUTION
Clinisol SF 15 % SOLUTION	IV	SOLUTION
Clinolipid 20 % EMULSION	IV	EMULSION
Clofarabine 1 MG/ML SOLUTION	IV	SOLUTION
Clolar 1 MG/ML SOLUTION	IV	SOLUTION
CloNIDine HCI (Analgesia) 100 MCG/ML SOLUTION	EP	SOLUTION
Cocaine HCI 40 MG/ML SOLUTION	NA	SOLUTION
Columvi 10 MG/10ML SOLUTION	IV	SOLUTION
Columvi 2.5 MG/2.5ML SOLUTION	IV	SOLUTION
Conexxence 60 MG/ML SOLN PRSYR	SC	SOLN PRSYR
Cosela 300 MG RECON SOLN	IV	RECON SOLN
Cosentyx 125 MG/5ML SOLUTION	IV	SOLUTION
Cosmegen 0.5 MG RECON SOLN	IV	RECON SOLN
Cromolyn Sodium 20 MG/2ML NEBU SOLN	IN	NEBU SOLN
Crysvita 10 MG/ML SOLUTION	SC	SOLUTION
Crysvita 20 MG/ML SOLUTION	SC	SOLUTION
Crysvita 30 MG/ML SOLUTION	SC	SOLUTION
Cupric Chloride 0.4 MG/ML SOLUTION	IV	SOLUTION
Cutaquig 1 GM/6ML SOLUTION	SC	SOLUTION
Cutaquig 1.65 GM/10ML SOLUTION	SC	SOLUTION
Cutaquig 2 GM/12ML SOLUTION	SC	SOLUTION
Cutaquig 3.3 GM/20ML SOLUTION	SC	SOLUTION
Cutaquig 4 GM/24ML SOLUTION	SC	SOLUTION
Cutaquig 8 GM/48ML SOLUTION	SC	SOLUTION
Cuvitru 1 GM/5ML SOLUTION	SC	SOLUTION
Cuvitru 10 GM/50ML SOLUTION	SC	SOLUTION
Cuvitru 2 GM/10ML SOLUTION	SC	SOLUTION
Cuvitru 4 GM/20ML SOLUTION	SC	SOLUTION
Cuvitru 8 GM/40ML SOLUTION	SC	SOLUTION
Cyclophosphamide 1 GM RECON SOLN	IJ	RECON SOLN
cycloPHOSphamide 1 GM/2ML SOLUTION	IV	SOLUTION
Cyclophosphamide 1 GM/5ML SOLUTION	IV	SOLUTION

PAGE 355 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
cycloPHOSphamide 1000 MG/10ML SOLUTION	IV	SOLUTION
Cyclophosphamide 2 GM RECON SOLN	IJ	RECON SOLN
Cyclophosphamide 2 GM/10ML SOLUTION	IV	SOLUTION
cycloPHOSphamide 2 GM/4ML SOLUTION	IV	SOLUTION
cycloPHOSphamide 2000 MG/20ML SOLUTION	IV	SOLUTION
Cyclophosphamide 25 MG CAP	PO	CAP
Cyclophosphamide 25 MG TAB	PO	TAB
Cyclophosphamide 50 MG CAP	PO	CAP
Cyclophosphamide 50 MG TAB	PO	TAB
Cyclophosphamide 500 MG RECON SOLN	IJ	RECON SOLN
Cyclophosphamide 500 MG/2.5ML SOLUTION	IV	SOLUTION
cycloPHOSphamide 500 MG/5ML SOLUTION	IV	SOLUTION
cycloPHOSphamide 500 MG/ML SOLUTION	IV	SOLUTION
CycloSPORINE 100 MG CAP	PO	CAP
CycloSPORINE 25 MG CAP	PO	CAP
CycloSPORINE 50 MG/ML SOLUTION	IV	SOLUTION
CycloSPORINE Modified 100 MG CAP	PO	CAP
CycloSPORINE Modified 100 MG/ML SOLUTION	PO	SOLUTION
CycloSPORINE Modified 25 MG CAP	PO	CAP
CycloSPORINE Modified 50 MG CAP	PO	CAP
Cyklokapron 1000 MG/10ML SOLUTION	IV	SOLUTION
Cyramza 100 MG/10ML SOLUTION	IV	SOLUTION
Cyramza 500 MG/50ML SOLUTION	IV	SOLUTION
Cytarabine (PF) 100 MG/ML SOLUTION	IJ	SOLUTION
Cytarabine (PF) 20 MG/ML SOLUTION	IJ	SOLUTION
Cytarabine 20 MG/ML SOLUTION	IJ	SOLUTION
Cytogam 50 MG/ML SOLUTION	IV	SOLUTION
Dacarbazine 100 MG RECON SOLN	IV	RECON SOLN
Dacarbazine 200 MG RECON SOLN	IV	RECON SOLN
Dacogen 50 MG RECON SOLN	IV	RECON SOLN
DACTINomycin 0.5 MG RECON SOLN	IV	RECON SOLN
Dalvance 500 MG RECON SOLN	IV	RECON SOLN
Danyelza 40 MG/10ML SOLUTION	IV	SOLUTION
DAPTOmycin-Sodium Chloride 1000-0.9 MG/100ML-% SOLUTION	IV	SOLUTION
DAPTOmycin-Sodium Chloride 350-0.9 MG/50ML-% SOLUTION	IV	SOLUTION
DAPTOmycin-Sodium Chloride 500-0.9 MG/50ML-% SOLUTION	IV	SOLUTION
DAPTOmycin-Sodium Chloride 700-0.9 MG/100ML- % SOLUTION	IV	SOLUTION
Darzalex 100 MG/5ML SOLUTION	IV	SOLUTION
Darzalex 400 MG/20ML SOLUTION	IV	SOLUTION
Darzalex Faspro 1800-30000 MG-UT/15ML SOLUTION	SC	SOLUTION

PAGE 356 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Datroway 100 MG RECON SOLN	IV	RECON SOLN
DAUNOrubicin HCl 20 MG/4ML SOLUTION	IV	SOLUTION
DAUNOrubicin HCl 50 MG/10ML SOLUTION	IV	SOLUTION
Decitabine 50 MG RECON SOLN	IV	RECON SOLN
Deferoxamine Mesylate 2 GM RECON SOLN	IJ	RECON SOLN
Deferoxamine Mesylate 500 MG RECON SOLN	IJ	RECON SOLN
Defitelio 200 MG/2.5ML SOLUTION	IV	SOLUTION
Demerol 100 MG/ML SOLUTION	IJ	SOLUTION
Demerol 25 MG/ML SOLUTION	IJ	SOLUTION
Demerol 50 MG/ML SOLUTION	IJ	SOLUTION
Demerol 75 MG/ML SOLUTION	IJ	SOLUTION
DEPO-Medrol 20 MG/ML SUSPENSION	IJ	SUSPENSION
Desferal 500 MG RECON SOLN	IJ	RECON SOLN
Dexameth Sod Phos (PF) +RFID 10 MG/ML SOLN PRSYR	IJ	SOLN PRSYR
dexAMETHasone Sod Phos (PF) 10 MG/ML SOLN PRSYR	IJ	SOLN PRSYR
Dexamethasone Sod Phosphate PF 10 MG/ML SOLUTION	IJ	SOLUTION
Dexamethasone Sodium Phosphate 10 MG/ML SOLUTION	IJ	SOLUTION
Dexamethasone Sodium Phosphate 100 MG/10ML SOLUTION	IJ	SOLUTION
Dexamethasone Sodium Phosphate 120 MG/30ML SOLUTION	IJ	SOLUTION
Dexamethasone Sodium Phosphate 20 MG/5ML SOLUTION	IJ	SOLUTION
Dexamethasone Sodium Phosphate 4 MG/ML SOLUTION	IJ	SOLUTION
Dexrazoxane 250 MG RECON SOLN	IV	RECON SOLN
Dexrazoxane HCI 250 MG RECON SOLN	IV	RECON SOLN
Dexrazoxane HCI 500 MG RECON SOLN	IV	RECON SOLN
Dextrose 20 % SOLUTION	IV	SOLUTION
Dextrose 250 MG/ML SOLUTION	IV	SOLUTION
Dextrose 30 % SOLUTION	IV	SOLUTION
Dextrose 40 % SOLUTION	IV	SOLUTION
Dextrose 5%/Electrolyte #48 SOLUTION	IV	SOLUTION
Dextrose 50 % SOLUTION	IV	SOLUTION
Dextrose 70 % SOLUTION	IV	SOLUTION
Dexycu 9 % SUSPENSION	Ю	SUSPENSION
diazePAM 10 MG/2ML SOLUTION	IJ	SOLUTION
DiazePAM 5 MG/ML SOLUTION	IJ	SOLUTION
Dicyclomine HCI 10 MG/ML SOLUTION	IM	SOLUTION
Digoxin 0.25 MG/ML SOLUTION	IJ	SOLUTION
DilTIAZem HCI 100 MG RECON SOLN	IV	RECON SOLN
DilTIAZem HCI 125 MG/25ML SOLUTION	IV	SOLUTION

PAGE 357 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
DilTIAZem HCl 25 MG/5ML SOLUTION	IV	SOLUTION
DilTIAZem HCI 50 MG/10ML SOLUTION	IV	SOLUTION
DOBUTamine HCI 12.5 MG/ML SOLUTION	IV	SOLUTION
DOBUTamine HCI 250 MG/20ML SOLUTION	IV	SOLUTION
DOBUTamine in D5W 2 MG/ML SOLUTION	IV	SOLUTION
DOBUTamine-Dextrose 1-5 MG/ML-% SOLUTION	IV	SOLUTION
DOBUTamine-Dextrose 4-5 MG/ML-% SOLUTION	IV	SOLUTION
DOCEtaxel 160 MG/16ML SOLUTION	IV	SOLUTION
DOCEtaxel 160 MG/8ML CONC	IV	CONC
DOCEtaxel 20 MG/2ML SOLUTION	IV	SOLUTION
DOCEtaxel 20 MG/ML CONC	IV	CONC
DOCEtaxel 80 MG/4ML CONC	IV	CONC
DOCEtaxel 80 MG/8ML SOLUTION	IV	SOLUTION
Docivyx 160 MG/16ML SOLUTION	IV	SOLUTION
Docivyx 20 MG/2ML SOLUTION	IV	SOLUTION
Docivyx 80 MG/8ML SOLUTION	IV	SOLUTION
DOPamine HCI 40 MG/ML SOLUTION	IV	SOLUTION
DOPamine in D5W 0.8-5 MG/ML-% SOLUTION	IV	SOLUTION
DOPamine in D5W 1.6-5 MG/ML-% SOLUTION	IV	SOLUTION
DOPamine in D5W 3.2-5 MG/ML-% SOLUTION	IV	SOLUTION
Doxercalciferol 0.5 MCG CAP	PO	CAP
Doxercalciferol 1 MCG CAP	PO	CAP
Doxercalciferol 2.5 MCG CAP	PO	CAP
Doxercalciferol 4 MCG/2ML SOLUTION	IV	SOLUTION
Doxil 2 MG/ML SUSPENSION	IV	SUSPENSION
DOXOrubicin HCI 10 MG RECON SOLN	IV	RECON SOLN
DOXOrubicin HCI 2 MG/ML SOLUTION	IV	SOLUTION
DOXOrubicin HCI 50 MG RECON SOLN	IV	RECON SOLN
DOXOrubicin HCI Liposomal 2 MG/ML SUSPENSION	IV	SUSPENSION
Duopa 4.63-20 MG/ML SUSPENSION	EN	SUSPENSION
Duracion 100 MCG/ML SOLUTION	EP	SOLUTION
Duramorph 0.5 MG/ML SOLUTION	IJ	SOLUTION
Duramorph 1 MG/ML SOLUTION	IJ	SOLUTION
Durysta 10 MCG IMPLANT	IO	IMPLANT
Dysport 300 UNIT RECON SOLN	IM	RECON SOLN
Dysport 500 UNIT RECON SOLN	IM	RECON SOLN
Edaravone 30 MG/100ML SOLUTION	IV	SOLUTION
Edaravone 60 MG/100ML SOLUTION	IV	SOLUTION
Elahere 100 MG/20ML SOLUTION	IV	SOLUTION
Elaprase 6 MG/3ML SOLUTION	IV	SOLUTION
Elcys 50 MG/ML SOLUTION	IV	SOLUTION
Elelyso 200 UNIT RECON SOLN	IV	RECON SOLN
Elfabrio 20 MG/10ML SOLUTION	IV	SOLUTION
Elfabrio 5 MG/2.5ML SOLUTION	IV	SOLUTION

PAGE 358 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Elitek 1.5 MG RECON SOLN	IV	RECON SOLN
Elitek 7.5 MG RECON SOLN	IV	RECON SOLN
Ella 30 MG TAB	PO	TAB
Ellence 200 MG/100ML SOLUTION	IV	SOLUTION
Ellence 50 MG/25ML SOLUTION	IV	SOLUTION
Elliotts B SOLUTION	IT	SOLUTION
Elrexfio 44 MG/1.1ML SOLUTION	SC	SOLUTION
Elrexfio 76 MG/1.9ML SOLUTION	SC	SOLUTION
Emend 125 MG/5ML RECON SUSP	PO	RECON SUSP
Emend 150 MG RECON SOLN	IV	RECON SOLN
Emend BiPack 80 MG CAP	PO	CAP
Emend Tri-Pack 80 & 125 MG CAP	PO	CAP
Empaveli 1080 MG/20ML SOLUTION	SC	SOLUTION
Empliciti 300 MG RECON SOLN	IV	RECON SOLN
Empliciti 400 MG RECON SOLN	IV	RECON SOLN
Emrelis 100 MG RECON SOLN	IV	RECON SOLN
Emrelis 20 MG RECON SOLN	IV	RECON SOLN
Enalaprilat 1.25 MG/ML SOLUTION	IV	SOLUTION
Engerix-B 10 MCG/0.5ML SUSP PRSYR	IJ	SUSP PRSYR
Engerix-B 20 MCG/ML SUSP PRSYR	IJ	SUSP PRSYR
Engerix-B 20 MCG/ML SUSPENSION	IJ	Suspension
Enhertu 100 MG RECON SOLN	IV	RECON SOLN
Enjaymo 1100 MG/22ML SOLUTION	IV	SOLUTION
Entyvio 300 MG RECON SOLN	IV	RECON SOLN
EPINEPHrine (Anaphylaxis) 1 MG/ML SOLUTION	IJ	SOLUTION
EPINEPHrine (Anaphylaxis) 30 MG/30ML SOLUTION	IJ	SOLUTION
EpiRUBicin HCl 200 MG/100ML SOLUTION	IV	SOLUTION
EpiRUBicin HCI 50 MG/25ML SOLUTION	IV	SOLUTION
Epkinly 4 MG/0.8ML SOLUTION	SC	SOLUTION
Epkinly 48 MG/0.8ML SOLUTION	SC	SOLUTION
Epogen 10000 UNIT/ML SOLUTION	IJ	SOLUTION
Epogen 2000 UNIT/ML SOLUTION	IJ	SOLUTION
Epogen 20000 UNIT/ML SOLUTION	IJ	SOLUTION
Epogen 3000 UNIT/ML SOLUTION	IJ	SOLUTION
Epogen 4000 UNIT/ML SOLUTION	IJ	SOLUTION
Epoprostenol Sodium 0.5 MG RECON SOLN	IV	RECON SOLN
Epoprostenol Sodium 1.5 MG RECON SOLN	IV	RECON SOLN
Epysqli 300 MG/30ML SOLUTION	IV	SOLUTION
Erbitux 100 MG/50ML SOLUTION	IV	SOLUTION
Erbitux 200 MG/100ML SOLUTION	IV	SOLUTION
eriBULin Mesylate 1 MG/2ML SOLUTION	IV	SOLUTION
Erzofri 117 MG/0.75ML SUSP PRSYR	IM	SUSP PRSYR
Erzofri 156 MG/ML SUSP PRSYR	IM	SUSP PRSYR
Erzofri 234 MG/1.5ML SUSP PRSYR	IM	SUSP PRSYR

PAGE 359 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Erzofri 351 MG/2.25ML SUSP PRSYR	IM	SUSP PRSYR
Erzofri 39 MG/0.25ML SUSP PRSYR	IM	SUSP PRSYR
Erzofri 78 MG/0.5ML SUSP PRSYR	IM	SUSP PRSYR
Ethacrynate Sodium 50 MG RECON SOLN	IV	RECON SOLN
Ethyol 500 MG RECON SOLN	IV	RECON SOLN
Etopophos 100 MG RECON SOLN	IV	RECON SOLN
Etoposide 1 GM/50ML SOLUTION	IV	SOLUTION
Etoposide 100 MG/5ML SOLUTION	IV	SOLUTION
Etoposide 500 MG/25ML SOLUTION	IV	SOLUTION
Evenity 105 MG/1.17ML SOLN PRSYR	SC	SOLN PRSYR
Everolimus 0.25 MG TAB	PO	TAB
Everolimus 0.5 MG TAB	PO	TAB
Everolimus 0.75 MG TAB	PO	TAB
Everolimus 1 MG TAB	PO	TAB
Evkeeza 1200 MG/8ML SOLUTION	IV	SOLUTION
Evkeeza 345 MG/2.3ML SOLUTION	IV	SOLUTION
Evomela 50 MG RECON SOLN	IV	RECON SOLN
Fabrazyme 35 MG RECON SOLN	IV	RECON SOLN
Fabrazyme 5 MG RECON SOLN	IV	RECON SOLN
Fasenra 10 MG/0.5ML SOLN PRSYR	SC	SOLN PRSYR
Fensolvi (6 Month) 45 MG KIT	SC	KIT
Flebogamma DIF 0.5 GM/10ML SOLUTION	IV	SOLUTION
Flebogamma DIF 10 GM/100ML SOLUTION	IV	SOLUTION
Flebogamma DIF 10 GM/200ML SOLUTION	IV	SOLUTION
Flebogamma DIF 2.5 GM/50ML SOLUTION	IV	SOLUTION
Flebogamma DIF 20 GM/200ML SOLUTION	IV	SOLUTION
Flebogamma DIF 20 GM/400ML SOLUTION	IV	SOLUTION
Flebogamma DIF 5 GM/100ML SOLUTION	IV	SOLUTION
Flebogamma DIF 5 GM/50ML SOLUTION	IV	SOLUTION
Flolan 0.5 MG RECON SOLN	IV	RECON SOLN
Flolan 1.5 MG RECON SOLN	IV	RECON SOLN
Floxuridine 0.5 GM RECON SOLN	IJ	RECON SOLN
Fludarabine Phosphate 25 MG/ML SOLUTION	IV	SOLUTION
Fludarabine Phosphate 50 MG RECON SOLN	IV	RECON SOLN
Fludarabine Phosphate 50 MG/2ML SOLUTION	IV	SOLUTION
Fluorouracil 1 GM/20ML SOLUTION	IV	SOLUTION
Fluorouracil 2.5 GM/50ML SOLUTION	IV	SOLUTION
Fluorouracil 5 GM/100ML SOLUTION	IV	SOLUTION
Fluorouracil 500 MG/10ML SOLUTION	IV	SOLUTION
Focinvez 150 MG/50ML SOLUTION	IV	SOLUTION
Folotyn 20 MG/ML SOLUTION	IV	SOLUTION
Folotyn 40 MG/2ML SOLUTION	IV	SOLUTION
Formoterol Fumarate 20 MCG/2ML NEBU SOLN	IN	NEBU SOLN
Fosaprepitant Dimeglumine 150 MG RECON SOLN	IV	RECON SOLN

PAGE 360 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Fosphenytoin Sodium 100 MG PE/2ML SOLUTION	IJ	SOLUTION
Fosphenytoin Sodium 500 MG PE/10ML SOLUTION	IJ	SOLUTION
Frindovyx 1 GM/2ML SOLUTION	IV	SOLUTION
Frindovyx 2 GM/4ML SOLUTION	IV	SOLUTION
Frindovyx 500 MG/ML SOLUTION	IV	SOLUTION
Fulphila 6 MG/0.6ML SOLN PRSYR	SC	SOLN PRSYR
Fyarro 100 MG RECON SUSP	IV	RECON SUSP
Fylnetra 6 MG/0.6ML SOLN PRSYR	SC	SOLN PRSYR
Gablofen 10000 MCG/20ML SOLN PRSYR	IT	SOLN PRSYR
Gablofen 20000 MCG/20ML SOLN PRSYR	IT	SOLN PRSYR
Gablofen 20000 MCG/20ML SOLUTION	IT	SOLUTION
Gablofen 40000 MCG/20ML SOLN PRSYR	IT	SOLN PRSYR
Gablofen 40000 MCG/20ML SOLUTION	IT	SOLUTION
Gablofen 50 MCG/ML SOLN PRSYR	IT	SOLN PRSYR
GamaSTAN SOLUTION	IM	SOLUTION
Gammagard 1 GM/10ML SOLUTION	IJ	SOLUTION
Gammagard 10 GM/100ML SOLUTION	IJ	SOLUTION
Gammagard 2.5 GM/25ML SOLUTION	IJ	SOLUTION
Gammagard 20 GM/200ML SOLUTION	IJ	SOLUTION
Gammagard 30 GM/300ML SOLUTION	IJ	SOLUTION
Gammagard 5 GM/50ML SOLUTION	IJ	SOLUTION
Gammagard S/D Less IgA 10 GM RECON SOLN	IV	RECON SOLN
Gammagard S/D Less IgA 5 GM RECON SOLN	IV	RECON SOLN
Gammaked 1 GM/10ML SOLUTION	IJ	SOLUTION
Gammaked 10 GM/100ML SOLUTION	IJ	SOLUTION
Gammaked 20 GM/200ML SOLUTION	IJ	SOLUTION
Gammaked 5 GM/50ML SOLUTION	IJ	SOLUTION
Gammaplex 10 GM/100ML SOLUTION	IV	SOLUTION
Gammaplex 10 GM/200ML SOLUTION	IV	SOLUTION
Gammaplex 20 GM/200ML SOLUTION	IV	SOLUTION
Gammaplex 20 GM/400ML SOLUTION	IV	SOLUTION
Gammaplex 5 GM/100ML SOLUTION	IV	SOLUTION
Gammaplex 5 GM/50ML SOLUTION	IV	SOLUTION
Ganciclovir 500 MG/250ML SOLUTION	IV	SOLUTION
Ganciclovir Sodium 500 MG RECON SOLN	IV	RECON SOLN
Ganciclovir Sodium 500 MG/10ML SOLUTION	IV	SOLUTION
Gazyva 1000 MG/40ML SOLUTION	IV	SOLUTION
Gemcitabine HCI 1 GM RECON SOLN	IV	RECON SOLN
Gemcitabine HCI 1 GM/10ML SOLUTION	IV	SOLUTION
Gemcitabine HCI 1 GM/26.3ML SOLUTION	IV	SOLUTION
Gemcitabine HCI 1.5 GM/15ML SOLUTION	IV	SOLUTION
Gemcitabine HCl 2 GM RECON SOLN	IV	RECON SOLN
Gemcitabine HCI 2 GM/20ML SOLUTION	IV	SOLUTION
Gemcitabine HCl 2 GM/52.6ML SOLUTION	IV	SOLUTION

PAGE 361 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Gemcitabine HCI 200 MG RECON SOLN	IV	RECON SOLN
Gemcitabine HCl 200 MG/2ML SOLUTION	IV	SOLUTION
Gemcitabine HCl 200 MG/5.26ML SOLUTION	IV	SOLUTION
Gengraf 100 MG CAP	PO	CAP
Gengraf 100 MG/ML SOLUTION	PO	SOLUTION
Gengraf 25 MG CAP	PO	CAP
Gentamicin in Saline 0.8-0.9 MG/ML-% SOLUTION	IV	SOLUTION
Gentamicin in Saline 1-0.9 MG/ML-% SOLUTION	IV	SOLUTION
Gentamicin in Saline 1.2-0.9 MG/ML-% SOLUTION	IV	SOLUTION
Gentamicin in Saline 1.6-0.9 MG/ML-% SOLUTION	IV	SOLUTION
Gentamicin in Saline 2-0.9 MG/ML-% SOLUTION	IV	SOLUTION
Givlaari 189 MG/ML SOLUTION	SC	SOLUTION
Glassia 1000 MG/50ML SOLUTION	IV	SOLUTION
Glassia 4 GM/200ML SOLUTION	IV	SOLUTION
Glassia 5 GM/250ML SOLUTION	IV	SOLUTION
Glucose (Dextrose) 50 % SOLUTION	IV	SOLUTION
Glycophos 1 MMOLE/ML SOLUTION	IV	SOLUTION
Goprelto 40 MG/ML SOLUTION	NA	SOLUTION
Grafapex 1 GM RECON SOLN	IV	RECON SOLN
Grafapex 5 GM RECON SOLN	IV	RECON SOLN
Granisetron HCl 1 MG TAB	РО	TAB
Granisetron HCl 1 MG/ML SOLUTION	IV	SOLUTION
Granisetron HCI 4 MG/4ML SOLUTION	IV	SOLUTION
Granix 300 MCG/0.5ML SOLN PRSYR	SC	SOLN PRSYR
Granix 300 MCG/ML SOLUTION	SC	SOLUTION
Granix 480 MCG/0.8ML SOLN PRSYR	SC	SOLN PRSYR
Granix 480 MCG/1.6ML SOLUTION	SC	SOLUTION
Halaven 1 MG/2ML SOLUTION	IV	SOLUTION
Hectorol 4 MCG/2ML SOLUTION	IV	SOLUTION
HepaGam B 312 UNIT/ML SOLUTION	IJ	SOLUTION
Heparin (Porcine) in NaCl 1000-0.9 UT/500ML-% SOLUTION	IV	SOLUTION
Heparin (Porcine) in NaCl 12500-0.45 UT/250ML-% SOLUTION	IV	SOLUTION
Heparin (Porcine) in NaCl 2000-0.9 UNIT/L-% SOLUTION	IV	SOLUTION
Heparin (Porcine) in NaCl 2500-0.9 UT/500ML-% SOLUTION	IV	SOLUTION
Heparin (Porcine) in NaCl 25000-0.45 UT/250ML-% SOLUTION	IV	SOLUTION
Heparin (Porcine) in NaCl 25000-0.45 UT/500ML-% SOLUTION	IV	SOLUTION
Heparin (Porcine) in NaCl 30000-0.9 UNIT/L-% SOLUTION	IV	SOLUTION
Heparin (Porcine) in NaCl 4000-0.9 UNIT/L-% SOLUTION	IV	SOLUTION

PAGE 362 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Heparin (Porcine) in NaCl 500-0.9 UT/500ML-%	D.7	0.011171011
SOLUTION Heparin (Porcine) in NaCl 5000-0.9 UNIT/L-%	IV	SOLUTION
SOLUTION	IV	SOLUTION
Heparin (Porcine) in NaCl 5000-0.9 UT/500ML-% SOLUTION	IV	SOLUTION
Heparin Sod (Porcine) in D5W 100 UNIT/ML SOLUTION	IV	SOLUTION
Heparin Sod (Porcine) in D5W 25000-5 UT/500ML-% SOLUTION	IV	SOLUTION
Heparin Sod (Porcine) in D5W 40-5 UNIT/ML-% SOLUTION	IV	SOLUTION
Heparin Sodium (Porcine) 1000 UNIT/ML SOLUTION	IJ	SOLUTION
Heparin Sodium (Porcine) 10000 UNIT/ML SOLUTION	IJ	SOLUTION
Heparin Sodium (Porcine) 20000 UNIT/ML SOLUTION	IJ	SOLUTION
Heparin Sodium (Porcine) 5000 UNIT/0.5ML SOLN PRSYR	IJ	SOLN PRSYR
Heparin Sodium (Porcine) 5000 UNIT/ML SOLUTION	IJ	SOLUTION
Heparin Sodium (Porcine) PF 1000 UNIT/ML SOLUTION	IJ	SOLUTION
Heparin Sodium (Porcine) PF 5000 UNIT/0.5ML SOLUTION	IJ	SOLUTION
Heparin Sodium (Porcine) PF 5000 UNIT/ML SOLUTION	IJ	SOLUTION
Heplisav-B 20 MCG/0.5ML SOLN PRSYR	IM	SOLN PRSYR
Herceptin 150 MG RECON SOLN	IV	RECON SOLN
Herceptin Hylecta 600-10000 MG-UNT/5ML SOLUTION	SC	SOLUTION
Hercessi 150 MG RECON SOLN	IV	RECON SOLN
Hercessi 420 MG RECON SOLN	IV	RECON SOLN
Herzuma 150 MG RECON SOLN	IV	RECON SOLN
Herzuma 420 MG RECON SOLN	IV	RECON SOLN
HumuLIN R U-500 (CONCENTRATED) 500 UNIT/ML SOLUTION	SC	SOLUTION
Hycamtin 4 MG RECON SOLN	IV	RECON SOLN
Hydrocortisone Sod Suc (PF) 100 MG RECON SOLN	IJ	RECON SOLN
HYDROmorphone HCI PF 10 MG/ML SOLUTION	IJ	SOLUTION
HYDROmorphone HCI PF 50 MG/5ML SOLUTION	IJ	SOLUTION
HYDROmorphone HCI PF 500 MG/50ML SOLUTION	IJ	SOLUTION
HydrOXYzine HCl 25 MG/ML SOLUTION	IM	SOLUTION
HydrOXYzine HCI 50 MG/ML SOLUTION	IM	SOLUTION
Hyoscyamine Sulfate 0.5 MG/ML SOLUTION	IJ	SOLUTION
HyperHEP B 110 UNIT/0.5ML SOLN PRSYR	IM	SOLN PRSYR
HyperHEP B 220 UNIT/ML SOLN PRSYR	IM	SOLN PRSYR
HyperHEP B 220 UNIT/ML SOLUTION	IM	SOLUTION

PAGE 363 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Hyperlyte-CR CONC	IV	CONC
HyperRAB 1500 UNIT/5ML SOLUTION	IJ	SOLUTION
HyperRAB 300 UNIT/ML SOLUTION	IJ	SOLUTION
HyperRAB 900 UNIT/3ML SOLUTION	IJ	SOLUTION
HyperRHO S/D 1500 UNIT SOLN PRSYR	IM	SOLN PRSYR
HyperRHO S/D 250 UNIT SOLN PRSYR	IM	SOLN PRSYR
Hyqvia 10 GM/100ML KIT	SC	KIT
Hyqvia 2.5 GM/25ML KIT	SC	KIT
Hyqvia 20 GM/200ML KIT	SC	KIT
Hyqvia 30 GM/300ML KIT	SC	KIT
Hyqvia 5 GM/50ML KIT	SC	KIT
Ibandronate Sodium 3 MG/3ML SOLUTION	IV	SOLUTION
Idamycin PFS 10 MG/10ML SOLUTION	IV	SOLUTION
Idamycin PFS 20 MG/20ML SOLUTION	IV	SOLUTION
Idamycin PFS 5 MG/5ML SOLUTION	IV	SOLUTION
IDArubicin HCI 10 MG/10ML SOLUTION	IV	SOLUTION
IDArubicin HCI 20 MG/20ML SOLUTION	IV	SOLUTION
IDArubicin HCI 5 MG/5ML SOLUTION	IV	SOLUTION
Ifex 1 GM RECON SOLN	IV	RECON SOLN
Ifex 3 GM RECON SOLN	IV	RECON SOLN
Ifosfamide 1 GM RECON SOLN	IV	RECON SOLN
Ifosfamide 1 GM/20ML SOLUTION	IV	SOLUTION
Ifosfamide 3 GM RECON SOLN	IV	RECON SOLN
Ifosfamide 3 GM/60ML SOLUTION	IV	SOLUTION
Imaavy 1200 MG/6.5ML SOLUTION	IV	SOLUTION
Imdelltra 1 MG RECON SOLN	IV	RECON SOLN
Imdelltra 10 MG RECON SOLN	IV	RECON SOLN
Imfinzi 120 MG/2.4ML SOLUTION	IV	SOLUTION
Imfinzi 500 MG/10ML SOLUTION	IV	SOLUTION
Imjudo 25 MG/1.25ML SOLUTION	IV	SOLUTION
Imjudo 300 MG/15ML SOLUTION	IV	SOLUTION
Imlygic 1000000 UNIT/ML SUSPENSION	LS	SUSPENSION
Imlygic 100000000 UNIT/ML SUSPENSION	LS	SUSPENSION
Imogam Rabies-HT 300 UNIT/2ML SOLUTION	IJ	SOLUTION
Imuldosa 130 MG/26ML SOLUTION	IV	SOLUTION
Imuran 50 MG TAB	PO	TAB
Inflectra 100 MG RECON SOLN	IV	RECON SOLN
inFLIXimab 100 MG RECON SOLN	IV	RECON SOLN
Infugem 1200-0.9 MG/120ML-% SOLUTION	IV	SOLUTION
Infugem 1300-0.9 MG/130ML-% SOLUTION	IV	SOLUTION
Infugem 1400-0.9 MG/140ML-% SOLUTION	IV	SOLUTION
Infugem 1500-0.9 MG/150ML-% SOLUTION	IV	SOLUTION
Infugem 1600-0.9 MG/160ML-% SOLUTION	IV	SOLUTION
Infugem 1700-0.9 MG/170ML-% SOLUTION	IV	SOLUTION

PAGE 364 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Infugem 1800-0.9 MG/180ML-% SOLUTION	IV	SOLUTION
Infugem 1900-0.9 MG/190ML-% SOLUTION	IV	SOLUTION
Infugem 2000-0.9 MG/200ML-% SOLUTION	IV	SOLUTION
Infugem 2200-0.9 MG/220ML-% SOLUTION	IV	SOLUTION
Infumorph 200 200 MG/20ML (10 MG/ML) SOLUTION	IJ	SOLUTION
Infumorph 500 500 MG/20ML (25 MG/ML) SOLUTION	IJ	SOLUTION
Intralipid 20 % EMULSION	IV	EMULSION
Intralipid 30 % EMULSION	IV	EMULSION
Invega Hafyera 1092 MG/3.5ML SUSP PRSYR	IM	SUSP PRSYR
Invega Hafyera 1560 MG/5ML SUSP PRSYR	IM	SUSP PRSYR
Invega Sustenna 117 MG/0.75ML SUSP PRSYR	IM	SUSP PRSYR
Invega Sustenna 156 MG/ML SUSP PRSYR	IM	SUSP PRSYR
Invega Sustenna 234 MG/1.5ML SUSP PRSYR	IM	SUSP PRSYR
Invega Sustenna 39 MG/0.25ML SUSP PRSYR	IM	SUSP PRSYR
Invega Sustenna 78 MG/0.5ML SUSP PRSYR	IM	SUSP PRSYR
Invega Trinza 273 MG/0.88ML SUSP PRSYR	IM	SUSP PRSYR
Invega Trinza 410 MG/1.32ML SUSP PRSYR	IM	SUSP PRSYR
Invega Trinza 546 MG/1.75ML SUSP PRSYR	IM	SUSP PRSYR
Invega Trinza 819 MG/2.63ML SUSP PRSYR	IM	SUSP PRSYR
Ionosol-MB in D5W SOLUTION	IV	SOLUTION
Ipratropium Bromide 0.02 % SOLUTION	IN	SOLUTION
Ipratropium-Albuterol 0.5-2.5 (3) MG/3ML SOLUTION	IN	SOLUTION
Irinotecan HCI 100 MG/5ML SOLUTION	IV	SOLUTION
Irinotecan HCI 300 MG/15ML SOLUTION	IV	SOLUTION
Irinotecan HCI 40 MG/2ML SOLUTION	IV	SOLUTION
Irinotecan HCI 500 MG/25ML SOLUTION	IV	SOLUTION
Isolyte-P in D5W SOLUTION	IV	SOLUTION
Isolyte-S SOLUTION	IV	SOLUTION
Isolyte-S pH 7.4 SOLUTION	IV	SOLUTION
Istodax 10 MG RECON SOLN	IV	RECON SOLN
Ivra 90 MG/ML SOLUTION	IV	SOLUTION
Ixempra Kit 15 MG RECON SOLN	IV	RECON SOLN
Ixempra Kit 45 MG RECON SOLN	IV	RECON SOLN
Jemperli 500 MG/10ML SOLUTION	IV	SOLUTION
Jevtana 60 MG/1.5ML SOLUTION	IV	SOLUTION
Jobevne 100 MG/4ML SOLUTION	IV	SOLUTION
Jobevne 400 MG/16ML SOLUTION	IV	SOLUTION
Jubbonti 60 MG/ML SOLN PRSYR	SC	SOLN PRSYR
Kabiven 3.3-10.8-3.9 % EMULSION	IV	EMULSION
Kadcyla 100 MG RECON SOLN	IV	RECON SOLN
Kadcyla 160 MG RECON SOLN	IV	RECON SOLN

PAGE 365 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Kanjinti 150 MG RECON SOLN	IV	RECON SOLN
Kanjinti 420 MG RECON SOLN	IV	RECON SOLN
Kanuma 20 MG/10ML SOLUTION	IV	SOLUTION
KCI (0.149%) in NaCl 20-0.45 MEQ/L-% SOLUTION	IV	SOLUTION
KCI (in NaCl 0.9%) 40 MEQ/500ML SOLUTION	IV	SOLUTION
KCI in Dextrose-NaCl 10-5-0.45 MEQ/L-%-% SOLUTION	IV	SOLUTION
KCI in Dextrose-NaCl 30-5-0.45 MEQ/L-%-% SOLUTION	IV	SOLUTION
KCI in Dextrose-NaCl 40-5-0.45 MEQ/L-%-% SOLUTION	IV	SOLUTION
Kedrab 1500 UNIT/10ML SOLUTION	IJ	SOLUTION
Kedrab 300 UNIT/2ML SOLUTION	IJ	SOLUTION
Kemoplat 50 MG/50ML SOLUTION	IV	SOLUTION
Kenalog-10 10 MG/ML SUSPENSION	IJ	SUSPENSION
Kenalog-40 40 MG/ML SUSPENSION	IJ	SUSPENSION
Kenalog-80 80 MG/ML SUSPENSION	IJ	SUSPENSION
Keppra 500 MG/5ML SOLUTION	IV	SOLUTION
Ketorolac Tromethamine 15 MG/ML SOLUTION	IJ	SOLUTION
Ketorolac Tromethamine 30 MG/ML SOLUTION	IJ	SOLUTION
Ketorolac Tromethamine 60 MG/2ML SOLUTION	IM	SOLUTION
Keytruda 100 MG/4ML SOLUTION	IV	SOLUTION
Keytruda Qlex 395-4800 MG -UNT/2.4ML SOLUTION	SC	SOLUTION
Keytruda Qlex 790-9600 MG -UNT/4.8ML SOLUTION	SC	SOLUTION
Khapzory 175 MG RECON SOLN	IV	RECON SOLN
Khapzory 300 MG RECON SOLN	IV	RECON SOLN
Kimmtrak 100 MCG/0.5ML SOLUTION	IV	SOLUTION
Kimyrsa 1200 MG RECON SOLN	IV	RECON SOLN
Kitabis Pak 300 MG/5ML NEBU SOLN	IN	NEBU SOLN
Krystexxa 8 MG/50ML SOLUTION	IV	SOLUTION
Krystexxa 8 MG/ML SOLUTION	IV	SOLUTION
Kyleena 19.5 MG IUD	IU	IUD
Kyprolis 10 MG RECON SOLN	IV	RECON SOLN
Kyprolis 30 MG RECON SOLN	IV	RECON SOLN
Kyprolis 60 MG RECON SOLN	IV	RECON SOLN
Kyxata 500 MG/50ML SOLUTION	IV	SOLUTION
Kyxata 80 MG/8ML SOLUTION	IV	SOLUTION
Lacosamide 200 MG/20ML SOLUTION	IV	SOLUTION
Lamzede 10 MG RECON SOLN	IV	RECON SOLN
Lanoxin 0.25 MG/ML SOLUTION	IJ	SOLUTION
Lanoxin Pediatric 0.1 MG/ML SOLUTION	IJ	SOLUTION
Lanreotide Acetate 120 MG/0.5ML SOLUTION	SC	SOLUTION
Lemtrada 12 MG/1.2ML SOLUTION	IV	SOLUTION
Leqvio 284 MG/1.5ML SOLN PRSYR	SC	SOLN PRSYR

PAGE 366 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
LevETIRAcetam 500 MG/5ML SOLUTION	IV	SOLUTION
LevETIRAcetam in NaCl 1000 MG/100ML SOLUTION	IV	SOLUTION
LevETIRAcetam in NaCl 1500 MG/100ML SOLUTION	IV	SOLUTION
levETIRAcetam in NaCl 250 MG/50ML SOLUTION	IV	SOLUTION
LevETIRAcetam in NaCl 500 MG/100ML SOLUTION	IV	SOLUTION
levOCARNitine 200 MG/ML SOLUTION	IV	SOLUTION
LevoFLOXacin in D5W 250 MG/50ML SOLUTION	IV	SOLUTION
LEVOleucovorin Calcium 50 MG RECON SOLN	IV	RECON SOLN
LEVOleucovorin Calcium PF 175 MG/17.5ML SOLUTION	IV	SOLUTION
LEVOleucovorin Calcium PF 250 MG/25ML SOLUTION	IV	SOLUTION
Levothyroxine Sodium 100 MCG RECON SOLN	IV	RECON SOLN
Levothyroxine Sodium 100 MCG/5ML SOLUTION	IV	SOLUTION
Levothyroxine Sodium 100 MCG/ML SOLUTION	IV	SOLUTION
Levothyroxine Sodium 200 MCG RECON SOLN	IV	RECON SOLN
Levothyroxine Sodium 200 MCG/5ML SOLUTION	IV	SOLUTION
Levothyroxine Sodium 500 MCG RECON SOLN	IV	RECON SOLN
Levothyroxine Sodium 500 MCG/5ML SOLUTION	IV	SOLUTION
Levsin 0.5 MG/ML SOLUTION	IJ	SOLUTION
Levulan Kerastick 20 % RECON SOLN	EX	RECON SOLN
Libtayo 350 MG/7ML SOLUTION	IV	SOLUTION
Lidocaine HCI (Cardiac) PF 100 MG/5ML SOLUTION	IV	SOLUTION
Lidocaine-EPINEPHrine (PF) 1.5 %-1:200000 SOLUTION	IJ	SOLUTION
Lidocaine-EPINEPHrine (PF) 2 %-1:200000 SOLUTION	IJ	SOLUTION
Lidocaine-Epinephrine 0.5 %-1:200000 SOLUTION	IJ	SOLUTION
Lidocaine-Epinephrine 1 %-1:100000 SOLUTION	IJ	SOLUTION
Lidocaine-Epinephrine 2 %-1:100000 SOLUTION	IJ	SOLUTION
Lidocaine-EPINEPHrine 2 %-1:200000 SOLUTION	IJ	SOLUTION
Lidocaine-Epinephrine 2 %-1:50000 SOLUTION	IJ	SOLUTION
Liletta (52 MG) 20.1 MCG/DAY IUD	IU	IUD
Lioresal 0.05 MG/ML SOLUTION	IT	SOLUTION
Lioresal 10 MG/5ML SOLUTION	IT	SOLUTION
Lioresal 40 MG/20ML SOLUTION	ΙŢ	SOLUTION
Liothyronine Sodium 10 MCG/ML SOLUTION	IV	SOLUTION
Logtorzi 240 MG/6ML SOLUTION	IV	SOLUTION
LORazepam 2 MG/ML SOLUTION	IJ	SOLUTION
LORazepam 4 MG/ML SOLUTION	IJ	SOLUTION
Lumizyme 50 MG RECON SOLN	IV	RECON SOLN
Lumoxiti 1 MG RECON SOLN	IV	RECON SOLN
Lunsumio 1 MG/ML SOLUTION	IV	SOLUTION
Lunsumio 30 MG/30ML SOLUTION	IV	SOLUTION
Lupron Depot-Ped (1-Month) 11.25 MG KIT	IM	KIT

PAGE 367 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Lupron Depot-Ped (1-Month) 15 MG KIT	IM	KIT
Lupron Depot-Ped (1-Month) 7.5 MG KIT	IM	KIT
Lupron Depot-Ped (3-Month) 11.25 MG (Ped) KIT	IM	KIT
Lupron Depot-Ped (3-Month) 30 MG KIT	IM	KIT
Lupron Depot-Ped (6-Month) 45 MG KIT	IM	KIT
Lynozyfic 200 MG/10ML SOLUTION	IV	SOLUTION
Lynozyfic 5 MG/2.5ML SOLUTION	IV	SOLUTION
Magnesium Sulfate 2 GM/50ML SOLUTION	IV	SOLUTION
Magnesium Sulfate 20 GM/500ML SOLUTION	IV	SOLUTION
Magnesium Sulfate 4 GM/100ML SOLUTION	IV	SOLUTION
Magnesium Sulfate 4 GM/50ML SOLUTION	IV	SOLUTION
Magnesium Sulfate 40 GM/1000ML SOLUTION	IV	SOLUTION
Magnesium Sulfate in D5W 1-5 GM/100ML-% SOLUTION	IV	SOLUTION
Magnesium Sulfate-NaCl 2-0.9 GM/50ML-% SOLUTION	IV	SOLUTION
Manganese Chloride 0.1 MG/ML SOLUTION	IV	SOLUTION
Mannitol 20 % SOLUTION	IV	SOLUTION
Mannitol 25 % SOLUTION	IV	SOLUTION
Margenza 250 MG/10ML SOLUTION	IV	SOLUTION
Marinol 10 MG CAP	PO	CAP
Marinol 2.5 MG CAP	PO	CAP
Marinol 5 MG CAP	PO	CAP
Marqibo 5 MG/31ML SUSPENSION	IV	SUSPENSION
Melphalan 2 MG TAB	PO	TAB
Melphalan HCI 50 MG RECON SOLN	IV	RECON SOLN
Meperidine HCI 100 MG/ML SOLUTION	IJ	SOLUTION
Meperidine HCI 25 MG/ML SOLUTION	IJ	SOLUTION
Meperidine HCI 50 MG/ML SOLUTION	IJ	SOLUTION
Mepsevii 10 MG/5ML SOLUTION	IV	SOLUTION
Methocarbamol 1000 MG/10ML SOLUTION	IJ	SOLUTION
Methotrexate Sodium (PF) 1 GM/40ML SOLUTION	IJ	SOLUTION
Methotrexate Sodium (PF) 1000 MG/40ML SOLUTION	IJ	SOLUTION
Methotrexate Sodium (PF) 250 MG/10ML SOLUTION	IJ	SOLUTION
Methotrexate Sodium (PF) 50 MG/2ML SOLUTION	IJ	SOLUTION
Methotrexate Sodium 1 GM RECON SOLN	IJ	RECON SOLN
Methotrexate Sodium 250 MG/10ML SOLUTION	IJ	SOLUTION
Methotrexate Sodium 50 MG/2ML SOLUTION	IJ	SOLUTION
MethylPREDNISolone Acetate 50 MG/ML SUSPENSION	IJ	SUSPENSION
MethylPREDNISolone Sodium Succ 1000 MG RECON SOLN	IJ	RECON SOLN
MethylPREDNISolone Sodium Succ 125 MG RECON SOLN	IJ	RECON SOLN

PAGE 368 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
methylPREDNISolone Sodium Succ 500 MG RECON		
SOLN	IJ	RECON SOLN
Metoprolol Tartrate 5 MG/5ML SOLUTION	IV	SOLUTION
Miacalcin 200 UNIT/ML SOLUTION	IJ	SOLUTION
MICRhoGAM Ultra-Filtered Plus 250 UNIT SOLN PRSYR	IM	SOLN PRSYR
Milrinone Lactate 10 MG/10ML SOLUTION	IV	SOLUTION
Milrinone Lactate 20 MG/20ML SOLUTION	IV	SOLUTION
Milrinone Lactate 50 MG/50ML SOLUTION	IV	SOLUTION
Milrinone Lactate in Dextrose 20-5 MG/100ML-% SOLUTION	IV	SOLUTION
Milrinone Lactate in Dextrose 40-5 MG/200ML-% SOLUTION	IV	SOLUTION
Minocin 100 MG RECON SOLN	IV	RECON SOLN
Mircera 100 MCG/0.3ML SOLN PRSYR	IJ	SOLN PRSYR
Mircera 120 MCG/0.3ML SOLN PRSYR	 IJ	SOLN PRSYR
Mircera 150 MCG/0.3ML SOLN PRSYR	IJ	SOLN PRSYR
Mircera 200 MCG/0.3ML SOLN PRSYR	IJ	SOLN PRSYR
Mircera 30 MCG/0.3ML SOLN PRSYR	IJ	SOLN PRSYR
Mircera 50 MCG/0.3ML SOLN PRSYR	IJ	SOLN PRSYR
Mircera 75 MCG/0.3ML SOLN PRSYR	IJ	SOLN PRSYR
Mirena (52 MG) 20 MCG/DAY IUD	IU	IUD
Mitigo 200 MG/20ML (10 MG/ML) SOLUTION	IJ	SOLUTION
Mitigo 500 MG/20ML (25 MG/ML) SOLUTION	IJ	SOLUTION
MitoMYcin 20 MG RECON SOLN	IV	RECON SOLN
MitoMYcin 40 MG RECON SOLN	IV	RECON SOLN
MitoMYcin 5 MG RECON SOLN	IV	RECON SOLN
MITOXANTRONE HCI 20 MG/10ML CONC	IV	CONC
MitoXANTRONE HCI 25 MG/12.5ML CONC	IV	CONC
MitoXANTRONE HCI 30 MG/15ML CONC	IV	CONC
Miudella Intrauterine Copper IUD	IU	IUD
Monjuvi 200 MG RECON SOLN	IV	RECON SOLN
Morphine Sulfate (PF) 0.5 MG/ML SOLUTION	IJ	SOLUTION
Morphine Sulfate (PF) 1 MG/ML SOLUTION	IJ	SOLUTION
Morphine Sulfate (PF) 1 MG/ML SOLUTION	IV	SOLUTION
Morphine Sulfate (PF) 10 MG/ML SOLUTION	IJ	SOLUTION
Morphine Sulfate (PF) 10 MG/ML SOLUTION	IV	SOLUTION
Morphine Sulfate (PF) 2 MG/ML SOLUTION	IJ	SOLUTION
Morphine Sulfate (PF) 2 MG/ML SOLUTION	IV	SOLUTION
Morphine Sulfate (PF) 4 MG/ML SOLUTION	IJ	SOLUTION
Morphine Sulfate (PF) 4 MG/ML SOLUTION	IV	SOLUTION
Morphine Sulfate (PF) 5 MG/ML SOLUTION	IJ	SOLUTION
Morphine Sulfate (PF) 8 MG/ML SOLUTION	IJ	SOLUTION
Morphine Sulfate (PF) 8 MG/ML SOLUTION	IV	SOLUTION
Morphine Sulfate 1 MG/ML SOLUTION	IJ	SOLUTION

PAGE 369 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Morphine Sulfate 2 MG/ML SOLUTION	IJ	SOLUTION
Morphine Sulfate 4 MG/ML SOLUTION	IJ	SOLUTION
Moxifloxacin HCI 400 MG/250ML SOLUTION	IV	SOLUTION
Moxifloxacin HCl in NaCl 400 MG/250ML SOLUTION	IV	SOLUTION
Multiple Electro Type 1 pH 5.5 SOLUTION	IV	SOLUTION
Multiple Electro Type 1 pH 7.4 SOLUTION	IV	SOLUTION
Mutamycin 20 MG RECON SOLN	IV	RECON SOLN
Mutamycin 40 MG RECON SOLN	IV	RECON SOLN
Mutamycin 5 MG RECON SOLN	IV	RECON SOLN
Mvasi 100 MG/4ML SOLUTION	IV	SOLUTION
Mvasi 400 MG/16ML SOLUTION	IV	SOLUTION
Mycophenolate Mofetil 200 MG/ML RECON SUSP	РО	RECON SUSP
Mycophenolate Mofetil 250 MG CAP	PO	CAP
Mycophenolate Mofetil 500 MG RECON SOLN	IV	RECON SOLN
Mycophenolate Mofetil 500 MG TAB	PO	TAB
Mycophenolate Mofetil HCI 500 MG RECON SOLN	IV	RECON SOLN
Mycophenolate Sodium 180 MG TAB DR	PO	TAB DR
Mycophenolate Sodium 360 MG TAB DR	PO	TAB DR
Mycophenolic Acid 180 MG TAB DR	PO	TAB DR
Mycophenolic Acid 360 MG TAB DR	PO	TAB DR
Myfortic 180 MG TAB DR	PO	TAB DR
Myfortic 360 MG TAB DR	PO	TAB DR
Myhibbin 200 MG/ML SUSPENSION	PO	SUSPENSION
Mylotarg 4.5 MG RECON SOLN	IV	RECON SOLN
Myobloc 10000 UNIT/2ML SOLUTION	IM	SOLUTION
Myobloc 2500 UNIT/0.5ML SOLUTION	IM	SOLUTION
Myobloc 5000 UNIT/ML SOLUTION	IM	SOLUTION
Nabi-HB 312 UNIT/ML SOLUTION	IM	SOLUTION
Nafcillin Sodium in Dextrose 1 GM/50ML SOLUTION	IV	SOLUTION
Nafcillin Sodium in Dextrose 2 GM/100ML SOLUTION	IV	SOLUTION
Naglazyme 1 MG/ML SOLUTION	IV	SOLUTION
Nalbuphine HCl 10 MG/ML SOLUTION	IJ	SOLUTION
Nalbuphine HCl 20 MG/ML SOLUTION	IJ	SOLUTION
Navelbine 10 MG/ML SOLUTION	IV	SOLUTION
Navelbine 50 MG/5ML SOLUTION	IV	SOLUTION
Nebupent 300 MG RECON SOLN	IN	RECON SOLN
Nelarabine 5 MG/ML SOLUTION	IV	SOLUTION
Neoral 100 MG CAP	PO	CAP
Neoral 100 MG/ML SOLUTION	PO	SOLUTION
Neoral 25 MG CAP	PO	CAP
Neulasta 6 MG/0.6ML SOLN PRSYR	\$C	SOLN PRSYR
Neulasta Onpro 6 MG/0.6ML SOLN PRSYR	SC SC	SOLN PRSYR
Neupogen 300 MCG/0.5ML SOLN PRSYR	IJ	SOLN PRSYR

PAGE 370 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Neupogen 300 MCG/ML SOLUTION	IJ	SOLUTION
Neupogen 480 MCG/0.8ML SOLN PRSYR	IJ	SOLN PRSYR
Neupogen 480 MCG/1.6ML SOLUTION	IJ	SOLUTION
Nexviazyme 100 MG RECON SOLN	IV	RECON SOLN
NiCARdipine HCI 2.5 MG/ML SOLUTION	IV	SOLUTION
Niktimvo 22 MG/0.44ML SOLUTION	IV	SOLUTION
Niktimvo 9 MG/0.18ML SOLUTION	IV	SOLUTION
Nipent 10 MG RECON SOLN	IV	RECON SOLN
Nitroglycerin 5 MG/ML SOLUTION	IV	SOLUTION
Nitroglycerin in D5W 100-5 MCG/ML-% SOLUTION	IV	SOLUTION
Nitroglycerin in D5W 200-5 MCG/ML-% SOLUTION	IV	SOLUTION
Nitroglycerin in D5W 400-5 MCG/ML-% SOLUTION	IV	SOLUTION
Normosol-R SOLUTION	IV	SOLUTION
Normosol-R in D5W SOLUTION	IV	SOLUTION
Normosol-R pH 7.4 SOLUTION	IV	SOLUTION
Novarel 10000 UNIT RECON SOLN	IM	RECON SOLN
Novarel 5000 UNIT RECON SOLN	IM	RECON SOLN
Noxafil 300 MG/16.7ML SOLUTION	IV	SOLUTION
Nplate 125 MCG RECON SOLN	SC	RECON SOLN
Nplate 250 MCG RECON SOLN	SC	RECON SOLN
Nplate 500 MCG RECON SOLN	SC	RECON SOLN
Nulibry 9.5 MG RECON SOLN	IV	RECON SOLN
Nulojix 250 MG RECON SOLN	IV	RECON SOLN
Numbrino 40 MG/ML SOLUTION	NA	SOLUTION
Nutrilipid 20 % EMULSION	IV	EMULSION
Nuzyra 100 MG RECON SOLN	IV	RECON SOLN
Nypozi 300 MCG/0.5ML SOLN PRSYR	IJ	SOLN PRSYR
Nypozi 480 MCG/0.8ML SOLN PRSYR	IJ	SOLN PRSYR
Ocrevus 300 MG/10ML SOLUTION	IV	SOLUTION
Ocrevus Zunovo 920-23000 MG-UT/23ML SOLUTION	SC	SOLUTION
Octagam 1 GM/20ML SOLUTION	IV	SOLUTION
Octagam 10 GM/100ML SOLUTION	IV	SOLUTION
Octagam 10 GM/200ML SOLUTION	IV	SOLUTION
Octagam 2 GM/20ML SOLUTION	IV	SOLUTION
Octagam 2.5 GM/50ML SOLUTION	IV	SOLUTION
Octagam 20 GM/200ML SOLUTION	IV	SOLUTION
Octagam 25 GM/500ML SOLUTION	IV	SOLUTION
Octagam 30 GM/300ML SOLUTION	IV	SOLUTION
Octagam 5 GM/100ML SOLUTION	IV	SOLUTION
Octagam 5 GM/50ML SOLUTION	IV	SOLUTION
Octreotide Acetate 20 MG KIT	IM	KIT
Octreotide Acetate 30 MG KIT	IM	KIT
Ofirmev 10 MG/ML SOLUTION	IV	SOLUTION
Ogivri 150 MG RECON SOLN	IV	RECON SOLN

PAGE 371 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Ogivri 420 MG RECON SOLN	IV	RECON SOLN
Ohtuvayre 3 MG/2.5ML SUSPENSION	IN	SUSPENSION
Omegaven 10 GM/100ML EMULSION	IV	EMULSION
Omegaven 5 GM/50ML EMULSION	IV	EMULSION
Omvoh 300 MG/15ML SOLUTION	IV	SOLUTION
Onapgo 98 MG/20ML SOLN CART	SC	SOLN CART
Oncaspar 750 UNIT/ML SOLUTION	IJ	SOLUTION
Ondansetron 4 MG TAB DISP	PO	TAB DISP
Ondansetron 8 MG TAB DISP	PO	TAB DISP
Ondansetron HCl 24 MG TAB	PO	TAB
Ondansetron HCI 4 MG TAB	PO	TAB
Ondansetron HCI 4 MG/2ML SOLN PRSYR	IJ	SOLN PRSYR
Ondansetron HCI 4 MG/2ML SOLUTION	IJ	SOLUTION
Ondansetron HCI 4 MG/5ML SOLUTION	PO	SOLUTION
Ondansetron HCI 40 MG/20ML SOLUTION	IJ	SOLUTION
Ondansetron HCI 8 MG TAB	PO	TAB
Onivyde 43 MG/10ML SUSPENSION	IV	SUSPENSION
Onpattro 10 MG/5ML SOLUTION	IV	SOLUTION
Ontruzant 150 MG RECON SOLN	IV	RECON SOLN
Ontruzant 420 MG RECON SOLN	IV	RECON SOLN
Opdivo 100 MG/10ML SOLUTION	IV	SOLUTION
Opdivo 120 MG/12ML SOLUTION	IV	SOLUTION
Opdivo 240 MG/24ML SOLUTION	IV	SOLUTION
Opdivo 40 MG/4ML SOLUTION	IV	SOLUTION
Opdivo Qvantig 600-10000 MG-UT/5ML SOLUTION	SC	SOLUTION
Opdualag 240-80 MG/20ML SOLUTION	IV	SOLUTION
Orbactiv 400 MG RECON SOLN	IV	RECON SOLN
Orphenadrine Citrate 30 MG/ML SOLUTION	IJ	SOLUTION
Osenvelt 120 MG/1.7ML SOLUTION	SC	SOLUTION
Osmitrol 10 % SOLUTION	IV	SOLUTION
Osmitrol 15 % SOLUTION	IV	SOLUTION
Osmitrol 20 % SOLUTION	IV	SOLUTION
Otulfi 130 MG/26ML SOLUTION	IV	SOLUTION
Oxacillin Sodium 1 GM RECON SOLN	IJ	RECON SOLN
Oxacillin Sodium 10 GM RECON SOLN	IV	RECON SOLN
Oxacillin Sodium 2 GM RECON SOLN	IJ	RECON SOLN
Oxacillin Sodium in Dextrose 1 GM/50ML SOLUTION	IV	SOLUTION
Oxacillin Sodium in Dextrose 2 GM/50ML SOLUTION	IV	SOLUTION
Oxaliplatin 100 MG RECON SOLN	IV	RECON SOLN
Oxaliplatin 100 MG/20ML SOLUTION	IV	SOLUTION
Oxaliplatin 200 MG/40ML SOLUTION	IV	SOLUTION
Oxaliplatin 50 MG RECON SOLN	IV	RECON SOLN
Oxaliplatin 50 MG/10ML SOLUTION	IV	SOLUTION
Oxlumo 94.5 MG/0.5ML SOLUTION	SC	SOLUTION

PAGE 372 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
PACLitaxel 100 MG/16.7ML CONC	IV	CONC
PACLitaxel 150 MG/25ML CONC	IV	CONC
PACLitaxel 30 MG/5ML CONC	IV	CONC
PACLitaxel 300 MG/50ML CONC	IV	CONC
PACLitaxel Protein-Bound Part 100 MG RECON		
SUSP	IV	RECON SUSP
Padcev 20 MG RECON SOLN	IV	RECON SOLN
Padcev 30 MG RECON SOLN	IV	RECON SOLN
Palonosetron HCl 0.25 MG/2ML SOLUTION	IV	SOLUTION
Palonosetron HCl 0.25 MG/5ML SOLN PRSYR	IV	SOLN PRSYR
Palonosetron HCI 0.25 MG/5ML SOLUTION	IV	SOLUTION
Pamidronate Disodium 30 MG/10ML SOLUTION	IV	SOLUTION
Pamidronate Disodium 6 MG/ML SOLUTION	IV	SOLUTION
Pamidronate Disodium 90 MG/10ML SOLUTION	IV	SOLUTION
Pantoprazole Sodium-NaCl 40-0.9 MG/100ML-% SOLUTION	IV	SOLUTION
Pantoprazole Sodium-NaCl 40-0.9 MG/50ML-% SOLUTION	IV	SOLUTION
Pantoprazole Sodium-NaCl 80-0.9 MG/100ML-% SOLUTION	IV	SOLUTION
Panzyga 1 GM/10ML SOLUTION	IV	SOLUTION
Panzyga 10 GM/100ML SOLUTION	IV	SOLUTION
Panzyga 2.5 GM/25ML SOLUTION	IV	SOLUTION
Panzyga 20 GM/200ML SOLUTION	IV	SOLUTION
Panzyga 30 GM/300ML SOLUTION	IV	SOLUTION
Panzyga 5 GM/50ML SOLUTION	IV	SOLUTION
Paragard Intrauterine Copper IUD	IU	IUD
Paraplatin 1000 MG/100ML SOLUTION	IV	SOLUTION
Paraplatin 150 MG/15ML SOLUTION	IV	SOLUTION
Paraplatin 450 MG/45ML SOLUTION	IV	SOLUTION
Paraplatin 50 MG/5ML SOLUTION	IV	SOLUTION
Paraplatin 600 MG/60ML SOLUTION	IV	SOLUTION
Paricalcitol 1 MCG CAP	PO	CAP
Paricalcitol 2 MCG CAP	PO	CAP
Paricalcitol 2 MCG/ML SOLUTION	IV	SOLUTION
Paricalcitol 4 MCG CAP	PO	CAP
Paricalcitol 5 MCG/ML SOLUTION	IV	SOLUTION
Pedmark 12.5 % SOLUTION	IV	SOLUTION
PEMEtrexed 1 GM/40ML SOLUTION	IV	SOLUTION
PEMEtrexed 100 MG/4ML SOLUTION	IV	SOLUTION
PEMEtrexed 500 MG/20ML SOLUTION	IV	SOLUTION
PEMEtrexed Dipotassium 100 MG RECON SOLN	IV	RECON SOLN
PEMEtrexed Dipotassium 500 MG RECON SOLN	IV	RECON SOLN
PEMEtrexed Disodium 1 GM/40ML SOLUTION	IV	SOLUTION
PEMEtrexed Disodium 100 MG RECON SOLN	IV	RECON SOLN

PAGE 373 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
PEMEtrexed Disodium 100 MG/4ML SOLUTION	IV	SOLUTION
PEMEtrexed Disodium 1000 MG RECON SOLN	IV	RECON SOLN
PEMEtrexed Disodium 500 MG RECON SOLN	IV	RECON SOLN
PEMEtrexed Disodium 500 MG/20ML SOLUTION	IV	SOLUTION
PEMEtrexed Disodium 750 MG RECON SOLN	IV	RECON SOLN
PEMEtrexed Disodium 850 MG/34ML SOLUTION	IV	SOLUTION
PEMEtrexed Ditromethamine 100 MG RECON SOLN	IV	RECON SOLN
PEMEtrexed Ditromethamine 500 MG RECON SOLN	IV	RECON SOLN
Pemfexy 500 MG/20ML SOLUTION	IV	SOLUTION
Pemrydi RTU 100 MG/10ML SOLUTION	IV	SOLUTION
Pemrydi RTU 500 MG/50ML SOLUTION	IV	SOLUTION
Penicillin G Pot in Dextrose 20000 UNIT/ML SOLUTION	IV	SOLUTION
Penicillin G Pot in Dextrose 40000 UNIT/ML SOLUTION	IV	SOLUTION
Penicillin G Pot in Dextrose 60000 UNIT/ML SOLUTION	IV	SOLUTION
Penicillin G Procaine 600000 UNIT/ML SUSPENSION	IM	SUSPENSION
Pentamidine Isethionate 300 MG RECON SOLN	IN	RECON SOLN
Pepaxto 20 MG RECON SOLN	IV	RECON SOLN
Perforomist 20 MCG/2ML NEBU SOLN	IN	NEBU SOLN
Perikabiven 2.4-6.8-3.5-0.5 % EMULSION	IV	EMULSION
Perjeta 420 MG/14ML SOLUTION	IV	SOLUTION
Perseris 120 MG PRSYR	SC	PRSYR
Perseris 90 MG PRSYR	SC	PRSYR
Phenergan 25 MG/ML SOLUTION	IJ	SOLUTION
Phenergan 50 MG/ML SOLUTION	IJ	SOLUTION
Phenytoin Sodium 50 MG/ML SOLUTION	IJ	SOLUTION
Phesgo 60-60-2000 MG-MG-U/ML SOLUTION	SC	SOLUTION
Phesgo 80-40-2000 MG-MG-U/ML SOLUTION	SC	SOLUTION
Piasky 340 MG/2ML SOLUTION	IJ	SOLUTION
Plasma-Lyte 148 SOLUTION	IV	SOLUTION
Plasma-Lyte A SOLUTION	IV	SOLUTION
Plenamine 15 % SOLUTION	IV	SOLUTION
Polivy 140 MG RECON SOLN	IV	RECON SOLN
Polivy 30 MG RECON SOLN	IV	RECON SOLN
Pombiliti 105 MG RECON SOLN	IV	RECON SOLN
Portrazza 800 MG/50ML SOLUTION	IV	SOLUTION
Posaconazole 300 MG/16.7ML SOLUTION	IV	SOLUTION
Posfrea 0.25 MG/5ML SOLUTION	IV	SOLUTION
Potassium Acetate 2 MEQ/ML SOLUTION	IV	SOLUTION
Potassium Chloride 10 MEQ/50ML SOLUTION	IV	SOLUTION
Potassium Chloride 20 MEQ/50ML SOLUTION	IV	SOLUTION

PAGE 374 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Potassium Chloride in Dextrose 10-5 MEQ/L-% SOLUTION	IV	SOLUTION
Potassium Chloride in NaCl 20 MEQ/250ML SOLUTION	IV	SOLUTION
Potassium Chloride in NaCl 20-0.45 MEQ/L-% SOLUTION	IV	SOLUTION
Potassium Phosphates 15 MMOLE/5ML SOLUTION	IV	SOLUTION
Potassium Phosphates 150 MMOLE/50ML SOLUTION	IV	SOLUTION
Potassium Phosphates 45 MMOLE/15ML SOLUTION	IV	SOLUTION
Potassium Phosphates (66 mEq K) 45 MMOLE/15ML SOLUTION	IV	SOLUTION
Potassium Phosphates (71 mEq K) 45 MMOLE/15ML SOLUTION	IV	SOLUTION
Potassium Phosphates-NaCl 15 MMOL/100ML SOLUTION	IV	SOLUTION
Potassium Phosphates-NaCl 15 MMOL/250ML SOLUTION	IV	SOLUTION
Potassium Phosphates-NaCl 30 MMOL/500ML SOLUTION	IV	SOLUTION
Poteligeo 20 MG/5ML SOLUTION	IV	SOLUTION
PRALAtrexate 20 MG/ML SOLUTION	IV	SOLUTION
PRALAtrexate 40 MG/2ML SOLUTION	IV	SOLUTION
Pregnyl 10000 UNIT RECON SOLN	IM	RECON SOLN
PreHevbrio 10 MCG/ML SUSPENSION	IM	SUSPENSION
Premasol 10 % SOLUTION	IV	SOLUTION
Prevymis 240 MG/12ML SOLUTION	IV	SOLUTION
Prevymis 480 MG/24ML SOLUTION	IV	SOLUTION
Prialt 100 MCG/ML SOLUTION	IT	SOLUTION
Prialt 500 MCG/20ML SOLUTION	IT	SOLUTION
Prialt 500 MCG/5ML SOLUTION	IT	SOLUTION
Privigen 10 GM/100ML SOLUTION	IV	SOLUTION
Privigen 20 GM/200ML SOLUTION	IV	SOLUTION
Privigen 40 GM/400ML SOLUTION	IV	SOLUTION
Privigen 5 GM/50ML SOLUTION	IV	SOLUTION
Procainamide HCI 100 MG/ML SOLUTION	IJ	SOLUTION
Procainamide HCI 500 MG/ML SOLUTION	IJ	SOLUTION
Procalamine 3 % SOLUTION	IV	SOLUTION
Prochlorperazine Edisylate 10 MG/2ML SOLUTION	IJ	SOLUTION
Prochlorperazine Edisylate 50 MG/10ML SOLUTION	IJ	SOLUTION
Procrit 10000 UNIT/ML SOLUTION	IJ	SOLUTION
Procrit 2000 UNIT/ML SOLUTION	IJ	SOLUTION
Procrit 20000 UNIT/ML SOLUTION	IJ	SOLUTION
Procrit 3000 UNIT/ML SOLUTION	IJ	SOLUTION
Procrit 4000 UNIT/ML SOLUTION	IJ	SOLUTION
Procrit 40000 UNIT/ML SOLUTION	IJ	SOLUTION

PAGE 375 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Prograf 0.5 MG CAP	PO	CAP
Prograf 1 MG CAP	PO	CAP
Prograf 5 MG CAP	PO	CAP
Prograf 5 MG/ML SOLUTION	IV	SOLUTION
Prolastin-C 1000 MG RECON SOLN	IV	RECON SOLN
Prolastin-C 1000 MG/20ML SOLUTION	IV	SOLUTION
Proleukin 22000000 UNIT RECON SOLN	IV	RECON SOLN
Promethazine HCl 25 MG/ML SOLUTION	IJ	SOLUTION
Promethazine HCl 50 MG/ML SOLUTION	IJ	SOLUTION
Propranolol HCI 1 MG/ML SOLUTION	IV	SOLUTION
Prosol 20 % SOLUTION	IV	SOLUTION
Pulmicort 0.25 MG/2ML SUSPENSION	IN	Suspension
Pulmicort 0.5 MG/2ML SUSPENSION	IN	SUSPENSION
Pulmicort 1 MG/2ML SUSPENSION	IN	Suspension
Pulmozyme 2.5 MG/2.5ML SOLUTION	IN	SOLUTION
Pyzchiva 130 MG/26ML SOLUTION	IV	SOLUTION
Radicava 30 MG/100ML SOLUTION	IV	SOLUTION
Rapamune 0.5 MG TAB	PO	TAB
Rapamune 1 MG TAB	PO	TAB
Rapamune 1 MG/ML SOLUTION	PO	SOLUTION
Rapamune 2 MG TAB	PO	TAB
Reblozyl 25 MG RECON SOLN	SC	RECON SOLN
Reblozyl 75 MG RECON SOLN	SC	RECON SOLN
Recarbrio 1.25 GM RECON SOLN	IV	RECON SOLN
Reclast 5 MG/100ML SOLUTION	IV	SOLUTION
Recombivax HB 10 MCG/ML SUSP PRSYR	IJ	SUSP PRSYR
Recombivax HB 10 MCG/ML SUSPENSION	IJ	SUSPENSION
Recombivax HB 40 MCG/ML SUSPENSION	IJ	SUSPENSION
Recombivax HB 5 MCG/0.5ML SUSP PRSYR	IJ	SUSP PRSYR
Recombivax HB 5 MCG/0.5ML SUSPENSION	IJ	Suspension
Regonol 10 MG/2ML SOLUTION	IV	SOLUTION
Releuko 300 MCG/0.5ML SOLN PRSYR	SC	SOLN PRSYR
Releuko 300 MCG/ML SOLUTION	IJ	SOLUTION
Releuko 480 MCG/0.8ML SOLN PRSYR	SC	SOLN PRSYR
Releuko 480 MCG/1.6ML SOLUTION	IJ	SOLUTION
Remicade 100 MG RECON SOLN	IV	RECON SOLN
Remodulin 100 MG/20ML SOLUTION	IJ	SOLUTION
Remodulin 20 MG/20ML SOLUTION	IJ	SOLUTION
Remodulin 200 MG/20ML SOLUTION	IJ	SOLUTION
Remodulin 50 MG/20ML SOLUTION	IJ	SOLUTION
Remodulin 8 MG/20ML SOLUTION	IJ	SOLUTION
Renflexis 100 MG RECON SOLN	IV	RECON SOLN
Revatio 10 MG/12.5ML SOLUTION	IV	SOLUTION
Rezzayo 200 MG RECON SOLN	IV	RECON SOLN

PAGE 376 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
RhoGAM Ultra-Filtered Plus 1500 UNIT SOLN PRSYR	IM	SOLN PRSYR
Rhophylac 1500 UNIT/2ML SOLN PRSYR	IJ	SOLN PRSYR
Riabni 100 MG/10ML SOLUTION	IV	SOLUTION
Riabni 500 MG/50ML SOLUTION	IV	SOLUTION
Ribavirin 6 GM RECON SOLN	IN	RECON SOLN
RisperDAL Consta 12.5 MG SRER	IM	
RisperDAL Consta 25 MG SRER	IM	
RisperDAL Consta 37.5 MG SRER	IM	
RisperDAL Consta 50 MG SRER	IM	
risperiDONE Microspheres ER 12.5 MG SRER	IM	
risperiDONE Microspheres ER 25 MG SRER	IM	
risperiDONE Microspheres ER 37.5 MG SRER	IM	
risperiDONE Microspheres ER 50 MG SRER	IM	
Rituxan 100 MG/10ML SOLUTION	IV	SOLUTION
Rituxan 500 MG/50ML SOLUTION	IV	SOLUTION
Rituxan Hycela 1400-23400 MG -UT/11.7ML SOLUTION	SC	SOLUTION
Rituxan Hycela 1600-26800 MG -UT/13.4ML SOLUTION	SC	SOLUTION
Robaxin 1000 MG/10ML SOLUTION	IJ	SOLUTION
Rocaltrol 0.25 MCG CAP	PO	CAP
Rocaltrol 0.5 MCG CAP	PO	CAP
Rocaltrol 1 MCG/ML SOLUTION	PO	SOLUTION
Rolvedon 13.2 MG/0.6ML SOLN PRSYR	SC	SOLN PRSYR
romiDEPsin 10 MG RECON SOLN	IV	RECON SOLN
romiDEPsin 27.5 MG/5.5ML SOLUTION	IV	SOLUTION
Ruxience 100 MG/10ML SOLUTION	IV	SOLUTION
Ruxience 500 MG/50ML SOLUTION	IV	SOLUTION
Rybrevant 350 MG/7ML SOLUTION	IV	SOLUTION
Rykindo 25 MG SRER	IM	
Rykindo 37.5 MG SRER	IM	
Rykindo 50 MG SRER	IM	
Rylaze 10 MG/0.5ML SOLUTION	IM	SOLUTION
Rystiggo 280 MG/2ML SOLUTION	SC	SOLUTION
Rystiggo 420 MG/3ML SOLUTION	SC	SOLUTION
Rystiggo 560 MG/4ML SOLUTION	SC	SOLUTION
Rystiggo 840 MG/6ML SOLUTION	SC	SOLUTION
Rytelo 188 MG RECON SOLN	IV	RECON SOLN
Rytelo 47 MG RECON SOLN	IV	RECON SOLN
Ryzneuta 20 MG/ML SOLN PRSYR	SC	SOLN PRSYR
SandIMMUNE 100 MG CAP	PO	CAP
SandIMMUNE 100 MG/ML SOLUTION	PO	SOLUTION
SandIMMUNE 25 MG CAP	PO	CAP
SandIMMUNE 50 MG/ML SOLUTION	IV	SOLUTION

PAGE 377 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
SandoSTATIN LAR Depot 10 MG KIT	IM	KIT
SandoSTATIN LAR Depot 20 MG KIT	IM	KIT
SandoSTATIN LAR Depot 30 MG KIT	IM	KIT
Saphnelo 300 MG/2ML SOLUTION	IV	SOLUTION
Sarclisa 100 MG/5ML SOLUTION	IV	SOLUTION
Sarclisa 500 MG/25ML SOLUTION	IV	SOLUTION
Selarsdi 130 MG/26ML SOLUTION	IV	SOLUTION
Sensipar 30 MG TAB	PO	TAB
Sensipar 60 MG TAB	PO	TAB
Sensipar 90 MG TAB	PO	TAB
Sezaby 100 MG RECON SOLN	IV	RECON SOLN
Sildenafil Citrate 10 MG/12.5ML SOLUTION	IV	SOLUTION
Simponi Aria 50 MG/4ML SOLUTION	IV	SOLUTION
Simulect 10 MG RECON SOLN	IV	RECON SOLN
Simulect 20 MG RECON SOLN	IV	RECON SOLN
Sirolimus 0.5 MG TAB	PO	TAB
Sirolimus 1 MG TAB	РО	TAB
Sirolimus 1 MG/ML SOLUTION	PO	SOLUTION
Sirolimus 2 MG TAB	PO	TAB
Sivextro 200 MG RECON SOLN	IV	RECON SOLN
Skyla 13.5 MG IUD	IU	IUD
SMOFlipid 20 % EMULSION	IV	EMULSION
Sodium Acetate 2 MEQ/ML SOLUTION	IV	SOLUTION
Sodium Acetate 4 MEQ/ML SOLUTION	IV	SOLUTION
Sodium Bicarbonate 4.2 % SOLUTION	IV	SOLUTION
Sodium Bicarbonate 7.5 % SOLUTION	IV	SOLUTION
Sodium Bicarbonate 8.4 % SOLUTION	IV	SOLUTION
Sodium Chloride 0.9 % SOLUTION	IJ	SOLUTION
Sodium Chloride 4 MEQ/ML SOLUTION	IV	SOLUTION
Sodium Diuril 500 MG RECON SOLN	IV	RECON SOLN
Sodium Edecrin 50 MG RECON SOLN	IV	RECON SOLN
Sodium Phosphates 15 MMOLE/5ML SOLUTION	IV	SOLUTION
Sodium Phosphates 150 MMOLE/50ML SOLUTION	IV	SOLUTION
Sodium Phosphates 45 MMOLE/15ML SOLUTION	IV	SOLUTION
Soliris 300 MG/30ML SOLUTION	IV	SOLUTION
Solu-CORTEF 100 MG RECON SOLN	IJ	RECON SOLN
Solu-CORTEF 1000 MG RECON SOLN	IJ	RECON SOLN
Solu-CORTEF 250 MG RECON SOLN	IJ	RECON SOLN
Solu-CORTEF 500 MG RECON SOLN	IJ	RECON SOLN
SOLU-Medrol (PF) 1000 MG RECON SOLN	IJ	RECON SOLN
SOLU-Medrol (PF) 125 MG RECON SOLN	IJ	RECON SOLN
SOLU-Medrol (PF) 40 MG RECON SOLN	IJ	RECON SOLN
SOLU-Medrol (PF) 500 MG RECON SOLN	IJ	RECON SOLN
SOLU-medrol 1000 MG RECON SOLN	IJ	RECON SOLN

PAGE 378 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
SOLU-Medrol 2 GM RECON SOLN	IJ	RECON SOLN
SOLU-medrol 500 MG RECON SOLN	IJ	RECON SOLN
Somatuline Depot 120 MG/0.5ML SOLUTION	SC	SOLUTION
Somatuline Depot 60 MG/0.2ML SOLUTION	SC	SOLUTION
Somatuline Depot 90 MG/0.3ML SOLUTION	SC	SOLUTION
Spevigo 450 MG/7.5ML SOLUTION	IV	SOLUTION
Spravato (56 MG Dose) 28 MG/DEVICE SOLN THPK	NA	SOLN THPK
Spravato (84 MG Dose) 28 MG/DEVICE SOLN THPK	NA	SOLN THPK
Stegeyma 130 MG/26ML SOLUTION	IV	SOLUTION
Stimufend 6 MG/0.6ML SOLN PRSYR	SC	SOLN PRSYR
Stoboclo 60 MG/ML SOLN PRSYR	SC	SOLN PRSYR
Sunlenca 463.5 MG/1.5ML SOLUTION	SC	SOLUTION
Sustol 10 MG/0.4ML PRSYR	SC	PRSYR
Sylvant 100 MG RECON SOLN	IV	RECON SOLN
Sylvant 400 MG RECON SOLN	IV	RECON SOLN
Synagis 100 MG/ML SOLUTION	IM	SOLUTION
Synagis 50 MG/0.5ML SOLUTION	IM	SOLUTION
Syndros 5 MG/ML SOLUTION	PO	SOLUTION
Synribo 3.5 MG RECON SOLN	SC	RECON SOLN
Tacrolimus 0.5 MG CAP	PO	CAP
Tacrolimus 1 MG CAP	PO	CAP
Tacrolimus 5 MG CAP	PO	CAP
Talvey 3 MG/1.5ML SOLUTION	SC	SOLUTION
Talvey 40 MG/ML SOLUTION	SC	SOLUTION
Tazicef 1 GM/50ML SOLUTION	IV	SOLUTION
Tecentria 1200 MG/20ML SOLUTION	IV	SOLUTION
Tecentriq 840 MG/14ML SOLUTION	IV	SOLUTION
Tecentria Hybreza 1875-30000 MG-UT/15ML SOLUTION	SC	SOLUTION
Temodar 100 MG RECON SOLN	IV	RECON SOLN
Temsirolimus 25 MG/ML SOLUTION	IV	SOLUTION
Tepadina 100 MG RECON SOLN	IJ	RECON SOLN
Tepadina 15 MG RECON SOLN	IJ	RECON SOLN
Tepadina 200 MG/200ML RECON SOLN	IV	RECON SOLN
Tepezza 500 MG RECON SOLN	IV	RECON SOLN
Tepylute 100 MG/10ML SOLUTION	IV	SOLUTION
Tepylute 15 MG/1.5ML SOLUTION	IV	SOLUTION
Tevimbra 100 MG/10ML SOLUTION	IV	SOLUTION
Tezspire 210 MG/1.91ML SOLN A-INJ	SC	SOLN A-INJ
Tezspire 210 MG/1.91ML SOLN PRSYR	SC	SOLN PRSYR
Thiotepa 100 MG RECON SOLN	IJ	RECON SOLN
Thiotepa 15 MG RECON SOLN	<u></u>  J	RECON SOLN
Thymoglobulin 25 MG RECON SOLN	IV	RECON SOLN
Tice BCG 50 MG RECON SUSP	IS	RECON SUSP

PAGE 379 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Tivdak 40 MG RECON SOLN	IV	RECON SOLN
Tobi 300 MG/5ML NEBU SOLN	IN	NEBU SOLN
Tofidence 200 MG/10ML SOLUTION	IV	SOLUTION
Tofidence 400 MG/20ML SOLUTION	IV	SOLUTION
Tofidence 80 MG/4ML SOLUTION	IV	SOLUTION
Toposar 1 GM/50ML SOLUTION	IV	SOLUTION
Toposar 100 MG/5ML SOLUTION	IV	SOLUTION
Toposar 500 MG/25ML SOLUTION	IV	SOLUTION
Topotecan HCI 4 MG RECON SOLN	IV	RECON SOLN
Topotecan HCl 4 MG/4ML SOLUTION	IV	SOLUTION
Torisel 25 MG/ML SOLUTION	IV	SOLUTION
Totect 500 MG RECON SOLN	IV	RECON SOLN
TPN Electrolytes CONC	IV	CONC
Tranexamic Acid 1000 MG/10ML SOLUTION	IV	SOLUTION
Travasol 10 % SOLUTION	IV	SOLUTION
Trazimera 150 MG RECON SOLN	IV	RECON SOLN
Trazimera 420 MG RECON SOLN	IV	RECON SOLN
Treanda 100 MG RECON SOLN	IV	RECON SOLN
Treanda 25 MG RECON SOLN	IV	RECON SOLN
Trelstar Mixject 11.25 MG RECON SUSP	IM	RECON SUSP
Trelstar Mixject 22.5 MG RECON SUSP	IM	RECON SUSP
Trelstar Mixject 3.75 MG RECON SUSP	IM	RECON SUSP
Tremfya 200 MG/20ML SOLUTION	IV	SOLUTION
Treprostinil 100 MG/20ML SOLUTION	IJ	SOLUTION
Treprostinil 20 MG/20ML SOLUTION	IJ	SOLUTION
Treprostinil 200 MG/20ML SOLUTION	IJ	SOLUTION
Treprostinil 50 MG/20ML SOLUTION	IJ	SOLUTION
Triamcinolone Acetonide 10 MG/ML SUSPENSION	IJ	SUSPENSION
Triamcinolone Acetonide 40 MG/ML SUSPENSION	IJ	SUSPENSION
Triamcinolone Acetonide 50 MG/ML SUSPENSION	IJ	SUSPENSION
Triamcinolone Acetonide 80 MG/ML SUSPENSION	IJ	SUSPENSION
Triesence 40 MG/ML SUSPENSION	IO	SUSPENSION
Triostat 10 MCG/ML SOLUTION	IV	SOLUTION
Triptodur 22.5 MG SRER	IM	
Trisenox 12 MG/6ML SOLUTION	IV	SOLUTION
Trodelvy 180 MG RECON SOLN	IV	RECON SOLN
TrophAmine 10 % SOLUTION	IV	SOLUTION
Truxima 100 MG/10ML SOLUTION	IV	SOLUTION
Truxima 500 MG/50ML SOLUTION	IV	SOLUTION
Twinrix 720-20 ELU-MCG/ML SUSP PRSYR	IM	SUSP PRSYR
Tyenne 200 MG/10ML SOLUTION	IV	SOLUTION
Tyenne 400 MG/20ML SOLUTION	IV	SOLUTION
Tyenne 80 MG/4ML SOLUTION	IV	SOLUTION
Tyruko 300 MG/15ML CONC	IV	CONC

PAGE 380 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Tysabri 300 MG/15ML CONC	IV	CONC
Tyvaso 0.6 MG/ML SOLUTION	IN	SOLUTION
Tyvaso Refill 0.6 MG/ML SOLUTION	IN	SOLUTION
Tyvaso Starter 0.6 MG/ML SOLUTION	IN	SOLUTION
Udenyca Onbody 6 MG/0.6ML SOLN PRSYR	SC	SOLN PRSYR
Ultomiris 1100 MG/11ML SOLUTION	IV	SOLUTION
Ultomiris 300 MG/30ML SOLUTION	IV	SOLUTION
Ultomiris 300 MG/3ML SOLUTION	IV	SOLUTION
Unituxin 17.5 MG/5ML SOLUTION	IV	SOLUTION
Unloxcyt 300 MG/5ML SOLUTION	IV	SOLUTION
Uplizna 100 MG/10ML SOLUTION	IV	SOLUTION
Uptravi 1800 MCG RECON SOLN	IV	RECON SOLN
Ustekinumab 130 MG/26ML SOLUTION	IV	SOLUTION
Ustekinumab-ttwe 130 MG/26ML SOLUTION	IV	SOLUTION
Uvadex 20 MCG/ML SOLUTION	EC	SOLUTION
Uzedy 100 MG/0.28ML SUSP PRSYR	SC	SUSP PRSYR
Uzedy 125 MG/0.35ML SUSP PRSYR	SC	SUSP PRSYR
Uzedy 150 MG/0.42ML SUSP PRSYR	SC	SUSP PRSYR
Uzedy 200 MG/0.56ML SUSP PRSYR	SC	SUSP PRSYR
Uzedy 250 MG/0.7ML SUSP PRSYR	SC	SUSP PRSYR
Uzedy 50 MG/0.14ML SUSP PRSYR	SC	SUSP PRSYR
Uzedy 75 MG/0.21ML SUSP PRSYR	SC	SUSP PRSYR
Vabomere 2 (1-1) GM RECON SOLN	IV	RECON SOLN
Valrubicin 40 MG/ML SOLUTION	IS	SOLUTION
Valstar 40 MG/ML SOLUTION	IS	SOLUTION
Vancomycin HCl 1000 MG/200ML SOLUTION	IV	SOLUTION
Vancomycin HCl 1250 MG/250ML SOLUTION	IV	SOLUTION
Vancomycin HCl 1500 MG/300ML SOLUTION	IV	SOLUTION
Vancomycin HCl 1750 MG/350ML SOLUTION	IV	SOLUTION
Vancomycin HCl 2000 MG/400ML SOLUTION	IV	SOLUTION
Vancomycin HCl 5 GM RECON SOLN	IV	RECON SOLN
Vancomycin HCl 500 MG/100ML SOLUTION	IV	SOLUTION
Vancomycin HCl 750 MG/150ML SOLUTION	IV	SOLUTION
Vancomycin HCl in Dextrose 1-5 GM/200ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in Dextrose 1.25-5 GM/250ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in Dextrose 1.5-5 GM/250ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in Dextrose 1.5-5 GM/300ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in Dextrose 500-5 MG/100ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in Dextrose 750-5 MG/150ML-% SOLUTION	IV	SOLUTION

PAGE 381 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Vancomycin HCl in NaCl 1-0.9 GM/200ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 1-0.9 GM/250ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 1.25-0.9 GM/250ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 1.5-0.9 GM/250ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 1.5-0.9 GM/500ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 1.75-0.9 GM/250ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 1.75-0.9 GM/500ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 2-0.9 GM/500ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 500-0.9 MG/100ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 750-0.9 MG/150ML-% SOLUTION	IV	SOLUTION
Vancomycin HCl in NaCl 750-0.9 MG/250ML-% SOLUTION	IV	SOLUTION
Varubi (180 MG Dose) 2 x 90 MG TAB THPK	PO	TAB THPK
Vectibix 100 MG/5ML SOLUTION	IV	SOLUTION
Vectibix 400 MG/20ML SOLUTION	IV	SOLUTION
Vegzelma 100 MG/4ML SOLUTION	IV	SOLUTION
Vegzelma 400 MG/16ML SOLUTION	IV	SOLUTION
Velcade 3.5 MG RECON SOLN	IJ	RECON SOLN
Veletri 0.5 MG RECON SOLN	IV	RECON SOLN
Veletri 1.5 MG RECON SOLN	IV	RECON SOLN
Ventavis 10 MCG/ML SOLUTION	IN	SOLUTION
Ventavis 20 MCG/ML SOLUTION	IN	SOLUTION
Veopoz 400 MG/2ML SOLUTION	IJ	SOLUTION
Verapamil HCI 2.5 MG/ML SOLUTION	IV	SOLUTION
Vfend IV 200 MG RECON SOLN	IV	RECON SOLN
Vibativ 750 MG RECON SOLN	IV	RECON SOLN
Vidaza 100 MG RECON SUSP	IJ	RECON SUSP
Vimizim 5 MG/5ML SOLUTION	IV	SOLUTION
Vimpat 200 MG/20ML SOLUTION	IV	SOLUTION
VinBLAStine Sulfate 1 MG/ML SOLUTION	IV	SOLUTION
Vincasar PFS 1 MG/ML SOLUTION	IV	SOLUTION
VinCRIStine Sulfate 1 MG/ML SOLUTION	IV	SOLUTION
vinCRIStine Sulfate 2 MG/2ML SOLUTION	IV	SOLUTION
Vinorelbine Tartrate 10 MG/ML SOLUTION	IV	SOLUTION
Vinorelbine Tartrate 50 MG/5ML SOLUTION	IV	SOLUTION
Virazole 6 GM RECON SOLN	IN	RECON SOLN
Vivimusta 100 MG/4ML SOLUTION	IV	SOLUTION

PAGE 382 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Vivitrol 380 MG RECON SUSP	IM	RECON SUSP
Voriconazole 200 MG RECON SOLN	IV	RECON SOLN
Vpriv 400 UNIT RECON SOLN	IV	RECON SOLN
Vyepti 100 MG/ML SOLUTION	IV	SOLUTION
Vyloy 100 MG RECON SOLN	IV	RECON SOLN
Vyloy 300 MG RECON SOLN	IV	RECON SOLN
Vyvgart 400 MG/20ML SOLUTION	IV	SOLUTION
Vyvgart Hytrulo 180-2000 MG-UNIT/ML SOLUTION	SC	SOLUTION
Vyxeos 44-100 MG RECON SUSP	IV	RECON SUSP
Wezlana 130 MG/26ML SOLUTION	IV	SOLUTION
Winrevair 2 x 45 MG KIT	SC	KIT
Winrevair 2 x 60 MG KIT	SC	KIT
Winrevair 45 MG KIT	SC	KIT
Winrevair 60 MG KIT	SC	KIT
WinRho SDF 1500 UNIT/1.3ML SOLUTION	IJ	SOLUTION
WinRho SDF 15000 UNIT/13ML SOLUTION	IJ	SOLUTION
WinRho SDF 2500 UNIT/2.2ML SOLUTION	IJ	SOLUTION
WinRho SDF 5000 UNIT/4.4ML SOLUTION	IJ	SOLUTION
Wyost 120 MG/1.7ML SOLUTION	SC	SOLUTION
Xembify 1 GM/5ML SOLUTION	SC	SOLUTION
Xembify 10 GM/50ML SOLUTION	SC	SOLUTION
Xembify 2 GM/10ML SOLUTION	SC	SOLUTION
Xembify 4 GM/20ML SOLUTION	SC	SOLUTION
Xenleta 150 MG/15ML SOLUTION	IV	SOLUTION
Xenpozyme 20 MG RECON SOLN	IV	RECON SOLN
Xenpozyme 4 MG RECON SOLN	IV	RECON SOLN
Xeomin 100 UNIT RECON SOLN	IM	RECON SOLN
Xeomin 200 UNIT RECON SOLN	IM	RECON SOLN
Xeomin 50 UNIT RECON SOLN	IM	RECON SOLN
Xerava 100 MG RECON SOLN	IV	RECON SOLN
Xerava 50 MG RECON SOLN	IV	RECON SOLN
Xipere 40 MG/ML SUSPENSION	IO	SUSPENSION
Xolair 150 MG RECON SOLN	SC	RECON SOLN
Xopenex 0.31 MG/3ML NEBU SOLN	IN	NEBU SOLN
Xopenex 0.63 MG/3ML NEBU SOLN	IN	NEBU SOLN
Xopenex 1.25 MG/3ML NEBU SOLN	IN	NEBU SOLN
Xopenex Concentrate 1.25 MG/0.5ML NEBU SOLN	IN	NEBU SOLN
Xylocaine-MPF/Epinephrine 1 %-1:200000 SOLUTION	IJ	SOLUTION
Xylocaine-MPF/Epinephrine 1.5 %-1:200000 SOLUTION	IJ	SOLUTION
Xylocaine-MPF/Epinephrine 2 %-1:200000 SOLUTION	IJ	SOLUTION
Xylocaine/Epinephrine 0.5 %-1:200000 SOLUTION	IJ	SOLUTION

PAGE 383 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Xylocaine/Epinephrine 1 %-1:100000 SOLUTION	IJ	SOLUTION
Xylocaine/Epinephrine 2 %-1:100000 SOLUTION	IJ	SOLUTION
Yervoy 200 MG/40ML SOLUTION	IV	SOLUTION
Yervoy 50 MG/10ML SOLUTION	IV	SOLUTION
Yesintek 130 MG/26ML SOLUTION	IV	SOLUTION
Yimmugo 10 GM/100ML SOLUTION	IV	SOLUTION
Yimmugo 20 GM/200ML SOLUTION	IV	SOLUTION
Yimmugo 5 GM/50ML SOLUTION	IV	SOLUTION
Yondelis 1 MG RECON SOLN	IV	RECON SOLN
Yupelri 175 MCG/3ML SOLUTION	IN	SOLUTION
Zaltrap 100 MG/4ML SOLUTION	IV	SOLUTION
Zaltrap 200 MG/8ML SOLUTION	IV	SOLUTION
Zanosar 1 GM RECON SOLN	IV	RECON SOLN
Zemaira 1000 MG RECON SOLN	IV	RECON SOLN
Zemaira 4000 MG RECON SOLN	IV	RECON SOLN
Zemaira 5000 MG RECON SOLN	IV	RECON SOLN
Zemdri 500 MG/10ML SOLUTION	IV	SOLUTION
Zemplar 1 MCG CAP	PO	CAP
Zemplar 2 MCG CAP	PO	CAP
Zemplar 2 MCG/ML SOLUTION	IV	SOLUTION
Zemplar 5 MCG/ML SOLUTION	IV	SOLUTION
Zepzelca 4 MG RECON SOLN	IV	RECON SOLN
Zerbaxa 1.5 (1-0.5) GM RECON SOLN	IV	RECON SOLN
Zevalin Y-90 3.2 MG/2ML KIT	IV	KIT
Ziextenzo 6 MG/0.6ML SOLN PRSYR	SC	SOLN PRSYR
Ziihera 300 MG RECON SOLN	IV	RECON SOLN
Zilretta 32 MG SRER	IX	
Zinplava 1000 MG/40ML SOLUTION	IV	SOLUTION
Zirabev 100 MG/4ML SOLUTION	IV	SOLUTION
Zirabev 400 MG/16ML SOLUTION	IV	SOLUTION
Zofran 4 MG TAB	PO	TAB
Zoladex 10.8 MG IMPLANT	SC	IMPLANT
Zoladex 3.6 MG IMPLANT	SC	IMPLANT
Zoledronic Acid 4 MG/100ML SOLUTION	IV	SOLUTION
Zoledronic Acid 4 MG/5ML CONC	IV	CONC
Zoledronic Acid 5 MG/100ML SOLUTION	IV	SOLUTION
Zortress 0.25 MG TAB	PO	TAB
Zortress 0.5 MG TAB	PO	TAB
Zortress 0.75 MG TAB	PO	TAB
Zortress 1 MG TAB	PO	TAB
Zulresso 100 MG/20ML SOLUTION	IV	SOLUTION
Zuplenz 4 MG FILM	PO	FILM
Zuplenz 8 MG FILM	PO	FILM
Zynlonta 10 MG RECON SOLN	IV	RECON SOLN

PAGE 384 EFFECTIVE 11/2025

MEDICATION NAME	ROUTE	DOSE FORM
Zynyz 500 MG/20ML SOLUTION	IV	SOLUTION
ZyPREXA Relprevv 210 MG RECON SUSP	IM	RECON SUSP
ZyPREXA Relprevv 300 MG RECON SUSP	IM	RECON SUSP
ZyPREXA Relprevv 405 MG RECON SUSP	IM	RECON SUSP

PAGE 385 EFFECTIVE 11/2025